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List and summary of papers 
The thesis is based on the following papers, which are referred to by roman numerals in the text: 
I Chiara Compagnin†, Francesca Moret†, Lucia Celotti, Giovanni Miotto, Josephine H. 
Woodhams, Alexander J. MacRobert, Dietrich Scheglmann, Selma Iratni and Elena 
Reddi. 
“Meta-tetra(hydroxyphenyl)chlorin-loaded liposomes sterically stabilised with 
poly(ethylene glycol) of different length and density: characterisation, in vitro
cellular uptake and phototoxicity.”
II Francesca Moret, Dietrich Scheglmann and Elena Reddi.
“Folate-targeted PEGylated liposomes improve the selectivity of PDT with meta-
tetra(hydroxyphenyl)chlorin (m-THPC).”
III Matija Rojnik, Petra Kocbek, Francesca Moret, Chiara Compagnin, Lucia Celotti, 
Melissa J. Bovis, Josephine H Woodhams, Alexander J MacRobert, Dietrich 
Scheglmann, Wijnand Helfrich, Marco J Verkaik, Emanuele Papini, Elena Reddi and 
Janko Kos. 
“In vitro and in vivo characterization of temoporfin-loaded PEGylated PLGA 
nanoparticles for use in photodynamic therapy.”
IV Francesco Selvestrel†, Francesca Moret†, Daniela Segat†, Josephine H. Woodhams†,
Giulio Fracasso†, Iria M. Rio Echevarria, Luca Baù, Federico Rastrelli, Chiara 
Compagnin, Elena Reddi, Chiara Fedeli, Emanuele Papini, Regina Tavano, Alexandra 
Mackenzie, Melissa Bovis, Elnaz Yaghini, Alexander MacRobert, Silvia Zanini, Anita 
Boscaini, Marco Colombatti and Fabrizio Mancin.
“Targeted delivery of photosensitizers: efficacy and selectivity issues revelead by 
multifunctional ORMOSIL nanovectors in cellular systems.”
V Francesca Moret, Francesco Selvestrel, Elisa Lubian, Chiara Compagnin, Maddalena 
Mognato, Lucia Celotti, Fabrizio Mancin and Elena Reddi. 
“PEGylation of ORMOSIL nanoparticles abolishes the toxicity toward some lung 
cells but not alveolar type II epithelial cells in vitro.”
† The authors contributed equally to the study.
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The papers were written in co-authorship, reflecting the collaboration among authors. Papers I, II 
and III are already published and collected data obtained during the European project 
NANOPHOTO, in which 4 academic groups (Padova University, Ljubljana University, 
University College London, Groningen University) and the industry Biolitec Research GmbH 
collaborated at the development of a nanovehicle for the delivery of the photosensitizer meta-
tetra(hydroxyphenyl)chlorin (m-THPC) for photodynamic therapy (PDT) of cancer. In particular, 
I am the first author of both papers I and II since the majority of the data were produced in my 
research group and during my PhD experience. My contribution to paper III is related to the 
studies on m-THPC-loaded PLGA nanoparticles uptake, dark and photo-toxicity in vitro. Paper 
IV that has been accepted by Nanoscale for publication but not already published, collected 
results related to different aspects of using functionalized ORMOSIL nanoparticles as drug 
delivery systems. My contribution is referred to the in vitro studies of intracellular uptake of 
nanoparticles functionalized with folate or RGD peptide. For paper V, that is being submitted, I 
had the main responsibility for the experiments as well as for writing the paper. 
Summary of Paper I
The study reports the in vitro characterization of PEGylated liposomes (namely Fospeg®)
developed for the delivery of the photosensitizer m-THPC to cancer cells. In particular, the 
effects of liposome PEG density and thickness on m-THPC cellular uptake as well as on dark 
and phototoxicity were evaluated in normal (CCD-34Lu) and in cancer (A549) lung cells. The 
photodynamic efficiency of the different Fospeg® formulations was compared to those of the 
photosensitizer delivered to cells by the standard solvent (Foscan®). The study highlighted how 
the delivery of m-THPC by PEGylated liposomes drastically reduced the dark side effects of the 
drug, and how the reduction of cytotoxicity correlated with the increase of the percentage of 
PEGylation. In addition, even if the encapsulation of the photosensitizer in PEGylated liposomes 
reduced by 30-40% his intracellular uptake with respect to the free drug, phototoxicity was only 
slightly affected. Intracellular localization studies revealed that both Foscan® and Fospeg®
localized in endoplasmic reticulum and Golgi apparatus, suggesting that part of the drug 
effectively entered the cells with the delivery systems but also that part of the drug is release 
before internalization and entered cells as complexes with serum proteins. 
Summary of Paper II
In this paper the design, the synthesis and the in vitro specific uptake and phototoxicity of a 
novel folate-targeted liposomal formulation (FA-Fospeg) for the delivery of m-THPC to cells 
over-expressing folate receptors (FR) are reported. Thus, m-THPC PEGylated liposomes 
(PEG750) bearing folate at the distal end of a PEG spacer (PEG5000) were synthesized and their 
specific internalization were compared to those of un-targeted liposomes in KB (FR-positive) 
and A549 (FR-negative) cells. Since, as demonstrated in Paper I, m-THPC release from Fospeg® 
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occurs and very likely affects the measure of the specific internalization of the drug via the
targeted nanovehicles, preliminary experiments were carried out using liposomes covalently 
labelled with carboxyfluorescein (CF-liposomes). Competition experiments using free FA 
revealed that only a modest fraction (~15%) of FA-targeted CF-liposomes entered KB cells via 
FR-mediated endocytosis while non-specific uptake of liposomes prevailed in both cell lines 
regardless the presence of the targeting agent. Instead, when FA-Fospeg was used, the selective 
uptake in KB cells was measured only at short incubation time (3h) while no difference in the 
photosensitizer uptake was measure after 24 h in both cell lines and for both liposome 
formulations due to the release of a large fraction of the drug at long incubation time. 
Nevertheless, despite the low contribution of FR-mediated uptake of FA-Fospeg, in KB cells the 
m-THPC uptake was doubled and translated into a 1.5-foldenhanced photo-killing efficiency. 
Summary of Paper III
The paper reports on an in vitro and in vivo evaluation of PEGylated poly-(D,L-lactide-co-
glycolide) nanoparticles (PEG PLGA NPs) as m-THPC drug delivery system for use in PDT and 
in fluorescence-based imaging of tumours. In the study bare and PEGylated PLGA NPs were 
synthesized using nanoprecipitation method, were photo-physically characterized and their 
ability to deliver m-THPC was evaluated in vitro in 3 different cell lines (A549, MCF10A neo T, 
U937) while their biodistribution was evaluated in vivo in mice. The results showed that within 
NPs m-THPC was aggregated with consequent self-quenching and that it was promptly released 
in the presence of serum proteins with a kinetics faster for PEG with respect non PEG PLGA 
NPs. Nevertheless, by using both bare and PEGylated NPs, m-THPC was efficiently delivered to 
the cells and localized in perinuclear region and/or acidic compartments. The reduced drug 
uptake measured for PEGylated NPs with respect to bare NPs confirmed the sheathing features 
of the delivery system. Interestingly, the dark cytotoxicity of m-THPC was highly reduced with
the encapsulation in PEG PLGA NPs while photo-toxicity resulted comparable to that of 
mTHPC delivered by standard solvent (Foscan®), notwithstanding the double uptake measured 
for Foscan®. Reduced uptake of NPs with respect to Foscan® was confirmed in vivo measuring 
the total body fluorescence of mice 24 h post-injection while biodistribution experiments 
revealed higher tumour-to-skin ratio for PLGA NPs with respect to Foscan® and reduced 
accumulation in lungs and colon of PEG PLGA NPs with respect to bare NPs. 
Summary of Paper IV
The study highlighted potentialities and limitations of ORganically MOdified SILica 
nanoparticles (ORMOSIL NPs) as targeted drug delivery system. For the first time the synthesis 
of highly PEGylated VTES-ORMOSIL NPs in which m-THPC was covalently entrapped after 
mono- or tetra-functionalisation with alkoxysilane was reported together with a detailed 
photophysical characterisation of the entrapped drug. It was found that the singlet oxygen 
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quantum yield was comparable to that of the free drug for the mono-silane derivative of m-THPC 
in NPs while was strongly reduced in the case of the tetra-silane in NPs. In vitro experiments 
revealed that the embedding of the photosensitizer in PEG NPs highly reduced his uptake in 
normal as well in cancer cells with respect to Foscan®, indicating that targeting of NPs could be 
a useful strategy in order to improve the selective uptake of m-THPC in cancer cells. Thus, NPs 
were functionalized with folate, RGD peptide or Cetuximab antibody and their ability was 
measured to target selectively cells over-expressing folate receptor (FR), integrin α5ß3 receptor 
and epidermal growth factor receptor (EGFR), respectively,. Folate-targeted NPs displayed no 
selective uptake very likely because of scarce exposure of the hydrophobic targeting agents that 
hides itself in the PEG layer. On the contrary, RGD-targeted and Cetuximab-targeted NPs were 
selectively taken up with respect to their control NPs RAD-NPs and BSA-NPs, respectively. 
However, selective targeting did not correlate with enhanced PDT efficiency since a modest 
increase of phototoxicity was measured for Cetuximab NPs but not for RGD NPs. The results 
obtained arise the paradox that at least in vitro selectivity of uptake by the targeted NPs is 
achievable only in conditions of low NP cell-loading with consequent delivery of an amount of 
m-THPC that is insufficient for inducing satisfactory cell photo-killing. 
Summary of Paper V
The paper reports an in vitro characterization of the cytotoxic profiles of bare and PEGylated 
ORMOSIL NPs in different normal (CCD-34Lu) and cancer (A549, NCI-H2347) lung cells. Cell 
viability measurements revealed that un-PEGylated NPs were highly cytotoxic toward all cell 
lines while PEGylation abolished cytotoxicity in CCD-34Lu and NCI-H2347 but not in A549 
cells. PEG NP exposure determined A549 cell death via necrosis since membrane 
permeabilization and LDH release were measured. In addition, gene expression profile studies 
using Agilent microarray revealed that the expression of hundred of genes involved in 
inflammation, receptor-mediated cell signalling and cell death were altered after A549 NP 
exposure. Furthermore, a significant increase in reactive oxygen species (ROS) production was 
measured but oxidative stress cannot be considered the determinant of A549 cell mortality since 
incubation of cells with ROS inhibitors reduced ROS level while did not protect cells from NP-
induced death. The uptake of PEG NPs in CCD-34Lu fibroblasts was comparable to that of 
A549 cells, ROS were produced following the 24 h incubation with NPs but cytotoxic effects 
could not be detected in these cells. Analysing the intracellular fate of NPs by transmission 
electron microscopy, we found that in A549 cells NPs were internalized in pulmonary surfactant-
containing lamellar bodies, peculiar of alveolar type II cells of which A549 represents a model. 
Immunofluorescence studies showed that PEG NPs caused a decrease of expression of specific 
pulmonary surfactant proteins (SP-A, SP-C). Overall the results suggest that the sensitivity of 
A549 to PEG ORMOSIL NPs was triggered by the interference of the nanostructures with the 
lung surfactant production and recycling. 
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Abstract 
The recent progresses offered by nanotechnology in the manipulation of matter lead to the 
development of several nanoparticles (NPs) and nanodevices for medical applications. In 
oncology, nanosized objects are particularly attractive as drug delivery systems since it is 
expected that engineered nanovehicles of appropriate size and functionalised with specific 
ligands/antibodies will improve the efficacy and selectivity of cancer therapies by exploiting 
both the passive and active mechanism of tumour targeting. The use of delivery systems is 
particularly appealing in those therapies in which the administration of the drug in aqueous 
formulations leads to drug aggregation with decreased activity or scarce bioavailability and 
tumour selectivity. This is the case of most of the photosensitizers used in photodynamic therapy 
(PDT), which display hydrophobicity and poor selective accumulation in malignant tissues. In 
the last decades, PDT is emerging as a promising cancer treatment modality in alternative to 
conventional therapies, which often demonstrate systemic drug toxicity and multidrug-resistance 
phenomena. PDT is based on the administration of a photosensitizer (PS) that accumulates in the 
tumour and after activation with light of appropriate wavelengths, reacts with surrounding 
molecular oxygen leading to the formation of cytotoxic reactive oxygen species (ROS) with 
consequent cellular and vasculature damages. 
In this PhD thesis, three different nanosystems, namely, liposomes, poly-(D,L-lactide-co-
glycolide) nanoparticles (PLGA NPs) and ORganically Modified SILica nanoparticles 
(ORMOSIL NPs) were considered for the delivery of the second generation PS meta-
tetra(hydroxyphenyl)chlorin (m-THPC, Temoporfin) to cancer cells in vitro. In particular, drug 
delivery efficiency, dark and phototoxicity of the m-THPC nanoparticle-based formulations were 
evaluated. To improve m-THPC bioavailability and tumour selectivity, in the design of the 
nanovehicles PEGylation and targeting of NPs were considered as essential strategies in order to 
prolong NP circulation in the bloodstream and exploit active mechanisms of tumour targeting. 
For the delivery of m-THPC using unilamellar liposomes, four different PEGylated liposomal
formulations (trade name Fospeg®, provided by Biolitec Research) in which the length (PEG750, 
PEG2000, PEG5000) and the density (2%, 8%) of PEG were varied, were tested in vitro in 
normal lung fibroblasts CCD-34Lu and in cancer A549 lung epithelial cells. Compared to drug 
delivered in the standard solvent (Foscan®, ethanol/PEG 400/water (20:30:50, by vol.)),
liposomal m-THPC showed a decreased intracellular uptake in both cell lines, but the presence of 
the delivery system highly reduced the dark cytotoxicity of the drug. The reduction of the PS 
dark toxicity increased with the increasing of PEG density on liposome surface, while the length 
of PEG chains did not affect significantly the toxic effect of m-THPC in the dark. However, 
photo-toxicity measured in A549 cells was only slightly affected by the reduced uptake of m-
THPC delivered by Fospeg®, and the efficiency of PDT-induced cell killing was comparable 
among the different liposomal formulations. Interestingly, the intracellular localization of m-
THPC delivered as Fospeg® or Foscan® was the same (Golgi apparatus and endoplasmic 
reticulum) suggesting drug release from liposomes, especially in the presence of the serum 
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proteins, being m-THPC only physically entrapped within liposomes. m-THPC release was 
confirmed by the fact that liposomes covalently labelled with rhodamine were effectively were 
taken up by cells but, differently from m-THPC, localized in the acidic compartments of the 
cells. In spite of m-THPC release from liposomes, the Fospeg® formulation was exploited to 
target actively cancer cells by liposome conjugation with folic acid (FA), being FA-receptors 
(FRs) over-expressed in several human tumours. Thus, specific uptake and photo-toxicity of FA-
targeted liposomes (FA-Fospeg) with respect to liposomes of the same composition but lacking 
FA (un-targeted Fospeg) was evaluated in KB (FR-positive) and in A549 (FR-negative) cells. 
The uptake of m-THPC delivered as FA-Fospeg was twice that of un-targeted Fospeg in KB 
cells; however only a modest fraction (~ 15%) of the targeted vehicle was effectively 
internalized by FR-mediated endocytosis while nonspecific internalization remained the 
prevailing mechanism of liposomes uptake in both cell lines. The improved m-THPC uptake 
obtained with FA-Fospeg in FR over-expressing cells translated into a 1.5 higher photo-induced 
toxicity. 
A novel formulation of bare and PEGylated PLGA NPs in which m-THPC was physically 
entrapped were synthesized (Prof J. Kos, University of Ljubljana) and evaluated in vitro and in 
vivo for phototherapy and fluorescence-based tumour imaging applications. In vitro studies 
carried out on A549, MCF10A neo T (breast cancer cells) and U937 (lymphoma derived pro-
monocytic cells) cell lines, showed reduced uptake of PEGylated NPs with respect to non 
PEGylated NPs. As for Fospeg®, the use of the delivery system led to a significant reduction of 
m-THPC dark toxicity.. As expected for PEGylated NPs, the efficiency of cell internalization of 
m-THPC entrapped in PEG PLGA was reduced by 50% with respect to that in the standard 
solvent, but surprisingly cytotoxicity induced in irradiated A549 cells was quite comparable. At 
24 h post-injection in vivo biodistribution of bare and PEGylated PLGA NPs compared to 
Foscan® was assessed in mice, showing very similar drug accumulation in the major organs but 
reduced skin uptake for both NP formulations. Thus, even if m-THPC release in the presence of 
serum proteins was measured in vitro, PEGylated PLGA NPs appeared potentially useful as 
stealth and biodegradable PS delivery systems. 
The premature release of the PS from the delivery system was completely avoided with the 
covalent link of m-THPC to the silane matrix of highly PEGylated ORMOSIL NPs (Prof. F. 
Mancin, University of Padova). This type of NPs exhibited a very low extent of cell 
internalization in vitro due to their high degree of PEGylation, making NP targeting an essential 
prerequisite to enhance intracellular drug delivery. In addition to FA, the RGD peptide and the 
antibody Cetuximab, which bind respectively the integrin α5ß3 receptor and epidermal growth 
factor receptor (EGFR), were exploited as targeting agents for ORMOSIL NPs and the specific 
uptake and photo-toxicity of m-THPC delivered by conjugated NPs were evaluated in vitro. The 
study revealed how the characteristics of the targeting agents are of crucial importance in 
determining the performances of targeted PEGylated nanosystems. In fact, the hydrophobic FA 
was very likely buried in the PEG layer and was unable to drive the selective uptake of 
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ORMOSIL NPs while RGD peptide and Cetuximab antibody displayed some selectivity toward 
cells over-expressing their receptors (HUVEC cells over-expressing integrin α5ß3 receptors and 
A431 cells over-expressing EGFR). Unfortunately, the enhanced and selective uptake of m-
THPC obtained by the two latter targeted ORMOSIL NPs was not accompanied by efficient and 
selective photo-induced cytotoxicity; it appeared that the selectivity of NP uptake was achieved 
in scarce drug cell loading conditions, determining only low PDT efficacy. 
The assessment of the biocompatibility of NPs is of fundamental importance for their safe use in 
nanomedicine. Since ORMOSIL NPs are not well characterised from this point of view, a 
toxicological characterization of empty ORMOSIL NPs were carried out in vitro in normal 
(CCD-34Lu) and cancer (A549, NCIH-2347) lung cells. The study included traditional cell 
viability and cytotoxicity tests (MTS test, LDH release assay, ROS production, cell membrane 
permeabilization measurements and electron microscopy analyses) in combination with a
genome-wide analysis of gene expression profiles of cells exposed to NPs. The results pointed 
out that different types of cells respond quite differently to NPs and PEGylation of NPs highly 
affected the cytotoxicity profiles. PEGylation of ORMOSIL NPs completely abolished the 
toxicity of the nanosystem in CCD-34Lu and NCIH-2347 cells. On the contrary PEG ORMOSIL 
NPs induced necrotic cell death of A549 by increasing the permeability of the plasma membrane. 
At sub-lethal concentrations alteration of gene expression and inflammation were measured in 
A549 cells exposed to. The different response to PEG NPs is very likely explained considering 
the peculiarity of the cell type and the particular interaction of NPs with cell and internalization 
mechanisms. In fact, it was shown clearly that NPs internalized in A549 cells localized in and 
affected the morphology and the functioning of pulmonary surfactant containing lamellar bodies, 
peculiar of alveolar type II cells of which A459 cells represents an in vitro models. 
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Riassunto 
Il recente progresso apportato dalla nanotecnologia nella manipolazione della materia ha portato 
al conseguente sviluppo di diversi tipi di nanoparticelle e nanodevices per applicazioni 
biomediche. In campo oncologico, oggetti dalle dimensioni nanometriche si sono dimostrati 
particolarmente interessanti in qualità di sistemi per la veicolazione di farmaci, poiché si 
presume che l’ingegnerizzazione dei nanoveicoli e la loro funzionalizzazione con specifici 
ligandi/anticorpi possa portare ad un miglioramento dell’efficacia e della selettività delle terapie 
antitumorali sfruttando meccanismi di targeting del tumore sia passivi che attivi. L’utilizzo di 
sistemi di veicolazione è particolarmente importante nel caso di terapie nelle quali la 
somministrazione dei farmaci in formulazioni acquose conduce a fenomeni di aggregazione con 
conseguente diminuzione di attività e di disponibilità nel circolo sanguineo, o nel caso di farmaci 
con scarsa selettività per il tumore. Appartengono a queste categorie la maggior parte dei 
fotosensibilizzanti utilizzati in terapia fotodinamica (PDT), poiché farmaci di natura idrofobica e
con scarsa selettività di accumulo nei tessuti maligni. Negli ultimi decenni, la PDT si è 
dimostrata una promettente tecnica di trattamento del cancro in alternativa alle terapie 
convenzionali che invece generalmente dimostrano alta tossicità sistemica e fenomeni di 
farmaco-resistenza. La PDT si basa sulla somministrazione di un fotosensibilizzante (PS) che 
accumulatosi nel tumore, e dopo essere stato attivato con opportune lunghezze d’onda di luce, è 
in grado di reagire con l’ossigeno molecolare che lo circonda generando specie reattive 
dell’ossigeno (ROS) altamente citotossiche con conseguente danno cellulare e vascolare. In 
questa tesi di dottorato, tre diversi nanosistemi quali liposomi, nanoparticelle PLGA (poly-(D,L-
lactide-co-glycolide)) e nanoparticelle di silice organicamente modificata (ORMOSIL), sono 
stati presi in considerazione per la veicolazione del fotosensibilizzante di seconda generazione 
meta-tetra(hydroxyphenyl)chlorin (m-THPC, Temoporfin) in cellule tumorali in vitro. In 
particolare, sono state valutate l’efficienza di veicolazione del farmaco, la tossicità buia e 
fotoindotta delle diverse formulazioni di m-THPC. Per migliorare la biodisponibilità e la 
selettività per il tumore della m-THPC, nella progettazione dei nanoveicoli sono state considerate 
quali strategie essenziali la pegilazione e il targeting delle particelle, in modo da prolungare la 
circolazione dei nanosistemi nel flusso sanguineo e in modo da sfruttare meccanismi attivi di 
targeting del tumore. 
Per la veicolazione della m-THPC utilizzando liposomi unilamellari sono state saggiate in vitro
quattro diverse formulazioni liposomiali pegilate (Fospeg®, fornito dalla ditta Biolitec Research) 
con lunghezza (PEG750, PEG2000, PEG5000) e densità del PEG (2%, 8%) variabili, utilizzando 
come linee cellulari fibroblasti di polmone normali (CCD-34Lu) e cellule tumorali di epitelio 
polmonare (A549). Se paragonate al farmaco somministrato in forma libera in soluzione 
(Foscan®, etanolo/PEG 400/acqua (20:30:50, vol/vol)), le formulazioni liposomiali di m-THPC 
hanno mostrato una ridotta internalizzazione in entrambe le linee cellulari, ma nello stesso tempo 
la presenza del sistema di veicolazione ha portato alla significativa riduzione della tossicità buia 
del farmaco. La riduzione della tossicità buia del farmaco è risultata proporzionale all’aumento 
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della densità di PEG sulla superficie del liposoma mentre la lunghezza delle catene di PEG 
sembra essere ininfluente nel limitare l’effetto tossico della m-THPC al buio. Comunque, la 
ridotta internalizzazione della m-THPC veicolata tramite Fospeg® influenza in modo solo 
parziale la fototossicità misurata in cellule A549, mentre l’efficienza d’induzione di mortalità in 
seguito a trattamento fotodinamico è risultata paragonabile tra le diverse formulazioni saggiate. 
Indipendentemente dalla veicolazione tramite Fospeg® o Foscan®, è stata riscontrata la 
medesima localizzazione intracellulare della m-THPC (apparato del Golgi e reticolo 
endoplasmatico) suggerendo il possibile rilascio del farmaco dalla formulazione liposomiale in 
presenza di proteine del siero, essendo la m-THPC solamente fisicamente intrappolata all’interno 
dei liposomi. Il rilascio della m-THPC è stato confermato dal fatto che liposomi nei quali viene 
legata covalentemente rodamina vengono effettivamente internalizzati dalle cellule e, 
differentemente dalla m-THPC, si accumulano nei compartimenti acidi intracellulari. 
Nonostante il rilascio del fotosensibilizzante dai liposomi, la formulazione Fospeg® è comunque 
stata utilizzata per veicolare selettivamente la m-THPC in cellule cancerose tramite la 
coniugazione dei liposomi con acido folico, essendo i recettori del folato sovraespressi in diversi 
tumori umani. Quindi sono state valutate l’internalizzazione specifica e la fototossicità di 
liposomi coniugati con folato (liposomi folato) rispetto a liposomi della stessa composizione ma 
privi di acido folico (liposomi non coniugati) in cellule KB e A549, rispettivamente positive e 
negative per l’espressione di recettori del folato. In cellule KB, l’internalizzazione della m-THPC 
si è rivelata doppia in caso di veicolazione con liposomi folato, malgrado solo una modesta parte 
(~15%) dei nanosistemi coniugati con folato siano effettivamente internalizzati tramite 
meccanismi di endocitosi mediata da recettore, essendo invece un’internalizzazione di tipo 
aspecifico il meccanismo prevalente per l’internalizzazione dei liposomi in entrambe le linee 
cellulari saggiate. In ogni caso, all’aumentato accumulo di m-THPC ottenuto tramite la
veicolazione con Fospeg coniugato con folato in cellule che sovra esprimono il recettore, ne è
conseguita una tossicità dopo irradiamento aumentata di circa 1.5 volte. 
Riguardo invece la veicolazione di m-THPC tramite particelle PLGA, formulazioni nude o 
pegilate sono state sintetizzate (Prof. J. Kos, Università di Lubiana) e saggiate sia in vitro che in 
vivo per la loro potenziale applicazione in fototerapia o in diagnosi dei tumori, sfruttando la 
fluorescenza del fotosensibilizzante fisicamente intrappolato all’interno delle particelle. Studi in 
vitro condotti su cellule A549, MCF10A neo T (derivate da tumore del seno) e U937 (cellule 
pro-monocitiche derivate da linfoma), hanno mostrato una ridotta internalizzazione della 
formulazione di m-THPC pegilata rispetto a quella nuda. Anche con particelle PLGA e come già 
visto per il Fospeg®, l’utilizzo di un sistema di veicolazione porta alla significativa riduzione 
della citotossicità buia della m-THPC. L’efficienza d’internalizzazione del fotosensibilizzante 
veicolato tramite particelle PLGA pegilate viene ridotta circa del 50% rispetto alla sua 
veicolazione nella formulazione standard ma sorprendentemente l’effetto citotossico indotto in 
cellule A549 irradiate è quasi paragonabile. La biodistribuzione della m-THPC (veicolata tramite 
nanoparticelle PLGA nude o pegilate o nella formulazione standard) è stata valutata 24 ore dopo 
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la sua iniezione in topi, mostrando una simile distribuzione nei vari organi ma una significativa 
riduzione dell’accumulo a livello epidermico per entrambe le formulazioni nanoparticellari. 
Quindi, nonostante anche per le particelle PLGA pegilate sia stato misurato il rilascio di m-
THPC in presenza di proteine sieriche, esse appaiono un buon sistema di veicolazione di 
fotosensibilizzanti soprattutto per le loro caratteristiche ‘stealth’ e per la loro biodegradabilità. 
Il rilascio prematuro del fotosensibilizzante è stato invece completamente limitato con il legame 
covalente della m-THPC alla matrice silanica di particelle ORMOSIL altamente pegilate (Prof. 
F. Mancin, Università di Padova). Tuttavia questo tipo di particelle ha mostrato 
un’internalizzazione intracellulare estremamente bassa derivata dall’elevato grado di 
pegilazione, ponendo come requisito essenziale il targeting delle particelle. In qualità di agenti di 
targeting per le particelle ORMOSIL pegilate sono stati valutati, oltre al folato, anche il peptide 
ciclico RGD e l’anticorpo Cetuximab, essendo questi ultimi in grado di legarsi rispettivamente 
ad integrine α5ß3 e al recettore del fattore di crescite dell’epidermide (EGFR). 
L’internalizzazione selettiva e la fototossicità della m-THPC veicolata tramite le tre diverse 
nanoparticelle funzionalizzate sono state valutate in vitro in opportuni sistemi cellulari. Tale 
studio ha mostrato come le caratteristiche dell’agente di targeting influenzino in modo 
sostanziale la selettività di tali nanosistemi pegilati. Infatti, mentre il folato altamente idrofobico 
si ripiega verosimilmente verso la corona di PEG rendendosi inefficace nel guidare 
selettivamente le particelle ORMOSIL, il peptide RGD e l’anticorpo Cetuximab hanno mostrato 
una certa selettività nei confronti di cellule sovraesprimenti i rispettivi recettori (cellule HUVEC 
sovraesprimenti recettori per le integrine α5ß3 e cellule A431 sovraesperimenti EGFR). Tuttavia, 
l’aumentato accumulo selettivo della m-THPC ottenuto tramite la coniugazione delle 
nanoparticelle con RGD e Cetuximab non ha portato ad una conseguente aumentata efficienza e 
selettività nell’induzione di citotossicità in seguito ad irradiamento. Tale risultato è
verosimilmente imputabile al fatto che la selettività di accumulo delle nanoparticelle viene 
raggiunta in condizioni nelle quali la disponibilità del farmaco nelle cellule è troppo bassa, con 
conseguente scarsa efficacia dopo trattamento fotodinamico. 
La valutazione della biocompatibilità delle nanoparticelle risulta di fondamentale importanza per 
un’applicazione sicura della nanotecnologia in campo medico. Quindi, poiché le nanoparticelle 
ORMOSIL non sono ancora state ben caratterizzate da tale punto di vista, un loro profilo 
tossicologico è stato tracciato in vitro in cellule polmonari normali (CCD-34Lu) e tumorali 
(A549, NCIH-2347). Nello studio sono stati combinati esperimenti tradizionali di valutazione 
della vitalità cellulare e della citotossicità (test MTS, saggio del rilascio di LDH, valutazione 
della produzione di ROS, misure di permeabilizzazione di membrana, analisi di microscopia 
elettronica) con un’analisi dei profili di espressione genica estesa all’intero genoma di cellule 
esposte alle nanoparticelle. I risultati hanno mostrato come diversi tipi di cellule rispondono in 
modo abbastanza differente all’esposizione alle nanoparticelle e come la pegilazione influisce 
fortemente sui profili di citotossicità. Infatti, la pegilazione delle particelle ORMOSIL è in grado 
di abolire completamente la tossicità dei nanosistemi in cellule CCD-34Lu e NCIH-2347 mentre 
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le stesse particelle pegilate inducono morte per necrosi in cellule A549, aumentandone la 
permeabilità di membrana. Inoltre nelle medesime cellule, concentrazioni sub-letali di 
nanoparticelle inducono infiammazione e alterazione dell’espressione genica. La differente 
risposta all’esposizione alle nanoparticelle pegilate delle cellule A549 è spiegabile considerando 
la peculiarità di questo tipo cellulare, e in particolare l’interazione delle particelle stesse con le 
cellule e il loro meccanismo d’internalizzazione. Infatti, è stato mostrato in modo chiaro che le 
nanoparticelle vengono internalizzate in corpi lamellari contenenti il surfattante polmonare,
peculiari di cellule alveolari di tipo II, delle quali le cellule A549 rappresentano un modello in
vitro. Tale accumulo delle nanoparticelle nei corpi lamellari porta alla modifica della morfologia 
degli stessi e una pesante alterazione della loro funzionalità. 
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Introduction 
In the last decades, the scientific knowledge in cancer biology has come on in leaps and bounds 
but has not translated into comparable advances in clinic practice. Thus, one of the major 
challenges still remains the improvement of cancer therapy, especially as regards an increase of 
the efficiency of therapeutics delivery and the concomitant obtainment of tumour selectivity. In 
fact, most of the conventional chemotherapeutics, after systemic administration, distribute in 
cancerous as well in healthy tissues with consequent side-effects and sub-optimal accumulation 
in the tumour (Wang et al. 2009). It appears that extraordinary opportunities to improve cancer 
therapy are offered by the emerging science of nanotechnology, which offers new starting point 
to be integrated with the established cancer research (Ferrari 2005, Ahmed et al. 2012).
However, even if many products developed with nanotechnological approaches have entered the 
market and clinical practice, most of the concepts that grounded under the term ‘nanomedicine’,
are for the most under continuous investigation by university and industry researchers. To date, 
many nanomaterials are at their infancy in the knowledge of their properties and require to be 
well characterized in vitro as well in vivo in animal models before their full potentials for 
application in medicine are completely understood. In fact, even if part of the research 
community is very confident in exploiting the potential of nanomedicine in the very near future 
(5-10 years), others are more cautious and feel that more time is needed before obtaining 
nanomaterials produced by large scale processes that can be safely used for disease treatments 
(Aguilar 2012). 
In the following paragraphs the concepts of nanotechnology and nanomedicine are expanded, 
with particular attention dedicated to the development of nanomaterials for drug delivery 
applications in photodynamic therapy of cancer that is the main topic of this thesis. 
Nanotechnology and Nanomedicine 
The science of nanotechnology manipulates matter properties at the nanoscale level in order to 
develop new capabilities of materials for potential applications in engineering, technology and 
medicine. Nanotechnology products, which have at least one dimension in the range of 1 to 100 
nm, possess unique chemical, electronic, optical, magnetic and catalytic properties, with respect 
to the bulk materials, that make them very attractive. Two different strategies of matter control 
and manipulation have been developed, the “bottom-up” and the “top-down” approaches. In the 
first, smaller molecules and atoms are assembled to form the nanoscale materials, while in the 
second micron-sized components are used to manipulate submicron materials. However, a 
convergence of the two approaches is needed for a practical use of the new developed 
nanomaterials in order to engineer nanoscale devices and to interface them with the outside 
world (Mazzola 2003). In the last 10 years, nanostructured material advantages have been 
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exploited in many different commercial fields with the development of several products for 
application in electronic industry, computer technology, pharmaceutical and medical research,
food industry and agriculture. Thus, nanotechnology market is growing exponentially with an 
increasing number of commercial products which are introduced every week, with a tremendous 
worldwide socio-economic impact (Roco 2003). Nanomaterials are currently introduced in 
sunscreen, cosmetics, food products, food packaging, paints, varnishes, clothing, computer 
hardware, and as catalysts in fuels. In addition, in the 20th century, in the second half, growing 
synthetic polymer chemistry and pioneering nanotechnologies led to the development of the first 
nano-drugs which entered routine clinical use two decades later (Duncan and Gaspar 2011).
From the 1930s, iron oxide nanoparticles appeared useful as parental iron infusion solution for 
the treatment of anemia (Marchasin and Wallerstein 1964, Silverstein and Rodgers 2004) while 
from the 1990s they were used as magnetic resonance imaging (MRI) contrasting agents with the 
acronym of SPIONs (Ferrucci 1991, Lin et al. 2008). Examples of first generation nano-drugs 
and imaging agents marketed and approved in clinical trials are liposome-based formulation such 
as the liposomal doxorubicin Myocet for cancer treatment or the liposomal morphine Depodur 
for pain relief, SPION dextran (Feridex, Endorem) coated nanoparticles for liver imaging, 
Abraxane albumin-based paclitaxel loaded nanoparticles for breast cancer therapy and polymeric 
drugs such as Copaxane, Renagel and Genoxol-PM (Duncan and Gaspar 2011, Cattaneo et al.
2010). However, the application of nanotechnology in medicine, referred with the term 
nanomedicine, not only provides new pharmaceutical formulations for optimized drug delivery 
but also exploits fields such as surgery (nanosurgery) (Ebbesen 2006), tissue engineering 
(Weeldon et al. 2011), DNA and RNA intracellular delivery for gene therapy (Chen et al. 2012, 
Shen et al. 2012) and molecular diagnosis for the early detection of diseases (Namiki et al.
2011). The concept that nanometric devices, with dimensions comparable with those of 
biological molecules such as proteins (5-50 nm), viruses (20-450 nm), genes (2 nm wide, 10-100 
nm long), can be used to exploit biological signature of diseases and at the same time to treat 
them, lay beside the term theranostic. Theranostics are ideally integrated nanotherapeutic 
systems which can diagnose, deliver targeted drugs and finally monitor the response to therapy 
(Warner 2004, Sumer and Gao 2008). Theranostic research is growing up very fast and has 
already resulted in the development of products made of different nanomaterials carrying 
contrasting agents and active drugs. Examples are represented by gold nanoparticles loaded with 
doxorubicin for diagnosis, tumour targeting and photothermal therapy (PPT) (Prabaharan et al.
2009), carbon nanotubes loaded with doxorubicin, paclitaxel or plasmid DNA for diagnosis, drug 
and gene delivery (Pantarotto et al. 2004, Liu et al. 2008), luminescent quantum dots containing 
methotrexate or doxorubicin for imaging, therapy and sensing (Savla et al. 2008, Yuan et al.
2009). 
The use of nanoparticles (NPs) as drug delivery systems in cancer makes them attractive for 
improving traditional chemotherapies since the pharmacokinetic profile of the drugs can be 
favourably modulated and therefore the therapeutic index can be improved and the systemic 
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toxicity reduced. To obtain these results, the so called “multifunctional nanoparticles” have been 
properly engineered, possessing ‘stealthlike feature’ to evade the immune system and prevent 
opsonization but also carrying targeting molecules to improve the selectivity of tumour uptake 
(Torchilin 2006, Cheng et al. 2012). 
Figure 1: Example of a multifunctional nanocarrier (figure from Ferrari 2005, with license from Nature 
Publishing Group). 
At the moment, several thousands of different types of nanovehicles are under investigations,
and the flexibility offered by nanotechnological approaches to modulate NP characteristics, to 
select therapeutics and biological targets, represents the ideal starting point for the future of a 
personalized medicine. 
Passive and active targeting of drug delivery systems to tumours 
All nano-formulations already approved by the Food and Drug Administration (FDA) are 
examples of non-targeted NPs based on polymers or liposomes, which accumulates within 
malignant lesions due to passive targeting. With the term passive targeting we refer to the ability 
of NPs to accumulate in the tumour matrix as the result of their nanometric size and the 
particular architecture of the tumour vasculature. In fact, the rapid angiogenesis in solid tumours 
produce blood vessels with large gaps (600-800 nm) between adjacent endothelial cells which, 
together with the poor lymphatic drainage of cancer tissues, creates the enhanced permeability 
and retention (EPR) effect (Maeda et al. 2000, Hirsjärvi et al. 2011). Thus, the leaky vasculature 
allows nanovehicles to accumulate and reside in tumour cell interstitial space. EPR-based drug 
delivery strategies have been exploited in clinical practice especially using liposomes and 
experiments in animal models showed that the EPR effect can increase by more than 50-folds NP
accumulation within tumour with respect to healthy tissues (Peer et al. 2007).
Several factors such as NP dimension, surface properties and circulation half-life but also the 
degree of tumour angiogenesis, may affect the selectivity of drug delivery (Allen and Cullis 
19
2004). Regarding size, NPs with diameter between 10 and 100 nm exhibited the most efficient 
tumour accumulation escaping renal filtering, but also particles of > 400 nm in size were shown 
to extravasate in animal tumour models (Torchilin 2000). However, it must be taken in account 
that the EPR effect is very heterogeneous and can vary substantially from one tumour model to 
another and there is no doubt that it is more evident in tumour models in animals than in patients. 
In addition, the EPR can vary even within the same tumour, with areas in which particles up to 
200 nm can easily extravasate and areas in which the endothelial lining is intact and constituted 
of pericytes, smooth muscle cells or fibroblasts, which compromise vascular permeability 
(Lammers et al. 2012). Thus, to evaluate the usefulness of EPR-based therapy considering EPR 
heterogeneity, theranostics to pre-screen patients and to monitor efficiency of tumour 
accumulation have been developed (Sun 2010). Nevertheless, upon reaching tumour 
extracellular matrix, for an effective delivery of the drug, NPs have to penetrate into tumour 
cells. Penetration is strongly affected and hampered by the high tumour cell density and high
interstitial density of the extracellular matrix, which prevent NPs from crossing more than one or 
two cell layers. The NP size also plays a pivotal role in determining efficiency of penetration. It
has been reported that upon intravenous injection (i.v.) of quantum dots of different diameters 
(12, 60, 125 nm) in mouse bearing Mu89 melanoma, only the smallest one penetrated into 
tumour cells efficiently, while larger NPs remained confined in the peri-vascular regions 
(Popovic et al. 2010). Strategies to overcome penetration barrier have been developed, including 
stimuli sensitive delivery systems for drug release in peri-vascular regions or pharmacological 
treatments (inflammatory mediators, inhibitors of fibrosis, matrix-degrading enzymes) (Kano et 
al. 2007) or radiotherapy (Davies et al. 2004) and are proposed in association to NP delivery. 
However, before extravasate and reaching tumour, the drug delivery system has to circulate in 
the bloodstream for long period, without being captured and cleared by monocytes and 
macrophages of the mononuclear phagocytic system (MPS), which identify NPs as foreign 
materials. In fact, once in the bloodstream, unprotected NPs interact and associate with plasma 
components such as serum proteins that favour the recognition by elements of the reticulo-
endothelial system (RES), especially hepatic Kupffer cells (Moghimi et al. 2001). This 
phenomenon has been extensively investigated using liposomes, studying the association of 
opsonins such as immunoglobulins, complement components and lipoproteins with the 
phospholipid outer monolayer, promoting clearance of opsonised liposomes by receptor-
mediated phagocytosis in liver and spleen (Moghimi 1998, Moghimi and Patel 1998, Yan et al.
2005). The degree of opsonization of particles depends on different factors such as NP size and 
shape (Canelas et al. 2009, Longmire et al. 2011, Albanese et al. 2012), but the surface 
properties of the delivery system are the major determinants of opsonisation. It has been shown 
that neutral NPs exhibit lower opsonin association than charged NPs (Roser et al. 1998) and 
hydrophobic surfaces enhance adsorption of blood proteins compared to hydrophilic ones 
(Carstensen et al. 1992, Norman et al. 1992). Therefore, it is expected that the modification of 
NP surface by the addition of groups that minimize those electrostatic and hydrophobic 
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interactions leading to opsonin absorption, creates the so called “stealth NP” with prolonged 
circulation in the bloodstream (Moghimi and Szebeni 2003, Owens III and Peppas, 2006). Non-
ionic surfactants incorporated during NP synthesis as well as hydrophilic polymers 
(polysaccharides, polyacrylamide, poly(vinyl alcohol)) have been exploited as coating elements 
and among the different molecules used polyethylene glycol (PEG) and PEG-containing 
copolymers were found to be the most effective. The conjugation of PEG molecules on NP 
surface (PEGylation) forms a flexible layer and creates a sort of steric hindrance not only 
preventing opsonin adsorption but also increasing biocompatibility (Romberg et al. 2008). PEG 
is poorly toxic, immunogenic and antigenic, is not biodegradable and consequently does not 
form toxic metabolites and is not accumulated by RES cells (Zalipsky 1995, Yamaoka et al.
1994). Prolonged circulation time and reduced toxicity have been reported for different types of 
PEGylated drug delivery systems such as liposomes, polymeric NPs and micelles (Amoozgar 
and Yeo 2012), dendrimers (Svenson 2009) and quantum dots (Clift and Stone 2012). As an 
example, the PEGylated liposomal formulation of doxorubicin Doxil/Caelix, clinically approved 
for the treatments of ovarian cancer and Kaposi’s sarcoma, exhibits a 100 time longer circulation 
half life compared to the free drug and a sevenfold reduced cardio-toxicity (O’Brien et al. 2004).
However, despite the presence of the PEG coating which ensure prolonged circulation, to some 
extent also stealth particles are captured in the MPS organs and cleared (Moghimi and Szebeni 
2003). Beyond size, it seems that the PEG layer characteristics are of crucial importance in 
determining the final distribution and the clearance rate of the drug delivery system since PEG 
thickness, charge, surface density and conformation affected opsonin interaction. Even if 
literature data on the most suitable PEG layer conformation are still conflicting across the 
various animal model tested, it appears that high molecular weight PEG polymers favoured 
longer blood circulation half-lives in vitro and in vivo (Gref et al. 1995, Gref et al. 2000, Dos et 
al. 2007). 
Recent studies reported on the so called “PEG dilemma”, since while PEGylation is fundamental 
for imparting favourable properties to NPs until their extravasation into tumour extracellular 
matrix, it interferes in the interaction between NPs and tumour cells, compromising the 
intracellular delivering of the payloads. Interferences of PEGylation have been reported 
especially in gene delivery therapy using liposomes, since DNA or siRNA must be internalized 
in the cytosol or in the nucleus to be efficacious and the surface aqueous phase formed by PEG 
corona limited the interactions of the gene delivery system with cell surface, resulting in very 
poor uptake (Hatakeyama et al. 2011). Furthermore, stabilization of NPs with the PEG layer 
resulted in increased stability of the nanocarriers, favouring poor endosomal escape and 
consequent degradation of cargos in the digestive compartments of the cells (Remaut et al.
2007). Thus, the ideal strategy to overcome the dilemma is represented by nanocarriers which 
during circulation carry the PEG corona while, after NP extravasation in the target site, lose PEG 
molecules by external stimuli (Kuai et al. 2010).
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Alternatively, increased intracellular accumulation of nanovehicles in tissues and cells 
can be achieved exploiting targeted NPs, carrying on surface, specific ligands in addition to 
PEG. Thus, active targeting strategies (targeted drug delivery), complementing with EPR effect,
propose to enhance drug accumulation and selectivity taking advantage of specific recognition 
and binding of the targeting moieties by tumour-associated antigens or receptors, leading to the 
internalization of the drug delivery system via receptor-mediated endocytosis. The targeting 
agent has to be specific for receptors that are over-expressed by cancer cells but minimally 
expressed in normal cells, in order to minimize drug accumulation in healthy tissues and reduce 
toxicity (Wang and Thanou 2010). The selection of targeted receptors/antigens and NP ligands 
are of crucial importance in the design of the targeted nanosystem, since the firsts should be 
highly and uniquely expressed on cancer cells, while the second has to trigger the internalization 
process for the optimization of drug therapeutic responses. In addition, it is expected that 
targeted delivery, which promotes drug internalization by endocytic processes, and therefore by-
passing glycoprotein efflux pumps, lead to reduced multidrug resistance (Yu et al. 2011). 
Numbers of ligands such as transferrin (Ishida et al. 2001), urokinase plasminogen activator 
(uPA) (Yang et al. 2009), RGD peptide (Schiffelers et al. 2003), folate (Pan and Lee 2004, 
Gabizon et al. 2003), anti human epidermal growth factor HER-2 antibodies (Park et al. 2002, 
Sheeda et al. 2009), prostate cancer-specific antigen (PSMA) antibodies (Gu et al. 2008) have 
been successfully conjugated with different types of nanovehicles, showing NP-targeting in 
cancer cells. In particular, folate, RGD peptide and Cetuximab antibody (monoclonal antibody 
against epidermal growth factor receptor (EGFR)) has been selected as targeting agents for the 
drug delivery systems objective of this PhD thesis and their advantages/disadvantages will be 
discussed in paper II and IV as ligands for liposomes and silica NPs, respectively. 
Nevertheless, even if the idea of targeted nanomedicine has been developed more than 30 years 
ago, only few targeted drug formulations have been proposed for clinical trials and none have 
been approved. Limits are represented especially by the targeting agent conjugation techniques 
which in some cases affects the affinity of binding of the ligands as a consequence of 
conformational changes, steric hindrance or inadequate orientation (Cheng et al. 2012). Finding 
the optimal density of targeting ligands on NP surface is of crucial importance in the design of 
targeted nanovehicles, since ligands concentration has to exceed a minimum threshold for 
binding. Nevertheless, it has been reported that an excess of targeting agent diminishes binding 
affinity, promotes non-specific interactions with endothelial and other non-cancerous cells, and 
increases immunogenicity, thereby causing the clearance of the NPs (Yu et al. 2012). Thus, the 
targeting ligands and the stealth layers on NP surfaces have to cooperate in the global process of 
intracellular internalization. In the case of PEGylated drug delivery systems, the use of PEG 
spacers carrying the targeting moieties at the extremity represented one of the most exploited 
strategies in order to avoid the shielding of the ligands into the polymer chains (Gabizon 1999, 
Gref et al. 2003, Shenoy et al. 2006, Kawano and Maitani 2011). However, optimized targeted
drug delivery systems which have demonstrate successful targeting in cancer cells in vitro, 
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demonstrated completely different behaviours in experimental models consequent to accelerated 
plasma clearance of targeted NPs (Gu et al. 2008, Sheeda et al. 2009). These observations stress 
the fact that in vivo experiments are absolutely required to follow targeted NP distribution 
throughout the body after i.v. administration, in normal and neoplastic tissues as well as to asses 
RES interference with targeting. Thus, multifunctional nanocarrier optimization cannot abstract 
from a complete understanding of the tumour biology and physiology as a basis for truly targeted 
drug delivery. 
Nanotechnologies in Photodynamic therapy 
Photodynamic therapy: an overview 
In cancer treatment, photodynamic therapy (PDT) has emerged as a compelling alternative or 
adjuvant to traditional chemotherapy, radiotherapy or surgery. PDT is a minimally invasive 
technique which exerts selective cytotoxic effects in target tissues (Agostinis et al. 2011). 
Currently, PDT is used in clinical for the treatments of several types of malignancies as well as 
for non-oncological diseases such as endometriosis, arteriosclerosis and age-related macular 
degeneration (Levy and Obochi 1996) but also for antimicrobial purposes (Hamblin and Hasan 
2004). 
PDT is based on the administration of three components which are individually non toxic: the 
photosensitizer (PS), light and molecular oxygen. Nevertheless the PSs, upon activation with 
appropriate wavelengths of light, exert cytotoxicity in the site of accumulation via production of 
highly reactive oxygen species (ROS), mainly singlet oxygen (1O2), which lead rapidly to cell 
death (Dougherty et al. 1998). 
Figure 1: PDT mechanisms of action (figure from Castano et al. 2005, with license from Nature 
Publishing Group). 
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PDT selectivity is due not only to the possibility to deliver the light from lasers to desired areas 
of the body using optical fibres but also to the tendency of PSs to localize in neoplastic lesions 
with some degree of selectivity (Konan et al. 2002). In fact, tumour peculiar characteristics such 
high proliferation rate and vascularisation, low extracellular pH values compared to surrounding 
healthy tissues, high expression of lipoprotein receptors (LDLs) together with the high 
hydrophobic nature of the PSs, lead to increased accumulation of PS drugs in malignancies with 
respect to healthy tissues offering a great opportunity for a targeted therapy based on EPR effect 
(Oenbrink et al. 1988, Friberg et al. 2003). It has been reported that hydrophobic PSs bind with 
high affinity to LDL and then are endocytosed by LDL receptor in cancer cells (Allison 1994, 
Polo et al. 2002) while more hydrophilic PSs tend to localize in the interstitial space and in the 
vascular stroma of tumours. Thus, the antitumor effects of PDT derive from the cytotoxicity 
exerted directly in tumour cells, but also to the tumour vasculature, accompanied by a significant 
inflammatory response, consequent of PDT-induced oxidative stress (Bhuvaneswari et al. 2009, 
Korbelik 2006).
Most of the PSs used in PDT of cancer are chlorins, porphyrins and phthalocyanins which, with 
their tetrapyrrolic structures, efficiently absorb light in the red and far red regions of the visible 
spectrum, the so called ‘PDT therapeutic window’ (600-800 nm). Local irradiation with red light 
wavelengths, allows deep penetration (> 1 cm) in the tissues as well as limited absorption of light 
by endogenous chromophores, limiting undesired cytotoxicity (Allison et al. 2006). In addition, 
the confined damages elicited by PDT are determined also by the very short lifetime of 1O2 in 
biological systems (~10-320 ns), which is able to diffuse from the site of production for at least 
10-55 nm (Dysart and Patterson 2005). 
Photochemical reactions which lead to the production of the highly reactive radicals and 1O2
upon irradiation of the PS proceed across the following steps (see Jablonski diagram, figure 3):
i) Absorption of photon by PS leads to the promotion of one PS’s electron from a low energy 
level in the singlet ground state (S0) (electrons with opposite spins) to an exited singlet level (S2)
characterized by higher energy level ii) Excited PS instability leads to emission of excess of 
energy by non-radiative processes to return to a lower energy level (S1) iii) The short-lived S1 (in 
the order of nanoseconds) can undergo inter system crossing (ICS) to form a long lived triplet 
state (T1) with inverted spin of one electron iii) From T1 the PS can either decay to S0 via 
radiative decay (phosphorescence) or can transfer its energy to molecular oxygen (O2), which is 
unique in being a triplet in its ground state, leading to the direct formation of 1O2 (Type II 
process). Instead, if a Type I processes occurs, the T1 state of PS reacts directly with 
neighbouring organic molecules, acquiring a hydrogen atom or electron to form a radical. In 
turn, radical intermediates may react with molecular oxygen to form several radical oxygen 
species (ROS) such as superoxides (•O2-), peroxidises (H2O2), and hydroxyl radicals (•OH).
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Figure 3: Simplified Jablonski diagram showing electronic transitions of a PS after photon absorption. 
At cellular level, produced ROS can trigger the activation of several biochemical, immunological 
and physiological responses consequent to the destruction of the cells of the irradiated tissues via 
apoptosis or necrosis; the mechanism of death mainly depends on the type of PS used and its 
intracellular localization (Castano et al. 2005, Oleinick et al. 2002). PSs can accumulated in 
plasma membrane, Golgi apparatus, endoplasmic reticulum, mitochondria, lysosomes while 
nuclear accumulation is not observed with the currently used PSs; this excludes DNA damages, 
mutation and carcinogenesis as a consequence of PDT. PS accumulation in plasma membranes 
leads to cell death mainly via necrosis while PS accumulation in mitochondria induces apoptosis 
(Calzavara-Pinton et al. 2006).
To obtain efficient PDT damages, the PS has to posses several ideal characteristics such as a
high quantum yield of generation of long-lived triplet state and ROS to assure damage to 
targeted molecules, efficient absorption in the therapeutic window, high chemical purity, 
solubility and low tendency to aggregation in formulations suitable for i.v. administration. In 
addition, for a safe medical use, PS has to be not toxic in the absence of light (negligible dark 
cytotoxicity), exhibit high selectivity for tumour tissues and be rapidly cleared from healthy 
tissues in order to avoid systemic toxicity and generalized skin photosensitization (Allison et al.
2004). 
Many different PS molecules have been approved for clinics and they are usually classified as 
first, second and third generation photosensitizers. Among the first generation PSs, Photofrin®, a 
purified form of an hematoporphyrin derivative (HPD), was the first approved in 1995 by the 
FDA. Although Photofrin® remains one of the most used PSs for treating cancer in patients, it is 
not very selective for tumours leading to long-lasting skin photosensitivity, it absorbs light in the 
red region very inefficiently and its chemical formulation and biological activity are difficult to 
be reproduced (Lam et al. 1987). Thus, second generation PSs such as porphyrins, chlorins, 
texaphyrins, purpurins and phthalocyanines have been developed with improved chemical 
properties (high purity, stability, solubility, optimal photo-physical properties) and improved 
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selectivity of tumour accumulation (Nyman and Hynninen 2004). Their improved PDT efficacy 
is related to a high singlet oxygen quantum yield and by the presence of chemical groups at the 
periphery of the tetrapyrrolic structure that positively affect photophysical and pharmacological 
properties. In the recent years, different strategies, such as peptides or antibodies conjugation, 
have been proposed in order to further increased tumour selectivity of these second generation 
PSs, leading to the development of the ‘third generation PSs’. In addition, the so called ‘pro-
drugs’ has been exploited in PDT, being molecules that are not PSs but that are converted in 
active PSs once inside the cells by metabolic processes. The most widely studied pro-drug in 
PDT is 5-aminolevulinic acid (5-ALA), a precursor in the biosynthetic of heme, that can induce 
the formation of the potent PS protoporphyrin IX (PpIX) and to his accumulation especially in 
cancer cells (Uehlinger et al. 2000, Collaud et al. 2004). PpIX natural fluorescence is exploited 
also for fluorescence diagnosis (ALA-FD) and fluorescence-guided resection of malignant 
tissues together with ALA-PDT are successfully applied since more than 25 years in 
dermatology, urology, neurosurgery, otorhinolaryngology, gynecology and gastroenterology 
(Krammer and Plaetzer 2008).
Among the second generation PSs, meta-tetra(hydroxyphenyl)chlorin (m-THPC) also 
known as Temoporfin, is one of the most potent PSs used in clinics. It has been approved by the 
European Medicines Agency (EMA) for the palliative PDT treatment of advanced head and neck 
carcinoma and for oral squamous carcinoma (Senge and Brandt 2011). mTHPC is a chlorin 
derived from the parent porphyrin 5,10,15,20-tetra(m-hydroxyphenyl)porphyrin) (m-THPP) and 
is formed by four pyrrolic sub-units linked by four carbon atoms which are meso-substituted 
with four hydroxylated phenyl groups. m-THPC absorption spectra is characterized by a high 
absorption peak (Soret band) set at 420 nm and by four absorption peaks of lower intensities (Q 
bands) in the region 500-700 nm (50, 540, 600, 650 nm). In addition m-THPC exhibits a red 
fluorescence with a maximum settled around 652 nm that makes it potentially useful for imaging 
and monitoring of drug accumulation, but it not yet approved for photodiagnosis.
Figure 4: chemical structure and absorption spectra of m-THPC. 
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For clinical application, because of his high hydrophobic degree, m-THPC is administered 
intravenously in a formulation containing ethanol and propylene glycol as co-solvent (Foscan®
formulation). To avoid unwanted phototoxic effects, in Foscan® PDT light treatment is 
performed 24 - 96 h after injection of the drug to guarantee sufficient clearance from healthy 
tissues Several studies reported a 100-200 fold increased PDT efficacy of Foscan® with respect 
to Photofrin®. Foscan® doses low as 0.1-0.15 mg kg-1 combined with low light fluences (10-20 J 
cm-2) gave tumour responses comparable to those elicited with 2 mg kg-1 Photofrin® and 100 J 
cm-2 of light (van Geel et al. 1995, Mlkvy et al. 1998, Ball et al. 1999, Mitra and Foster 2005).
However, in spite of the improvement obtained with Foscan®-PDT, the drawbacks of the therapy 
remain considerable. Foscan® is only partially selective for malignant tissues and distribution and 
retention throughout the body determine prolonged skin and eye photosensivity (up to 6 weeks) 
as well as hemorrage, constipation, vomiting, mouth necrosis and face edema (D’Cruz et al.
2004, Hopper et al. 2004). The high hydrophobic nature of the PS induces drug precipitation 
inside blood vessels, especially at the injection site with consequent local pains and decreased 
drug concentration in the bloodstream. In addition, the low water-solubility of m-THPC favour 
aggregation in aqueous media that compromise photodynamic efficiency, being aggregated PSs 
much less efficient than monomeric PSs in the 1O2 production (Bonnet et al. 2001). Thus, new 
formulations for m-THPC and other potentially useful hydrophobic PSs are needed in order to 
improve bio-distribution, pharmacokinetics and PDT efficacy. In the development of these new 
PS formulations, it appears that nanotechnology offers unique opportunities for the engineering 
of nanovehicles that overcome problems related to drug hydrophobicity from one hand and takes 
the drug specifically into target tissue and cells on the other.
Drug delivery systems in PDT 
Different types of delivery systems for PSs have been developed. These include liposomes, 
micelles, bio-degradable and non-biodegradable polymeric NPs, metallic NPs and ceramic NPs, 
often functionalised to impart stealthy properties or carrying targeting agent for the so called 
targeted PDT (TPDT) (Zeisser-Labouèbe et al. 2006, Bugaj 2011). However, the majority of the 
results so far published are limited to in vitro investigations probably because many of the in 
vivo challenges have not been adequately addressed and inconsistent levels of drug accumulated 
in tissues.have been reported (Master et al. 2013).
In addition to modulation of size, shapes and superficial characteristics of nanocarriers to fully 
exploit passive and active targeting, PS loading efficiency is a crucial parameter in the design of 
the delivery system. In fact, differently from conventional chemotherapeutics, where the higher
drug loading produces the higher cytotoxic effects, for PS, high loading can lead to drug 
aggregation and self-quenching of ROS during irradiation, with consequent reduced photo-
efficiency. Therefore, nanoparticles based formulations of PS have to ensure the delivery of
optimal doses of photodinamically active drug and ideally, PS molecules within the nanocarrier 
should be monomers or become monomers soon after delivery at the target site. Loss of the drug 
cargo has been reported for different types of NPs and payloads, especially after incubation in 
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the presence of serum proteins. It is well known that most the PSs possess high affinity for serum 
proteins that easily adsorb on NP surface forming a corona. As a consequence PSs are 
transferred from the inside of the NPs to serum proteins and PS-protein complexes are formed 
(Konan et al. 2003, Sasnouski et al. 2005, Cedervall et al. 2007, Compagnin et al. 2009). Thus, 
to avoid PS release and partitioning to plasma proteins before reaching target sites, strategies has 
been developed to chemically conjugate the PS to the vehicles, without interfering with the PS 
photo-physical properties. In fact, once in targeted cells, the release of PSs from the carrier is not 
required, since the nanometric dimensions of NPs allows the diffusion of oxygen and ROS out of 
the vehicle to cause cellular damages. In addition, it is expected that the dark cytotoxicity of the 
PS can be significantly reduced embedding the drug within the NPs and preventing his escape 
and accumulation in healthy tissues. 
Theranostic approaches have been exploited also in PDT with the developing of multifunctional 
delivery systems carrying PSs, fluorescent probes (or the PS itself if fluorescent) or magnetic 
resonance agents for the in situ evaluation of PDT-induced effects (Kopelman et al. 2005, van 
Vlerken et al. 2006). As an example, Reddy et al. designed a multifunctional nanoplatform for 
TPDT based on polyacrylamide NPs loaded with Photofrin® and with iron oxide as imaging 
agent and bearing F3 peptide linked by PEG spacer on NP surface for the selective targeting of 
brain tumour cells and vasculature. Multifunctionality of NPs leads also to the combination of 
different therapies, as PDT and chemotherapy, using as an example the same delivery system for 
the PS methylene blue (MB) and doxorubicin (Khdair et al. 2009). Moreover, the introduction of 
magnetic components offers the possibilities of combining PDT with radiotherapy or 
hyperthermia (Chen and Zhang 2006, Zhang et al. 2008). Zhang et al. demonstrated the efficacy 
in vitro and in vivo of a novel nanosystem for combined PDT and photohyperthermia, using zinc 
phthalocyanine (ZnPc) as PDT agent loaded in single-wall carbon nanohorns with holes opened 
(SWNHox) conjugates with bovine serum albumin (BSA) to enhance NP biocompatibility. 
Recently, the development of the so called ‘upconversion nanoparticles’ seem to offers the 
opportunity to enhance the activation of PSs using deep penetrating light making PDT useful for 
the treatment of deep-seated tumours. PDT upconversion-based NPs, exploited the capability of 
upconversion elements to absorb light in the near infrared region (NIR, 700-1110 nm) having 
great penetration in tissue, and to re-emitted light at shorter wavelength in order to activated PSs 
loaded in the same nanovehicles (Chatterjee and Yong 2008, Cui et al. 2012). However, even if 
the efficacy of upconversion NPs have been demonstrated in vitro and in vivo (Idris et al. 2012), 
the safe biomedical use of upconverting elements need to be further assessed before starting 
clinical trials (Chen and Zhao 2012). 
Nanoparticles as drug delivery system for m-THPC 
Several studies reported the successful loading of m-THPC in different type of NPs including 
liposomes (Buchholz et al. 2005, Pegaz et al. 2006, Lasalle et al. 2009, Kiesslich et al. 2007), 
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micelles (Hofman et al. 2008, Shieh et al. 2010, Syu et al. 2012), nanocapsules (Bourdon et al.
2002), silica-based NPs (Yan and Kopelman 2003), human serum bovine based polymers (HSA) 
NPs (Wacker et al. 2010), pH-sensitive methacrylate-based NPs (Peng et al. 2010), calcium 
phosphate NPs (Klesing et al. 2010), and their ability to deliver the PS to cancer cells both in 
vitro and in vivo.
In the European project called “Nanophoto”, of which the work of this thesis is part, the main 
purpose was the design of one or more nanosystems for the improvement of efficiency and 
selectivity of m-THPC-based PDT and m-THPC fluorescence-based diagnosis of cancer. For this 
purpose, three different types of nanovehicles were selected, namely, liposomes, poly-(D,L-
lactide-co-glycolide) (PLGA) NPs, and silica NPs, that for their different chemical 
characteristics could differently affect biodistribution and biocompatibility of the drug. The 
prolonged circulation in the blood and improved biodistribution of NPs, biocompatibility and 
selective accumulation in tumours, are ideally guaranteed by the stealth-like features of these 
PEGylated nanocarriers and by their specific targeting to cancer cells. In the following 
paragraphs each type of drug delivery system is described with some hints on the state of the art, 
general chemical features and synthesis processes, potential advantages/disadvantages in m-
THPC delivery. 
Liposomes 
Liposomes are extensively investigated as drug carriers since 50 years, due to their high 
biocompatibility and versatility of drug entrapment, being artificial spherical vesicles composed 
of phospholipid bilayers surrounding an internal aqueous space. Therefore, they can carry both 
hydrophilic and hydrophobic drugs entrapped in the aqueous space or within the phospholipid 
bilayer, respectively. Thus, liposomes are suitable nanocarriers also for the hydrophobic m-
THPC and may offer the opportunity of creating a m-THPC formulation guaranteeing improved 
drug bioavailability and less side effects when compared to the currently used formulation 
Foscan®.
Biolitec, the producer/distributor of Foscan®, developed two m-THPC liposomal formulations, 
Foslip® and Fospeg® made respectively of non PEGylated and PEGylated liposomes. 
Both formulations are dipalmitoylphosphatydilcholine/dipalmitoylphosphatydilglycerol 
(DPPC/DPPG) based unilamellar liposomes in which m-THPC is only physically entrapped in 
the bilayers during synthesis using the conventional film method followed by extrusion 
(Bangham and Lea 1978).
Several studies reported the improvement of m-THPC PDT using liposomal formulations with 
respect to Foscan®. The comparative pharmacokinetics in mice with an HT29 tumour model,
showed more rapid accumulation and slightly higher selectivity for tumour and muscle for 
Foslip® compared to Foscan® but also lower blood concentration indicating faster biodistribution 
and clearance of liposomal m-THPC. D’Hallewin and colleagues studied Foslip®-PDT in a 
mouse mammary carcinoma and found low and inhomogeneous tumour accumulation of drug at 
short times with a maximun 24 h post-injection as a consequence of m-THPC release from 
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liposomes. Drug release from liposomes and redistribution of m-THPC to serum components 
was studied in vitro by Reshetov et al. who reported faster drug release from Fospeg® than from 
Foslip®, as confirmed in Paper I and Paper II of this thesis. Despite faster m-THPC release, 
improved PDT efficiency using Fospeg® was reported by Pegaz et al. in an in vivo preclinical 
study with a chicken chorioallontoic membrane (CAM) model. They measured significantly 
higher photothrombic activities on CAM model using Fospeg® with respect to Foslip®.
Accordingly, Buchholz et al. treated with PDT spontaneous feline squamous cell carcinoma in 
vivo and reported higher drug bioavailability, shorter biodistribution half-life and improved 
selectivity for Fospeg® compared to Foscan®. In addition, it has been reported that the delivery of 
m-THPC using liposome formulations limited the dark cytotoxicity of the drug at least in vitro
(Berlanda et al. 2010, Kiesslich et al. 2007). Hence in this compelling context, the advantages of 
using three different formulations of Fospeg® with different density and thickness of the PEG 
layer has been evaluated in comparison to Foscan® in vitro (see Paper I). Further, attempts were 
made to improve the selectivity of Fospeg®-PDT by conjugating liposomes with folic acid to
target ovarian cancer cells in vitro (see Paper II). 
Poly-(D,L-lactide-co-glycolide) (PLGA) NPs  
The use of biodegradable polymeric NPs as carriers for PSs has been widely investigated, with 
several polymers and methods of synthesis that can be selected based on the physicochemical 
characteristics of the incorporated drug. A definition of polymeric NPs classified them as 
submicron (<1000 nm) colloidal systems made of solid polymers. These NPs are generally 
classified in nanocapsules and nanospheres, with the drug entrapped in a liquid core or 
entrapped/adsorbed on the surface of the polymeric matrix, respectively. For drug delivery 
applications, polyesters as poly(lactic acid) (PLA) and copolymers as poly(lactic-co-glycolic 
acid) (PLGA) are the mostly used since they have been approved for use in humans by FDA and 
by EMA. It is expected that PLGA hydrolysis proceeds within the body, and that the metabolites 
lactic acid and glycolic acid enter Krebs cycle, minimizing systemic toxicity (Kumari et al.
2010). PLA is used less than PLGA for the synthesis of NPs for medical applications because its 
degradation rate is lower (Danhier et al. 2012). The degradation rate can vary from several 
months to years and can be easily modulated during the design of NPs because it strictly depends 
on the molecular weight and ratio of the copolymers (Vert et al. 1994). Despite the high
versatility of composition and surface modification (e.g. addition of PEG, poloxamer, 
poloxamine, chitosan to impart stealthy properties and/or addition of targeting moieties for 
selective drug delivery), two main pitfalls limited the efficacy of PLGA NPs as delivery systems:
the poor drug loading (usually around 1%) and the release of the drug. The latter was largely 
documented by Kumari et al. that identified five mechanisms of drug release from polymeric 
NPs that are determined by the polymers used and the drug loading. Thus, if the drug is adsorbed 
on NP surface can desorb, while if the drug is entrapped in the NP core can diffuse through the 
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polymer matrix and escape from NPs. In addition to diffusion, drug release can be triggered by 
the erosion of the NP matrix due to degradation.
Different methods of PLGA NPs preparation have been reported; the drug can be incorporated in 
the NPs during synthesis or can be adsorbed on NPs after the synthesis. For the preparation of 
NPs containing hydrophobic drugs two methods are generally considered: the emulsification-
solvent evaporation technique and nanoprecipitation method. Using the first technique, which is 
based on the formation of an emulsion in which polymers and drugs are solubilised in an organic 
solvent, several PS-loaded NPs have been prepared, as for example PLGA NPs containing ZnPc 
(Ricci-Júnior and Marchetti 2006, Fadel et al. 2010), meso-tetra(p-hydroxyphenyl)porphyrin 
(mTHPP) (Vargas et al. 2009), In(III)-meso-tetraphenylporphyrin (InTPP) (Da Silva et al. 2009) 
and have been tested for PDT-efficacy in vitro and in vivo. Regarding the nanoprecipitation 
method, Paper III is the first published report on PS-loaded PLGA NPs synthesized using this 
method. The synthesis of bare or PEGylated m-THPC-loaded PLGA NPs, has been successfully 
accomplished (Kocbek et al. 2010), by dissolving PLGA or/and PEG-PLGA copolymers and m-
THPC in acetone and slowly injecting the resulting solution into a Poloxamer 188 water solution 
to form NPs. Non incorporated drug and excess of stabilizer were removed by NP dispersion,
and centrifugation followed by resuspension in trehalose and freeze drying.
The loading of m-THPC in bare PLGA NPs was reported also by Löw group, which compared 
accumulation and PDT-induced toxicity of such NPs to Foscan® in human colon carcinoma cells.
In Paper III, the photo-physical characterization, PDT efficiency in vitro and fluorescence-based 
imaging in vivo of bare and, for the first time PEGylated m-THPC PLGA NPs, are reported.
ORganically MOdified SILica (ORMOSIL) NPs 
Among ceramic nanomaterials, silica NPs and ORMOSIL NPs have been exploited as useful PS 
delivery systems because they are chemically inert, not susceptible to swelling or changes with 
varying pH, or vulnerable to microbial attack (Weetall 1970). Particle dimension, shape, mono-
dispersibility and porosity can be controlled during the simple process of synthesis that requires 
ambient temperature conditions (Couleaud et al. 2010). The porosity of silica matrix allows the 
molecular oxygen diffusion through the pores and interaction with the irradiated PS while the 
produced 1O2 can diffuse out to exert cytotoxicity and this does not require the release of PS 
once the NPs are inside the cells. Therefore, the PS can be either physically entrapped within the 
silica matrix or covalently linked to the matrix to avoid the release of the PS before 
internalisation into the target cell. 
Silica NPs are synthesized by the base-catalyzed polymerization of silicon alkoxides (pure silica) 
or of organosilane precursors (ORMOSIL NPs) in an ethanol-water solution (Stöber protocol) 
(Stöber et al. 1968), or in reverse microemulsions (Osseo-Asare and Arriagada 1999), or in 
aqueous micellar solutions (Prasad method) (Roy et al. 2003, Roy et al. 2005). 
In 2003 the group of Prasad reported a new method for the entrapment of the PS 2-devinyl-2-(1-
hexyloxyethyl)pyropheophorbide (HPPH) in ORMOSIL NPs, synthesized in the non polar core 
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of micelles by hydrolysis of triethoxyvinylsilane (Roy et al. 2003). They demonstrated that the 
encapsulated PS maintained the ability to produces 1O2 upon irradiation and that PS loaded NPs 
taken up by UCI-107 and Hela cells, were able to induce cytotoxicity after PDT. In 2007, the 
same group reported the covalent incorporation of HPPP in ORMOSIL NPs, without alteration 
of PS spectroscopic and photophysical properties (Ohulchanskyy et al. 2007).
Regarding m-THPC, the first example of loading this PS in Stöber-like silica NPs was reported 
in 2003 by Yan and Kopelman that also reported higher production of 1O2 for NP-embedded PS 
than for PS in solution. More recently, our group (Compagnin et al. 2009) reported on the 
physical entrapment of m-THPC in ORMOSIL NPs synthesized with the Prasad’s method.
Interestingly, we reported that the monomeric NP-entrapped m-THPC was able to produce 1O2
with high efficiency but, when NPs were incubated in the presence of serum, the PS was rapidly 
transferred to serum proteins. PS delivery and PDT efficiency of m-THPC NPs compared to 
Foscan® were studied in vitro in KYSE-510 cells, showing comparable cytotoxic effects upon 
irradiation notwithstanding the 50% reduced uptake of NPs. In the same work we reported that 
PEGylation of NPs is a strategy to limit m-THPC escape from NPs by decreasing protein 
absorption. In any case, the release can be completely prevented only with the covalent linking 
of the PS to the silane matrix. Thus, since PEGylation revealed itself an efficient strategy to 
limited NP-proteins interactions, within Nanophoto project the group of Prof. Mancin (Chemical 
Science Department, Padova University) developed a one-pot procedure to synthesize highly 
PEGylated ORMOSIL NPs (Rio-Echevarria IM et al. 2010). In vitro studies confirmed the 
stealthy features of these NPs compared to non-PEGylated NPs, as documented by reduced 
macrophage capture.
NP preparation procedure consists in the ammonia-catalyzed co-polymerization of vinyltriethoxy 
silane (VTES) and PEG-silane derivatives in an aqueous solution of a non-ionic surfactant 
(Brij35) and n-butanol. The easy and controlled synthesis, as well as fast purification procedure 
using surfactant-removing resin, offers potential large scale preparation. In addition, the use of 
VTES offers a low polarity NP interior that favours the inclusion of hydrophobic drugs while 
PEG-silane derivatives can be easily functionalized for the bioconjugation of NPs. Thus, the 
potentialities offer by PEG ORMOSIL NPs has been explored in Paper IV, with the synthesis of 
covalently linked m-THPC NPs carrying different targeting agents (folic acid, RGD peptide, 
Cetuximab antibody) for targeted PDT. In additional, a toxicological profile of empty PEGylated 
ORMOSIL NPs against cancer and normal cells in vitro is reported for the first time in Paper V. 
Safe use of NPs as drug delivery systems 
In addition to nanomedicine, nanotoxicology is growing up in order to address the potential 
adverse health effects caused by nanomaterials (Donaldson et al. 2004). To this purpose 
nanotoxicology analyzes NP physicochemical determinants, routes of exposure, nanoparticulate 
biodistribution, interactions with/and effects on cellular components, and dictates the use of 
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robust test protocols for nanomaterial risk assessment for human and environment (Lewinski et 
al. 2008). The knowledge of the toxicological profiles of nanosized materials is of fundamental 
importance especially in the case of medical applications in which NPs are directly ingested or 
injected but also unintentional exposure (e.g. occupational, environmental) to NPs may represent 
a serious danger. Health risks are very likely related to the unusual physicochemical properties of 
engineered nanomaterials determined by small size (surface area and size distribution), chemical 
composition (purity, cristallinity, electronic properties), surface structure (surface reactivity, 
surface groups, inorganic/organic coatings), solubility, shape and aggregation. Thus, this 
combination of effects may generate adverse biological responses in living cells otherwise not 
seen with the bulk materials (Nel et al. 2006). Especially the extremely small size of NPs, which 
determines the high surface area to volume ratio with an increased numbers of potential reactive 
groups, renders them highly harmful toward biological systems (Arora et al. 2012). In addition, 
the effects of particle size can be further modified by surface coating and treatments, and by 
particle aggregation. Therefore, it is possible that contrary to monodisperse NPs, aggregates 
exert toxicity, even if for general assumption smaller particles easily enter and pass through 
tissues, cells and organelles (Fadeel and Garcia-Bennet 2010). 
Nanomaterials can enter the body by intentional or non intentional routes. Intravenous 
administration, inhalation, oral, intraperitoneal, dermal, and subcutaneous exposure represent the 
main route of entrance of NPs into the organism. Intravenously, administered NPs have been 
found to be distributed in various organs such as colon, lungs, bone marrow, liver, spleen and 
lymphatic system, even if their distribution is followed by their clearance from systemic 
circulation by macrophages of liver and spleen (Hagens et al. 2007). Even in the case of 
inhalation, NP distribution in lungs, hearth, liver, spleen and brain occurs, while clearance is 
promoted especially in the alveolar region via phagocytosis by macrophages facilitated by 
chemotactic attraction of alveolar macrophages in the site of NP deposition (Garnett and 
Kallinteri 2006). Interestingly, Oberdörster et al. calculated that the average half-life of NPs in 
the human respiratory tract is about 700 days. NPs administered orally distribute mainly in the 
kidneys, liver, spleen, lungs, brain and gastrointestinal tract, where NPs pass through and are 
absorbed in the systemic circulation and eliminated with feces and urines. Regarding NPs 
administered via intraperitoneal injection, they can cross transplacental membrane or peritoneal 
cavity into uterus, affecting embryo development and even causing embryo death (Vega-Villa et 
al. 2008). Dermal exposure to nanomaterials, which occurs in the occupational environment as 
well as during the intentional application of topical creams and drug treatments, can lead to NP 
penetration in the dermis and translocation to the systemic circulation via lymphatic system and 
regional lymph (Oberdörster et al. 2005).
It is well accepted that the interaction of nanomaterials with biological tissue culminates in free 
radicals generation and oxidative stress is the best-developed paradigm to explain cytotoxic 
effects (Shvedova et al. 2005, Nel et al. 2006). The extent of ROS generation depends on size, 
shape and aggregation state of NPs but also surface coating, metal impurities or experimental 
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conditions (e.g. UV light exposure) can contribute to trigger oxidative stress. One of the direct 
consequences of oxidative stress is the activation of an inflammatory response through the 
activation of pro-inflammatory signalling cascades (e.g. mitogen-activated protein kinase 
(MAPK) and nuclear factor κB (NF- κB) cascades) (Curtis et al. 2006). NP-promoted ROS can 
react with DNA, proteins, carbohydrates and lipids leading to genotoxicity, protein denaturation, 
lipid peroxidation and finally to cell death via apoptosis or necrosis. In addition, nanomaterials 
can display antigenicity, evoking immunogenic response due to their intrinsic characteristics 
or/and to the complexes that they form with cellular biomolecules. Thus, the cytotoxic profile of 
nanomaterials is highly dependent on the microenvironment conditions and is determined by NP 
opsonization by serum components, NP surface modification by absorbed proteins or lipids such 
as albumin and surfactants (Unfried et al. 2007). The NP-corona, which can be constituted by the 
adsorption of over 3700 plasma proteins, is continuously modified in the biological fluids and is 
highly dependent on protein concentrations and protein affinity for NPs (Lynch and Dawson 
2008). Beyond affecting NP internalization, proteins interacting with the large surface area of 
NPs can be modified or denatured, with consequent mal-functioning which in turn may lead to 
pathogenesis (Borm and Kreyling 2004). Thus, since the numbers of new nanosized materials is 
increasing exponentially while toxicological aspects are not adequately addressed, there is the 
urgent need of standard protocols for in vitro and in vivo evaluation of cytotoxicity in order to 
guarantee a safe use of nanotechnology products. In vitro studies using different cell lines 
present several advantages such as i) the assessment of primary effects on target cells without 
secondary effects caused by inflammation or physiological and compensatory factors, ii) 
efficiency, iii) rapidity, iv) cost-effectiveness, v) reduction of variability between experiments vi) 
reduced requirement of test materials vii) models for the design of subsequent whole animal 
studies (Huang et al. 2010, Takhar and Mahant 2011, Arora et al. 2012). However, the 
experimental condition used for the in vitro assays (i.e. cell type, differentiation status, 
incubation carried out in the presence/absence of serum, time of NP exposure, etc) may influence 
the toxicological profile of a nanomaterial. Hence, in vitro studies represent the starting point for 
the knowledge of nanomaterial interaction with biological systems, knowledge that require 
further evaluation in vivo in animal models and possibly in whole ecosystems. 
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Aim of the thesis 
The overall aim of this thesis is the in vitro characterization of the cytotoxicity and the delivery 
efficiency of 3 different nanosystems loaded with the second generation photosensitizer meta-
tetra(hydroxyphenyl)chlorin (m-THPC), used for photodynamic therapy (PDT) of cancer. Thus, 
in 4 of the 5 papers collecting the work of this thesis the potentialities and limits of using 
liposomes (Paper I, II), poly-(D,L-lactide-co-glycolide) nanoparticles (PLGA NPs) (Paper III)
and ORganically Modified SILica nanoparticles (ORMOSIL NPs) (Paper IV) as m-THPC 
nanocarriers are critically discussed. In addition, in Paper V the potential adverse health effects 
of using ORMOSIL NPs for medical applications were investigated in vitro in different lung cell 
models. 
Firstly, un-targeted PEGylated nanovehicles were synthesized and characterized for their PDT 
efficiency in vitro and secondly the potentialities of targeted PDT were evaluated by the 
functionalisation of PEGylated liposomes (Paper II) and ORMOSIL NPs (Paper IV) with 
selected targeting agents (folic acid, RGD peptide, Cetuximab antibody). 
The suitability of the three delivery systems as nanocarriers of m-THPC and associated PDT 
efficiency was evaluated with: 
-measurements of photochemical and photophysical properties of m-THPC in nanovehicles with 
respect to m-THPC in the standard solvent (Paper I, III, IV).
-investigations of nanovehicles PEGylation influences on m-THPC intracellular delivery and 
cytotoxicity (Paper I, III).
-measurements of intracellular uptake and localization of m-THPC delivered by nanoparticles 
with respect to m-THPC delivered in the standard solvent (Paper I, III, IV) 
-investigations of targeted nanosystem selective uptake in cells over-expressing receptors able to 
be recognized by the targeting agents (Paper II, Paper IV). 
-evaluation of phototoxic effects (PDT in vitro) of m-THPC delivered by un-targeted NPs 
(Paper I, III) and targeted NPs (Paper II, IV). 
The toxicological profile of ORMOSIL NPs was evaluated in normal and cancer lung cells by 
performing: 
- in vitro tests for the measurement of cell viability and cytotoxicity. 
-genome-wide studies of gene expression alteration using Agilent microarray. 
-investigations of NP intracellular uptake using fluorescence-based imaging techniques or 
electron microscopy techniques (scanning electron microscopy and transmission electron 
microscopy. 
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Meta-tetra(hydroxyphenyl)chlorin-loaded liposomes sterically stabilised with
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cellular uptake and phototoxicity
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We studied the effects of density and thickness of PEG coating on in vitro cellular uptake, and dark- and
photo-toxicity of liposomal formulations (Fospeg) of the photodynamic agent meta-tetrahydroxyphenyl
chlorin (m-THPC). The cellular uptake of various Fospeg formulations was determined by flow
cytometry in CCD-34Lu human normal fibroblasts and A549 lung cancer cells. Dark and light-induced
cytotoxicity was measured by MTS assay after exposure to increasing concentrations of Fospeg only
and followed by irradiation with red light. Intracellular localization of m-THPC delivered by Fospeg
was determined by fluorescence microscopy. The studies were carried out in comparison with m-THPC
delivered by the standard solvent. In the dark all Fospeg formulations were less cytotoxic than m-THPC
in standard solvent (ethanol/poly(ethylene glycol 400/water; 20 : 30 : 50 by vol.) and cytotoxicity
decreased by increasing PEGylation. m-THPC delivered as Fospeg was internalised by endocytosis and
localised mainly in the Golgi apparatus and endoplasmic reticulum. The efficiency of cellular uptake of
Fospeg was reduced by 30–40% with respect to m-THPC in standard solution causing a slight reduction
of the phototoxicity but without serious impairment of the efficacy of the treatment. Our study suggests
that PEGylated liposomes are promising nanocarriers for the delivery of photosensitisers for
photodynamic therapy because they reduce dark cytotoxicity while preserving therapeutic efficacy.
Introduction
It is well established that photodynamic therapy (PDT) is a
valuable method for treatment of a number of oncological, der-
matological and ophthalmological diseases.1,2 PDT is based on the
light-activation of a photosensitising molecule that localises in the
diseased tissue andproduces reactive oxygen species (ROS),mainly
singlet oxygen, to induce cell death.3 These cytotoxic species are
short lived and cannot diffuse far from the site of production,
therefore the tissue damage is limited to the proximity of their site
of production. PDT is becoming widely accepted and has been
approved for the treatment of several types of solid tumours.Meta-
tetra(hydroxyphenyl)chlorin (m-THPC, temoporfin) is one of the
most potent second generation photosensitisers and is approved
aDepartment of Biology, University of Padova, via U. Bassi 58/B, 35121,
Padova, Italy. E-mail: elena.reddi@unipd.it; Fax: +39 049 8276300;
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bDepartment of Biological Chemistry, University of Padova, via U. Bassi
58/B, 35121, Padova, Italy
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dResearch &Development Biolitec AG, Otto-Schott-Strasse 15, 07745, Jena,
Germany
† These authors contributed equally to the study
in Europe for the palliative treatment of patients with advanced
head and neck cancers.4,5 Clinical trials have shown that basal
cell carcinomas,6 pancreatic7 and prostate cancers8 can also be
treated successfully with PDT. While the clinical benefit of PDT
has been demonstrated, various strategies are being considered to
optimise its efficacy and selectivity. In the past, various delivery
systems have been proposed to overcome the problems related to
the administration of the hydrophobic photosensitisers9 and in
this context liposomes were particularly useful for their capacity
to solubilise such molecules in their phospholipid bilayer. The
major draw-back of these conventional liposomes is the rapid
clearance fromplasma caused by the recognition and uptake in the
phagocytic cells of the reticulo-endothelial system (RES) following
systemic administration.10 Stealth or long-circulating liposomes,
having the surface coated with a hydrophilic polymer, which
prevents the adsorption of blood plasma opsonins and recognition
by macrophages, appear to be promising delivery systems for
targeting the tumour, passively taking advantage of the enhanced
permeability and retention (EPR) effect.11,12 It is expected that
hydrophobic photosensitisers can be administered in the form
of highly photoactive monomers by using stealth liposomes as
delivery vehicles, which should also lead to more efficient and
selective targeting of the tumour. Hopefully, the increased and
This journal is © The Royal Society of Chemistry and Owner Societies 2011 Photochem. Photobiol. Sci., 2011, 10, 1751–1759 | 1751
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ita
 d
i P
ad
ov
a 
on
 0
4 
N
ov
em
be
r 2
01
1
Pu
bl
is
he
d 
on
 2
6 
A
ug
us
t 2
01
1 
on
 h
ttp
://
pu
bs
.rs
c.
or
g 
| d
oi
:1
0.
10
39
/C
1P
P0
51
63
F
View Online / Journal Homepage / Table of Contents for this issue
41
selective accumulation of the photosensitiser in the target tissue
should allow the administration of lower doses of drug with fewer
side effects, in particular less skin photosensitivity.
The method largely used for the production of stealth nanopar-
ticles and liposomes is based on the coating of their surface with
poly(ethylene glycol) (PEG), which is inert and biocompatible.13
Pre-clinical studies using the chick chorioallantoic membrane
model showed that m-THPC encapsulated in PEGylated lipo-
somes (Fospeg) exhibited a rate of extravasation similar to that
of conventional liposomes (Foslip) but the phototrombic activity
was much higher, making the Fospeg a suitable formulation for
the treatment of choroidal neovascularisation associated with
age-related macular degeneration.14 PEGylated liposomal m-
THPC was also proven to be suitable for the PDT treatment of
rheumatoid arthritis, due to more favourable accumulation in the
inflamed arthritic joints in comparison to m-THPC in standard
solvent or non-PEGylated liposomes.15 Buchholz et al.16 reported
that the plasma concentration and bioavailability were approx.
3 times higher with the PEGylated liposomes compared to the
standard formulation ofm-THPC. The superior pharmacokinetic
properties resulted in a more favourable response to PDT of
feline squamous carcinomas. Thus, it appears that PEGylated
liposomesmay be a useful tool to increase the therapeutic response
to PDT in various pathological situations. In this context, we
felt it was important to establish how the density and thickness
of the PEG corona could affect the stability of the m-THPC
liposomal formulation and its ability to deliver the photosensitizer
to cultured cells. In this paper, we report the characterisation of
several liposomal formulations of m-THPC (Fospeg) in which the
PEG length and density was varied. Furthermore the efficiency of
uptake of various Fospeg formulations in normal and cancer cells,
as well as cytotoxicity in the dark and after irradiation with red
light are reported in comparison with m-THPC delivered to the
cells in the standard solvent.
Experimental
Materials
Rhodamine–DPPE [1,2-dipalmitoyl-sn-glycero-3-phospho-
ethanolamine-N-(lissamine rhodamine B sulfonyl)] was purcha-
sed from Avanti Polar Lipids (Alabaster, USA). DPPC [1,2-Dip-
almitoyl-sn-glycero-3-phosphocholine]; DPPG [1,2-dipalmitoyl-
sn-glycero-3-phosphoglycerol]; mPEG-750-DSPE [N-(carbonyl-
methoxypolyethyleneglycol 750)-1,2 distearoyl-sn-glycero-3-phos-
phoethanolamine]; mPEG-2000-DSPE [N-(carbonyl-methoxy-
polyethyleneglycol 2000)-1,2 distearoyl-sn-glycero-3-phospho-
ethanolamine]; and mPEG-5000-DSPE [N-(carbonyl-
methoxypolyethyleneglycol 5000)-1,2 distearoyl-sn-glycero-3-pho-
sphoethanolamine] were purchased from Genzyme Phar-
maceuticals (Liestal, Switzerland). Temoporfin (m-THPC)
[3,3¢,3¢¢,3¢¢¢-(2,3-dihydroporphyrin-5,10,15,20-tetrayl)tetraphe-
nol] was provided by Biolitec AG (Jena, Germany). Rhodamine
123 (R123), N-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-
s-indacene-3-pentanoyl)sphingosine (BODIPY R© FL C5-
ceramide), LysoTracker Green DND-26 and ER-TrackerTM
Green (glibenclamide BODIPYR© FL) were purchased from
Invitrogen Molecular Probes (Milan, Italy). Bicinchoninic acid
(BCA) assay was from Pierce (Rockford, IL). The CellTiter
96R© Aqueous One Solution Cell proliferation Assay (MTS) was
from Promega Co (Madison, WI, USA). Genistein, filipin III,
chlorpromazine hydrochloride, amiloride, 5-(N,N-dimethyl)-
hydrochloride were obtained from Sigma-Aldrich (St. Louis, MO,
USA). Solvents and commercially available reagents were used as
received.
Preparation and characterization of m-THPC liposomal formu-
lations (Fospeg). Liposomes were prepared by the conventional
film method. m-THPC was dissolved in an organic solution of
phospholipids (chloroform/methanol). This mixture was dried to
a thin film at 50 ◦C using the rotary evaporator. The obtained
film was kept under vacuum (1 mbar) for 2 h at room temperature
and afterwards flushed with nitrogen. The film was then hydrated
with 10 mM histidine buffer pH 6.5 with 5% glucose for 30
min. Afterwards the liposome dispersion was extruded through
polycarbonatemembranes of different pore sizes (400 nm, 200 nm,
100 nm). Liposomal size was measured by Photon Correlation
Spectroscopy (PCS) with a Zetasizer Nano S90 from Malvern
InstrumentsGmbH (Herrenberg,Germany).m-THPC concentra-
tion was determined byUV-Vis spectroscopy. In Table 1, we report
the list and composition of the Fospeg preparations considered in
this study.
For the photophysical studies, Fospeg 2%-2000 and Fospeg
8%-2000 stock solutions were diluted in 10 mM histidine buffer,
containing 5% glucose at pH 6.5, to give a 0.5 mM m-THPC
concentration. The m-THPC loading was the same for both
formulations with a dye : lipid ratio of 13.3. Comparative studies
were carried out in dimethyl sulfoxide (DMSO, Sigma–Aldrich,
UK) at the same m-THPC concentration.
Cell cultures. The cell line A549, derived from human lung
carcinoma, and the human normal lung fibroblasts CCD-34Lu
were obtained from American Type Culture Collection (ATCC,
Rockville, USA). The cells were maintained at 37 ◦C in a humid-
ified atmosphere containing 5% CO2. A549 cells were cultured
in F-12 K medium supplemented with 10% heat-inactivated
foetal bovine serum (FBS) (Gibco, Invitrogen, Milan, Italy),
Table 1 Composition of the Fospeg liposomal formulations
Formulation DPPC DPPG mPEG-750-DSPE mPEG-2000-DSPE mPEG-5000-DSPE m-THPC
Fospeg 2%-2000 18.0 2.0 — 2.0 — 1.5
Fospeg 8%-750 18.0 2.0 3.7 — — 1.5
Fospeg 8%-2000 18.0 2.0 — 6.8 — 1.5
Fospeg 8%-5000 18.0 2.0 — — 14.1 1.5
Values are in mg ml-1 of the preparation after extrusion. Watery phase in all formulations: 10 mM histidine buffer with 5% glucose. The concentrations
of mPEG-DSPE correspond to 2 or 8 mol% of total phospholipids.
1752 | Photochem. Photobiol. Sci., 2011, 10, 1751–1759 This journal is © The Royal Society of Chemistry and Owner Societies 2011
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2 mM L-glutamine, 2.5 g l-1 sodium bicarbonate, 38 units ml-1
streptomycin and 100 units ml-1 penicillin G (Sigma-Aldrich).
CCD-34Lu cells were grown in Dulbecco’s Modified Eagle’s
Medium (DMEM) with 3.7 g l-1 sodium bicarbonate, 4.5 g l-1
glucose, and supplemented with 38 units ml-1 streptomycin and
100 units ml-1 penicillin G, 0.1 mM MEM non essential amino
acids, 0.02 M HEPES and 10% FBS. A549 and CCD-34Lu cells
have a doubling time of 22 and 24 h, respectively.
Photophysical characterisation
Absorption spectra were measured using a Perkin–Elmer Lambda
25 UV/Vis spectrometer (Perkin–Elmer, Beaconsfield, UK) with
quartz cuvettes. Fluorescence emission spectra were measured
using a LS50B Perkin–Elmer spectrofluorimeter (Perkin–Elmer,
Beaconsfield, UK). Spectra were acquired using a multimode
bifurcated fibre-optic probe to provide front surface excita-
tion/detection geometry, which is unaffected by polarization
effects, unlike the conventional orthogonal excitation/detection
configuration. Fluorescence lifetimes were measured using the
time-correlated single photon counting method (TCSPC). For the
fluorescence studies, dilute solutions were employed with an m-
THPC concentration of 0.5 mM.The light source for TCSPCwas a
405 nm picosecond laser diode (EPL-405, Edinburgh Instruments
Ltd., Livingston, UK) with a pulse duration of 90 picoseconds,
and a 5 MHz repetition rate. Fluorescence was detected using
a fast multialkali photomultiplier module (model H5773-04,
HamamatsuPhotonicsUKLtd,Hertfordshire,UK) via a longpass
filter (OG510, Schott, Stafford, UK) and a monochromator
(model M300, Bentham Instrument Ltd, Berkshire, UK). A Lyot
depolarizer (Thorlabs Ltd, Ely, UK) was used to minimise any
fluorescence polarization effects. TCSPC was carried out using a
PC-mounted board (TimeHarp100, PicoQuant GmbH, Berlin,
Germany) and lifetimes were derived using FluoFit software
(PicoQuant GmbH, Berlin, Germany). The Instrument Response
Function (IRF) was obtained from a non-fluorescent scattering
Ludox R© solution (Sigmal–Aldrich, Gillingham, UK). Optimum
fitting with minimisation of the residuals was confirmed using a
chi-squared value c2 < 1.4.
Dark and photo toxicity of m-THPC delivered by standard solvent
or by Fospeg
For the dark cytotoxicity experiments A549 and CCD-34Lu cells
were seeded in 96-well plates (3000 cells well-1) in 200 ml of culture
medium (F-12 K and DMEM, respectively) supplemented with
10% FBS. After 24 h the medium was removed and replaced
with 150 ml of fresh medium containing 3% FBS and increasing
concentrations of m-THPC delivered in free form by standard
solvent (ethanol/poly(ethylene glycol) 400/water; 20:30 : 50, by
vol.) or by liposomal formulations (Fospeg). Before the addition
to the cells, Fospeg was diluted 1 : 10 in sterile water and then 1 : 2
in culture medium added with 3% FBS. The cells were incubated
in the dark and cell viability was measured with MTS test after 24
h of treatment (24 h) as well as after 24 h of treatment followed
by additional 24 h in which the cells were kept in m-THPC-free
medium containing 10% FBS (24 + 24 h). For MTS assay the
cell medium was replaced with 100 ml of serum-free medium and
20 ml of CellTiter 96R© Reagent and the wells were incubated for
1.5 h at 37 ◦C. The absorbance at 492 nm was measured with
Biotrak II (Amersham, GE Healthcare, NJ, USA) plate reader
and the viability of treated cells was expressed as percentage of the
absorbance of control cells that was taken as 100% viability.
The in vitro phototoxic effect ofm-THPC delivered by standard
solvent or Fospeg was evaluated in A549 cells. The cells were
seeded in 96-well plates and incubated for 24 h at 37 ◦C in the dark
with increasing and non toxic concentrations of m-THPC (0.25–
1.5 mM) as determined with the experiments of dark toxicity. At
the end of the incubation time, cells were washed twice with 150 ml
of PBS with Ca2+ andMg2+, and irradiated in PBS with 0.24 J cm-2
of red light (600–700 nm) emitted from a Waldmann PDT 1200
lamp (Waldmann Medizintechnik, Germany). The fluence rate at
level of the cell monolayer was 12 mW cm-2, as measured with
the radiometer IL 1700 (International Light, Newburyport, MA).
Immediately after irradiation the cells were brought back to the
incubator after replacement of PBS with fresh medium containing
10% FBS. Cell viability was measured with the MTS test after
additional 24 h.
Cellular uptake of m-THPC delivered by standard solvent or
Fospeg
A549 or CCD-34Lu cells (105) were seeded in 2 ml of complete
medium in 35 mm diameter tissue culture dishes. After 24 h, the
cells were incubated with increasing concentrations of m-THPC
(0.25–1.75mM),deliveredby standard solvent orFospeg, in culture
medium supplementedwith 3%FBS.After 24 h of incubationwith
m-THPC the cellswerewashed twicewith 2ml of versene, detached
with 500 ml of trypsin (Gibco) that was neutralized with the
addition of 200 ml of FBS. Cells were centrifuged and resuspended
in 700 ml of versene before measuring m-THPC fluorescence by
flow cytometry with a BD FACSCantoTM II (Becton Dickinson,
San Jose, California, USA) instrument. The blue laser at 488 nm
was used as the excitation source and wavelengths longer than
670 nm (PerCP channel) were used for the detection of the
m-THPC fluorescence. 105 events sample-1 were acquired and
analyzed with the FACSDiva Software. The uptake of m-THPC
in A549 cells was also determined as a function of the incubation
time, up to 24 h, with 1mMm-THPC in standard solvent or Fospeg
8%-2000. The uptake of Fospeg 8%-2000 (1.5 mM m-THPC) was
also measured after 2 h of incubation in the presence of 3 and 10%
FBS or without FBS.
To study the effect of the incubation temperature on the uptake
of 1 mM m-THPC in standard solvent and Fospeg 8%-2000,
A549 cells were incubated at 4 ◦C and 37 ◦C and then analyzed
by flow cytometry. Furthermore, cell samples were preincubated
(30min)with selected inhibitors of endocytosis before the addition
of m-THPC to the culture medium. The inhibitors tested were:
chlorpromazine hydrochloride (10 mg ml-1), filipin III (5 mg
ml-1), amiloride, 5-(N,N-dimethyl)-hydrochloride (34 mg ml-1)
and genistein (54 mg ml-1). For these experiments the cells were
incubated with m-THPC for 2 h.
Quantification of cellular uptake of m-THPC
For selected concentrations of m-THPC in standard solvent and
Fospeg 8%-2000, the data of cellular uptake measured by flow
cytometry were validated with the traditional chemical extraction
This journal is © The Royal Society of Chemistry and Owner Societies 2011 Photochem. Photobiol. Sci., 2011, 10, 1751–1759 | 1753
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method. After 24 h incubation with 0.5 or 1 mM m-THPC, A549
cells were washed twice with 2 ml of PBS with Ca2+ and Mg2+ and
lysed with 800 ml of 2% sodium-dodecyl sulfate (SDS). Cell lysates
were kept under magnetic stirring for 1 h before measuring the m-
THPC fluorescence with a fluorescence spectrophotometer (Cary
Eclipse). The intensity of the fluorescence emission spectrum of
m-THPC in the 600–800 nm range (lmax em = 652 nm)was registered
after excitation with 420 nm light. The m-THPC concentrations
in the cell lysates was calculated from calibration plots built
up with known m-THPC concentrations. The solutions for the
calibration plot were prepared by adding known amounts of m-
THPC from stocks in standard solution or in Fospeg to aliquots of
lysate obtained from cells not incubated with the photosensitizer
and containing the same amounts of cellular protein as the
samples. The protein content of the cell lysates was measured
by the bicinchoninic acid (BCA) assay and was used to express
the m-THPC uptake in cells as nmoles of m-THPC mg-1 of
proteins.
Fluorescence microscopy
The intracellular localization of m-THPC in A549 cells was
determined by fluorescence microscopy taking advantage of its
red fluorescence. 105 cells were seeded in complete medium in
35 mm diameter tissue culture dishes containing a glass coverslip.
After 24 h, the cells were incubated at 37 ◦C for 5 h with
fresh F-12 K medium supplemented with 3% FBS and 1.5 mM
m-THPC delivered by standard solvent or Fospeg 8%-2000.
The intracellular localization of the PEGylated liposomes was
determined in cells incubated with liposomes with the same
composition as Fospeg 8%-2000 and labeled with the fluorescent
phospholipid rhodamine–DPPE. At the end of the incubation
time, the cells were washed twice with 2 ml of PBS and observed
with the Olympus IMT-2 microscope equipped with a refrigerated
CCD camera (Micromax, Princeton Instruments) and a 75 W
xenon lamp. Fluorescence images obtained with 60¥ 1.4 NA
oil immersion objective (Olympus) were acquired and analyzed
with the imaging software Metamorph (Universal Imaging). The
cellular distribution of the fluorescence ofm-THPCor rhodamine-
DPPE was compared with that of R123, LysoTracker Green
DND-26, BODIPY R© FL C5-ceramide and ER-TrackerTM Green,
used asmarkers formitochondria, lysosomes,Golgi apparatus and
endoplasmic reticulum, respectively. R123 (0.2 mM), Lysotracker
Green (75 nM), BODIPY R© FL C5-ceramide (5 mM) and ER-
TrackerTM Green (1 mM)were added to the cell monolayers 15 min
before completing the incubation with m-THPC or fluorescent
liposomes. For the m-THPC fluorescence detection a set of filters
with 400 nm excitation and 620 nm emission were used, whereas
475 nm excitation and 520 nm emission were used for the other
probes.
Results
Characterisation of Fospeg formulations
Each liposomal formulation used during this study was prepared
with the same method and identical devices. The composition
of each formulation as determined after extrusion is reported in
Table 1.
To evaluate particle size and storage stability, sizemeasurements
were carried out after extrusion and after storage at 25 ◦C
for 6 months. Directly after extrusion, the mean particle size
(PCS z-average) of the liposomes was between 105 and 125 nm.
Polydispersity indices (PDI) were between 0.04 and 0.15 in all
cases, indicating narrow size distributions.
The liposomes have been found to be stable with respect to
size and optical appearance over the storage time of 6 months. A
small decrease in size (about 5%) was only detected in liposomes
containing PEG 2000 or 5000, whereas the PEG 750 preparations
have been found to be completely stable in size. Further, no drug
precipitates or aggregates were observed in light microscopy.
Fluorescence spectroscopic studies
The fluorescence emission spectra and lifetimes were recorded for
the liposomes at 2 and 8% PEGylation and identical m-THPC
loading diluted in buffer. Peak emission using 423 nm excitation
was recorded at 652 nm in each case but a higher peak intensitywas
noted for the 8% PEGylation: the ratio of fluorescence intensities
for the solutions containing 8 vs. 2% PEGylated liposomes was
1.25. Peak absorption in the Soret band was at 423 nm for both
liposomes.
In DMSO, a mono-exponential decay was observed with a
lifetime of 9.6 ns. In liposomes, multi-exponential decays with
significantly shorter lifetimes were observed for the PEGylated
liposomes. Using tri-exponential fitting, both 2% and 8% PEGy-
lated liposomes exhibited long lived lifetime components of 7.3
and 9.8 ns, respectively but the pre-exponential factor (normalized
to unity) was significantly larger at 0.22 for 8% compared with
0.02 for 2% PEGylation. For a mono-exponential decay, the pre-
exponential factor or effectively the ‘weighting’ is unity, whereas
for multi-exponential decays the sum of various pre-exponential
factors is unity. Therefore pre-exponential factors of 0.22 and 0.02
for these longer lifetimes show that they are minor components in
the decay profile. Both liposomes exhibited two similar short-lived
lifetime components with comparable pre-exponential factors:
for 2% PEGylation, 2.5 and 0.9 ns with corresponding pre-
exponential factors of 0.53 and 0.45, and for 8% PEGylation,
3.0 and 1.1 ns with pre-exponential factors of 0.35 and 0.43.
Dark cytotoxicity of Fospeg vs. m-THPC in standard solvent
TheFospeg formulations listed in Table 1 were used to evaluate the
cytotoxicity of liposomal m-THPC in the dark toward the A549
tumour cells and theCCD-34Lu normal fibroblasts in comparison
to m-THPC in standard solvent. The cells were incubated with
concentrations of m-THPC up to 5 mM for 24 h. The MTS
test showed that all formulations were non-toxic to the cells
with m-THPC concentrations lower than 1 mM. However, higher
concentrations ofm-THPC caused a reduction of the cell viability
thatwas dependent on the concentration and the formulation. Five
micromolar m-THPC in standard solvent reduced the viability of
both cell lines to about 20% (Fig. 1, A and C) at 24 h and close
to zero, especially in CCD-34Lu, at 24 + 24 h (Fig. 1, B and
D). All liposomal formulations were less toxic than the m-THPC
standard and the decreased toxicity was dependent on the degree
of PEGylation. Fospeg 2%-2000 reduced the viability of A549
cells to about 70% at 24 and 24 + 24 h and to about 30% in
1754 | Photochem. Photobiol. Sci., 2011, 10, 1751–1759 This journal is © The Royal Society of Chemistry and Owner Societies 2011
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Fig. 1 Viability of A549 (A, B) and CCD-34Lu (C, D) cells after exposure to m-THPC standard formulation and different Fospeg formulations. Cell
viability was measured byMTS assay at the end of 24 h of incubation in the dark (24 h) with increasing concentrations ofm-THPC, delivered by standard
formulation or Fospeg (A, C), and 24 h after the release in m-THPC-free complete medium (24 + 24 h) (B, D). Data are presented as means ± S.D. (n =
9) from three independent triplicate experiments. A and B: ◦, p < 0.01 vs. Fospeg 8%-5000; ***, p < 0.001 vs. Fospeg 2%-2000, 8%-2000, -750, -5000. C
and D: ◦◦◦, p < 0.001 vs. Fospeg 8%-2000, -750, -5000; ***, p < 0.001 Fospeg 2%-2000, 8%-2000, -750, -5000 (Student t test).
CCD-34Lu fibroblasts. Cell toxicity was abolished when PEGyla-
tion was increased to 8% with PEG ranging from 750 to 5000.
Cellular uptake of Fospeg vs. m-THPC in standard solvent
The uptake of m-THPC delivered as Fospeg in comparison to
standard formulation was determined in A549 cells and CCD-
34Lu fibroblasts after 24 h of incubation in mediumwith 3% FCS.
The uptake studies were performed with m-THPC concentrations
up to 1.75 mM because below this concentration none of the
formulations showed dark toxicity at 24 h (Fig. 2). The relative
amount of m-THPC taken up by the cells was determined by
flow cytometry. The data showed less uptake (about 30%) of m-
THPC in the CCD-34Lu in comparison to A549 cells with all
formulations. In both cell lines the uptake of m-THPC delivered
with the Fospeg formulations reached or approached a plateau
as with Fospeg 2% 2000, at concentrations above 1.5 mM while
the uptake steadily increased with the standard formulation. This
difference could suggest a different modality of m-THPC uptake
with the standard formulation in comparison to Fospeg or the
presence of scarcely fluorescent aggregates of m-THPC in the
Fospeg formulations with the consequent underestimate of its
intracellular concentration when measured by flow cytometry.
To rule out the latter possibility, in selected samples of cells
incubated with Foscan or Fospeg, cell lysates were analysed by
spectrofluorimetry to determine the intracellular concentration of
m-THPC. The results (Table 2) confirmed that, especially at the
high concentrations, m-THPC standard formulation is taken up
more efficiently than Fospeg.
In A549 cells, we measured the time-dependent uptake of m-
THPC standard formulation and Fospeg 8%-2000 and found that
uptake of m-THPC in standard solvent steadily increased with
time while with Fospeg was biphasic. At short times the rate of
uptake of Fospeg was lower than that of free m-THPC standard
Table 2 Uptake in A549 cells of 0.5 and 1 mM m-THPC delivered with
standard formulation, Fospeg 2%-2000 and Fospeg 8%-2000 quantified by
the chemical extraction method
nmol m-THPC/mg cell proteins
Formulation m-THPC 0.5 mM m-THPC 1 mM
Standard 0.62 ± 0.02 1.52 ± 0.27
Fospeg 2%-2000 0.46 ± 0.01 0.90 ± 0.02
Fospeg 8%-2000 0.52 ± 0.09 0.94 ± 0.18
The cellular uptake was determined after 24 h of incubation at 37 ◦C
in culture medium containing 3% FBS and expressed as nmoles of m-
THPC mg-1 of cell proteins. The data represent means ±S.D. from three
independent experiments.
This journal is © The Royal Society of Chemistry and Owner Societies 2011 Photochem. Photobiol. Sci., 2011, 10, 1751–1759 | 1755
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Fig. 2 Cellular uptake of increasing concentrations of m-THPC delivered by standard formulation or Fospeg in A549 (A) and CCD-34Lu (B) cells.
Flow cytometry was used for measuring m-THPC fluorescence signals after 24 h of incubation. Data are presented as means ± S.D. (n = 3) from three
independent experiments. *, p < 0.05; **, p < 0.005; ***, p < 0.001 compared to m-THPC in standard solvent (Student t test).
formulation and a plateau could be detected around 7 h, but later
the uptake raised again with no sign of plateau up to 24 h (Fig. 3).
Fig. 3 Time-dependent uptake in A549 cells of 1 mM m-THPC in
standard solvent or Fospeg 8%-2000. The uptake was measured by flow
cytometry at various times up to 24 h of incubation. Data are presented as
means ± S.D. from three independent experiments.
In the absence of FBS in the incubation medium the uptake
of Fospeg 8%-2000 was about twice that in the presence of
3% FBS and about three times higher than with 10% FBS
(Table 3).
The uptake of Fospeg 8%-2000 and freem-THPC was inhibited
by about 95% by lowering the temperature from 37 ◦C to
4 ◦C during the incubation, suggesting that the internalisation
Table 3 Uptake in A549 cells of m-THPC (1.5 mM) delivered as Fospeg
8%-20000 in absence and presence of 3 and 10% FBS
FBS (%) m-THPC fluorescence (a.u.)
0 3299 ± 116
3 1776 ± 532
10 1130 ± 71
The intracellular uptake was determined by flow cytometry after 2 h
of incubation at 37 ◦C. The data represent means ± S.D. from three
independent experiments.
of both formulations occurred via endocytosis. The addition
of 10 mg ml-1 of chlorpromazine, an inhibitor of the clathrin-
mediated endocytosis, to the cell medium 30 min before start-
ing the incubation, reduced the uptake of free m-THPC and
Fospeg 8%-2000 by about 30 and 20%, respectively. On the
contrary, the addition of filipin III or genistein, used as in-
hibitors of the caveolae-mediated endocytosis, and amiloride,
an inhibitor of macropinocytosis, did not reduce the uptake
of free m-THPC or Fospeg 8%-2000 in A549 carcinoma cells
(data not shown).
Fluorescence microscopy studies
Fluorescence microscopy analyses of A549 cells incubated for 5 h
with 1.5 mM m-THPC standard formulation or Fospeg 8%-2000
showed an intracellular distribution of m-THPC fluorescence,
which co-localised with that of BODIPY R© FL C5-ceramide and
ER-TrackerTM Green (Fig. 4), indicating that the Golgi apparatus
and endoplasmic reticulum were the major sites of localisation of
m-THPC. In the cells incubated with Fospeg 8%-2000 in absence
of FBS, the intracellular localisation of m-THPC was the same as
in cells incubated in presence of 3 or 10%FBS (not shown). PEGy-
lated liposomes with the same composition as in Fospeg 8%-2000
and containing rhodamine–DPPE were used to assess the intra-
cellular localisation of the liposomes in comparison to m-THPC.
After 5 h of incubation at 37 ◦C the liposome fluorescence ap-
peared punctuated throughout the cytoplasm and colocalisedwith
LysotrackerGreen suggesting an endosome/lysosome localisation
(Fig. 5).
Phototoxicity of Fospeg formulations vs. m-THPC in standard
solvent
The phototoxicity of the Fospeg formulations was determined
in A549 carcinoma cells in comparison with free m-THPC in
standard solvent. The cells incubated with 0.25–1.5 mM m-THPC
for 24 h were irradiated with 0.24 J cm-2 of red light. The
dose-response curves (Fig. 6) showed that the tested Fospeg
formulations had very similar phototoxic effects on A549 cells
and were slightly less phototoxic than free m-THPC. The lower
1756 | Photochem. Photobiol. Sci., 2011, 10, 1751–1759 This journal is © The Royal Society of Chemistry and Owner Societies 2011
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Fig. 4 Subcellular distribution of the red fluorescence ofm-THPC (1.5 mM) delivered as Fospeg 8%-2000 (B, F and J) in A549 cells after 5 h of incubation
at 37 ◦C. The m-THPC fluorescence co-localised with the green fluorescence of BODIPYR© FL C5-ceramide(C) and ER-TrackerTM Green (G), but not
with LysoTracker Green DND-26 (K), used respectively as markers for the Golgi apparatus, endoplasmic reticulum and lysosomes. The Differential
Interference Contrast images of cells are shown in A, E and I; the merge images for each probe are shown in D, H, and L.
Fig. 5 Localisation in A549 cells of PEGylated liposomes with the same phospholipid composition as Fospeg 8%-2000 and labeled with
rhodamine-DPPE. The punctuated red fluorescence of the rhodamine–DPPE (B) co-localised (merge image D) with that of LysoTracker Green DND-26
(C), used as marker for lysosomes. The differential interference contrast image of cells is shown in A.
Fig. 6 Light-induced toxicity in A549 cells. Cells were irradiated with
0.24 J cm-2 of red light (600–700 nm) after 24 h incubation with increasing
doses of m-THPC in standard solvent or Fospeg. Cell viability was
measured 24 h post-irradiation by MTS assay and expressed as mean
percentage ± S.D. (n = 12) with respect to untreated and unirradiated
control cells. ◦◦◦, p < 0.001 vs. Fospeg 8%-2000 and -5000; **, p < 0.005;
***, p < 0.001 Fospeg 2%-2000 and 8%-750 (Student t test).
phototoxicity correlated with the lower uptake of the liposomal
m-THPC in comparison to the free form.
Discussion
One of the ideal properties of a photosensitising agent for the
PDT of tumours is low toxicity in the absence of light. For this
reason, we have tested the dark toxicity of the Fospeg formulations
towards A549 carcinoma cells and CCD-34Lu normal fibroblasts
in vitro.We had already reported that freem-THPC in the standard
formulation is toxic to oesophageal carcinoma cells in the dark
at concentrations above 1.75 mM.17 Here, we found a similar
threshold of dark toxicity in two other cell lines and confirmed
that m-THPC can cause cell death without irradiation at rather
low concentrations. In this context, the findings reported here on
the dark toxicity of Fospeg appear particularly interesting. We
have found that all Fospeg formulations with 8% PEGylation did
not cause any toxicity to the cells up to them-THPC concentration
of 5 mM (Fig. 1). On the contrary, Fospeg with a lower degree of
PEGylation (2%) exhibited some dark toxicity especially to CDD-
34Lu fibroblasts. In any case, the cytotoxicity of Fospeg 2%-2000
was much reduced in comparison to free m-THPC. Lower dark
cytotoxicity of m-THPC liposomal formulation in comparison to
Foscan was reported also by Kiesslich et al., who tested Foslip,
the non PEGylated liposomal formulation ofm-THPC, on biliary
tract cancer cells.18 Similarly, Berlanda et al. found that a Fospeg
formulation was less toxic than Foscan to epidermoid carcinoma
This journal is © The Royal Society of Chemistry and Owner Societies 2011 Photochem. Photobiol. Sci., 2011, 10, 1751–1759 | 1757
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cells, but the characteristics of the PEG layer coating the liposome
surface were not reported.19 Our data suggest that the length of
PEG chains had no influence on dark toxicity of Fospeg while the
increasing density of PEG layer coating the liposomes decreased
the cytotoxicity. Because of the loss of stability of the liposomal
vesicles in Fospeg formulations with a degree of PEGylation
higher than 8%, we could not test the effects of higher levels of
PEGylation. The much lower toxicity of Fospeg in comparison
to m-THPC in standard solvent may be attributed to multiple
factors. The lower uptake of m-THPC in Fospeg formulation in
comparison to standard solvent certainly accounts for the lower
toxicity. In fact a significantly lower uptake ofm-THPCwas found
in A549 and CCD-34Lu cells after 24 h of incubation with Fospeg
in comparison to the standard formulation. Both flow cytometry
(Fig. 2) and chemical extraction (Table 2) showed reduced uptake
of Fospeg. The reduction was concentration dependent and
increased by increasing concentrations of m-THPC. In A549 cells
the uptake of Fospeg was reduced by 25–30% and about 40% at,
respectively, 0.5 and 1 mM m-THPC. However, the lower uptake
of m-THPC does not fully explain our dark toxicity data because
the uptake of Fospeg 2%-2000 was not significantly different from
that of Fospeg 8%PEGbut its toxicity was higher. Thus, it appears
that the increasing level of PEGylation of liposomes diminishes
the dark toxicity of m-THPC. The different kinetics of cellular
uptake of Fospeg vs. m-THPC standard formulation may also
have an effect on dark toxicity of m-THPC. Our studies showed
that the uptake of Fospeg was biphasic and slower than that of free
m-THPC (Fig. 3), suggesting some differences in their modality
of cell internalisation. Kiesslich et al.18 reported that the kinetics
of Foslip and extent of cellular uptake in the presence of FBS
were very similar to Foscan and concluded that, in both cases
m-THPC attached to the serum components that mediated its
cellular uptake. The coating of the liposomes with a layer of PEG
should limit the interaction with serum proteins and increase the
probability that the photosensitiser can enter the cells while still
encapsulated in the liposomes.
The fluorescence lifetime data indicate that the m-THPC fluo-
rescence is strongly quenched in the liposomes, in comparison to
monomeric m-THPC, which exhibits a longer mono-exponential
lifetime of 9.6 ns in DMSO. The results are consistent with
the occurrence of fluorescence self-quenching due to dimerisa-
tion in combination with energy-transfer between adjacent m-
THPC monomers and weakly fluorescent aggregates within the
liposomes. These time-resolved data are in accordance with the
steady-state studies reported by Reshetov et al.,20 who observed
lower fluorescence yields whenm-THPCwas incorporated in both
PEGylated (Fospeg 2%-2000, as used here) and unPEGylated
liposomes (Foslip). We also studied m-THPC in Fospeg 8% and
observed higher fluorescence emission by a factor of 1.25 over
that from the same concentration of m-THPC in the Fospeg
2% solution. Although the fluorescence lifetimes are multi-
exponential, the higher fluorescence efficiency of m-THPC in
Fospeg 8% appears to correlate with the higher pre-exponential
factor observed for the long-lived lifetime component with Fospeg
8%.
Since m-THPC is water-insoluble it should reside within the
liposomal membrane but it has recently been suggested that
some partitioning of m-THPC may also occur in the PEGylated
coating of the liposomes.20 The higher degree of PEGylation
for Fospeg 8% may favour more partioning of m-THPC to this
layer.Multi-exponential fluorescence decays usually arise from the
presence of aggregates as well as monomers and/or the presence
of different microenvironments. In the latter case, the measured
pre-exponential factors would then correlate with the relative
concentrations or populations of the fluorophore in the different
microenvironments. From the fluorescence lifetime analysis, the
significantly higher pre-exponential factor (0.22) observed for the
long-lived lifetime component (9.8 ns) for Fospeg 8% could be
explained by the presence of a higher relative population of m-
THPC dispersed within the PEGylated layer either as aggregates
or more likely in monomeric form. Our studies were carried out
at 25 ◦C, which, as noted by Reshetov et al.,20 should promote
more partitioning into the PEGylated layer compared to 37 ◦C.
However, further studies using much lower m-THPC loading
would be required before drawing any firm conclusion.
We have previously reported that PEGylation of ORMOSIL
nanoparticles limits the release of the physically entrapped m-
THPC17 and a similar effect could be expected also for liposomes.
Contrary to this hypothesis, it was found that about 40% of m-
THPCwas releasedmore rapidly fromFospeg 2% than fromFoslip
and only the remaining fraction redistributed much slower.20 We
found that the time-dependent cellular uptake of Fospeg 8% is
biphasic and this might be explained by the initial slow uptake
of m-THPC still entrapped in the liposomes while the second
fast wave of uptake could depend on m-THPC that with time
escaped from liposomes and associated to serum proteins. The
fluorescence microscopy studies performed with the fluorescent
labelled liposomes (rhodamine–DPPE) suggest that at least some
liposomes enter the cells and localise in the endosomal/lysosomal
compartments, as shown by their colocalisation with LysoTracker
Green (Fig. 5). Fospeg is a DPPC-based liposomal formulation
with a phase transition temperature of 41 ◦C and liposomes are
stable also in the presence of serum proteins. In this connection,
Pegaz et al., in their studies on the chick chorioallantoicmembrane
model, found that the extravasation of m-THPC delivered with
Fospeg was strongly reduced when compared to Visudyne R©,
which is based on more fluid lipids, namely dimyristoylphos-
phatidylcholine and egg yolk phosphatidylglycerol.14 The authors
concluded that the leakage of m-THPC from Fospeg was slow
and its transfer to serum proteins delayed. Our studies also
suggest that, following liposome internalisation, m-THPC was
promptly released and localised mainly in the Golgi apparatus
and endoplasmic reticulum (Fig. 4) as reported for other types
of cells.18,21 In fact, the red fluorescence of m-THPC co-localized
with the green fluorescence of BODIPY R© FL C5-ceramide and
ER-TrackerTM but not LysoTracker Green as did the fluorescence
of the labelled phospholipid (Fig. 4 and 5). The images of Fig. 4
and 5 were acquired after 5 h of incubation but a very similar
m-THPC localisation was found at shorter and longer (up to
24 h) incubation times. Some uptake experiments with Fospeg
8%-2000 were carried out in the absence of FBS and showed
a very efficient uptake of m-THPC (Table 3). It is reasonable
to assume that, because of its lipophilicity, in the absence of
FBS, m-THPC was internalised only entrapped in the PEGylated
liposomes, but, also in this case, was localised (not shown) in the
Golgi apparatus and endoplasmic reticulum, confirming its release
from liposomes after internalisation. The presence of FBS clearly
inhibited the uptake of m-THPC delivered as Fospeg (Table 3),
1758 | Photochem. Photobiol. Sci., 2011, 10, 1751–1759 This journal is © The Royal Society of Chemistry and Owner Societies 2011
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suggesting some competition for m-THPC binding, interactions
between liposomes and serum components, possible release of
m-THPC to serum components and consequent cellular internal-
isation as serum protein complexes. With increasing incubation
time, the m-THPC uptake mediated by serum proteins prevails
over the uptake mediated by liposomes that takes place at the
beginning of the incubation. In all cases the internalisation of m-
THPC occurred via endocytosis because at 4 ◦C the process was
inhibited by 95%. The reduced m-THPC uptake in the presence
of chlorpromazine, an inhibitor of clathrin-mediated endocytosis,
suggested that some m-THPC enters the cells with this type of
endocytosis.
The A549 carcinoma cells were irradiated with red light (0.24
J cm-2) following incubation with increasing concentrations of
m-THPC in the various formulations. As expected based on the
uptake of m-THPC delivered by the different formulations (Fig.
2), a slightly lower phototoxic effect was found with Fospeg in
comparison to standard formulation (Fig. 6). The LD50 for free
m-THPCwas approx 0.5 mMwhile it was in the range of 0.75–0.85
mM for the Fospeg formulations with no significant differences
among the various types of Fospeg.
Conclusions
We have shown that Fospeg formulations with a degree of
PEGylation up to 8% are stable over time with respect to the size
of the liposomes and the content ofm-THPC. The in vitro cellular
studies demonstrated that the uptake of Fospeg was lower than
that of m-THPC in standard solvent but the photo-toxicity was
only slightly reduced. On the contrary, the dark toxicity of Fospeg
was strongly reduced especially with the formulations containing
8% PEG. These findings suggest that PEGylated liposome-based
formulations are promising for the delivery of photosensitising
drugs, such asm-THPC, to cancer cells. Future investigations with
tumor-bearing animals will define pharmacokinetic properties, in
vivo PDT efficacy and side effects of Fospeg with respect to m-
THPC in standard formulation and further assess their potential
benefit for clinical PDT.
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Folate-targeted PEGylated liposomes improve the
selectivity of PDTwith meta-tetra(hydroxyphenyl)-
chlorin (m-THPC)†
Francesca Moret,a Dietrich Scheglmannb and Elena Reddi*a
The folate receptor (FR) is over-expressed in many human tumours and is being intensively studied also
in the field of nanomedicine as a target to enhance the selectivity of drug delivery to cancer cells by
using nanocarriers bearing folic acid (FA) on their surface. In this study we report the encapsulation of
the photosensitizer (PS) meta-tetra(hydroxyphenyl)chlorin (m-THPC) in FA-targeted PEGylated liposomes
used as a novel drug delivery system for photodynamic therapy (PDT) of cancer. Our in vitro investigations
revealed that only a modest fraction of targeted liposomes were internalized by specific endocytosis in
FR-positive KB cells. However, FA-liposomes doubled the uptake of the entrapped m-THPC with respect
to un-targeted liposomes and enhanced the photo-induced cytotoxicity in KB cells. In contrast, in FR-
negative A549 cells FA-targeted or un-targeted liposomes exhibited a very similar extent of internaliza-
tion and as a consequence the same photo-killing efficiency.
Introduction
Photodynamic therapy (PDT) is a clinically approved, mini-
mally invasive therapeutic procedure that can induce cytotoxic
effects in tumour tissues with some selectivity.1 PDT is based
on the administration of a photosensitizer (PS) which displays
no detectable toxicity in the absence of light but, after acti-
vation with light of suitable wavelengths, generates highly reac-
tive oxygen species, inducing oxidative damage mainly in the
cellular compartments of PS accumulation.2 Currently, PDT is
applied for the treatment of different types of solid tumours as
well as some non-cancerous diseases, such as age-related
macular degeneration, endometriosis,3 and microbial infec-
tions.4 Unlike conventional cancer treatments, PDT does not
cause major systemic toxicity; however, it has some important
limitations that prevent PDT from becoming a more widely
established method for treating cancer. Following systemic
administration, PSs accumulate in the tumour as well as in the
normal tissues and cause prolonged skin photosensitivity.5 In
addition, most of the PSs for PDT exhibit low water solubility
that makes drug delivery difficult and impairs efficacy because
of the formation of aggregates with poor photoactivity.6 In
recent years, it appears that the development of various types
of nanocarriers as delivery systems for photosensitizing agents
can bring substantial improvement of PDT outcome.7–11
Following intravenous administration, properly engineered
nanocarriers can accumulate selectively in tumours, which
have relatively “leaky” vasculature, and deliver high concen-
trations of PS photoactive monomers.12 Based on this a
number of PSs encapsulated in a variety of biodegradable or
non-biodegradable nanocarriers were investigated. Hydro-
phobic PSs such as 5,10,15,20-tetrakis(meso-hydroxyphenyl)
porphyrin (m-THPP) and silicon phthalocyanine (Pc4) loaded
in the internal core of biodegradable synthetic polymeric
micelles were highly phototoxic to cancer cells while micelles
without PS did not show cytotoxicity.13,14 Protoporphyrin IX
(PpIX) encapsulated into chitosan nanoparticles or PEG–
polypropylene imine dendrimers was more phototoxic both
in vitro and in vivo than free PpIX.15,16 Non-biodegradable,
silica-based or gold nanoparticles were also investigated and
are considered promising nanocarriers of hydrophobic
PSs.17,18
meta-Tetra(hydroxyphenyl)chlorin (m-THPC, temoporfin,
trade name Foscan®) is a highly potent second generation PS
approved, in Europe and in Japan, for the palliative treatment
of patients with advanced head and neck cancers. m-THPC
was efficiently loaded in micelles,19,20 organically modified
silica nanoparticles,21 poly-(D,L-lactide-co-glycolide) (PLGA)
nanoparticles22 and liposomes and all these nanosystems
could deliver the drug to cancer cells.23–25 However, liposomes
were shown to be particularly suitable for the encapsulation of
large amounts of the hydrophobic m-THPC within their lipid
†Electronic supplementary information (ESI) available. See DOI:
10.1039/c3pp25384h
aDepartment of Biology, University of Padova, via Ugo Bassi 58/B, 35121 Padova,
Italy. E-mail: elena.reddi@unipd.it; Fax: +39 049 8276300; Tel: +39 049 8276335
bBiolitec Research GmbH, Otto-Schott-Strasse 15, 07745 Jena, Germany
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bilayer without altering its photo-physical properties. Lipo-
somes also showed long-term stability and suitability for the
addition of a poly(ethylene glycol) (PEG) corona.26 The PEG
coating sterically stabilises the liposomes, minimises the
adhesion of opsonins and the recognition and clearance by
the macrophages of the reticuloendothelial system (RES).27,28
Recently, decreased pro-coagulant activity of PEGylated vs.
non-PEGylated liposomes has been also reported,29 indicating
that PEGylation is a successful strategy to increase the lipo-
some biocompatibility in addition to circulation lifetimes in
the blood stream.
Previously, we have reported on the characterization,
in vitro uptake and phototoxicity of m-THPC loaded in lipo-
somes sterically stabilised with PEG (Fospeg®).30 Compared to
Foscan®, Fospeg® decreased significantly the dark cytotoxicity
of m-THPC and decreased to a minor extent the cell photo-
killing efficiency. In vivo, Fospeg® showed improved biodistri-
bution and tumour uptake leading to higher tumour necrosis
after PDT, in comparison to Foscan®.31 The increased selectiv-
ity was explained with the passive targeting of the tumour by
the PEGylated liposomes exploiting the enhanced permeability
and retention (EPR) effect.32 Despite the substantial improve-
ment of PDT with m-THPC using Fospeg® formulation, we
attempted to further optimise the delivery of m-THPC to
cancer cells by adding a targeting agent on the liposome
surface. This strategy allows the exploitation of active mechan-
isms of targeting with delivery of the drugs carried by the
nanocarriers specifically inside cancer cells or cells of the
tumour vasculature over-expressing receptors for the targeting
agents on their surface. To enable selective drug delivery to
cancer tissue, the ideal targeting ligand needs to bind recep-
tors that are homogeneously over-expressed by tumour cells or
tumour vasculature, but are poorly expressed in normal cells
and vasculature. The drug-loaded nanocarrier is then interna-
lized via receptor-mediated endocytosis.33 The most studied
and promising targets are transferrin receptors, folate recep-
tors (FR) and epidermal growth factor receptors (EGFR) for tar-
geting cancer cells and vascular endothelial growth factor
receptors (VEGFR), αvβ3 integrins, vascular cell adhesion mole-
cule-1 (VCAM-1) and matrix metalloproteinases (MMPs) for tar-
geting tumour vasculature.
The vitamin folic acid (FA) is very attractive as a targeting
molecule because it binds a high affinity receptor over-
expressed in about 40% of human tumours and absent in
most normal tissues.33 Furthermore, when compared to other
targeting agents, FA presents several advantages: (i) it is in-
expensive; (ii) it is not toxic or immunogenic; (iii) it is stable,
and (iv) it can be easily coupled to the surface of nanocarriers
properly functionalised or can be conjugated to PS with the
aid of suitable spacers. Schneider et al. conjugated FA to 4-car-
boxyphenylporphyrin via a short PEG spacer and showed that
the conjugate accumulated 7-fold more efficiently than the free
porphyrin in FR-overexpressing KB cells and induced more
efficient cell photo-killing.34 The in vivo studies carried out by
Gravier et al. demonstrated that a m-THPC-like PS conjugated
to FA with the same PEG spacer accumulated more efficiently
(∼2-fold) than the unconjugated PS in KB tumours with a
tumour to normal tissue ratio of 5 : 1 at 4 h post-injection.35
Similarly, pyropheophorbide a conjugated to FA via a short
peptide showed enhanced accumulation and PDT efficacy in
FR-positive KB cells with respect to FR-negative HT 1080 cells.
In vivo, the selective accumulation in KB tumours of the
construct carrying FA was confirmed by detection of the PS
fluorescence 24 h after injection; at this post-injection time no
fluorescence could be detected in normal tissues and HT 1080
tumours. Interestingly, the peptide inserted as a spacer favour-
ably modulated the PS biodistribution and this observation
makes this construct very promising for diagnosis and PDT.36
As the use of nanocarriers has emerged as a strategy to achieve
efficient and selective delivery of PSs in tumours, FA has been
exploited also as a homing molecule for carrying PS-loaded
nanocarriers into FR-overexpressing cancer cells. The FR-
mediated pathway allowed the cell internalisation of FA-conju-
gated liposomes loaded with a sulphonated phthalocyanine
unable to efficiently cross the plasma membrane of target
cells without a nanocarrier.37 FA-conjugated chitosan nano-
particles were developed for enhancing the selective delivery of
5-aminolaevulinic acid and the synthesis of PpIX in colorectal
cancers to facilitate their detection by an endoscopic fluore-
scence-based technique. Only in vitro data are reported
showing that the intracellular accumulation of PpIX correlated
with the expression of FR in the cell models used.38 Recently,
Syu et al. developed FA-conjugated polymeric micelles loaded
with m-THPC and showed accumulation in FR-overexpressing
KB cells in vitro and in vivo. The FA-conjugated delivery system
reduced skin photosensitivity and one third the usual dose of
m-THPC required to achieve in vivo the same PDT effect as
with free PS.20 NIR absorbing quantum dots have emerged
as an alternative to the existing organic PSs and it has
been reported that their conjugation to FA, using the short
PEG 2,2′-(ethylenedioxy)-bis-ethylamine as a spacer, signifi-
cantly improved photodynamic efficiency in FR-positive KB
cells but not in FR-negative HT 29 cells.39
In the present work, FA was used as a targeting ligand for
PEGylated liposomes with the aim to obtain selective delivery
of m-THPC to FR-overexpressing cells. The in vitro intracellular
uptake of FA-targeted PEGylated liposomes mediated by FR
was first assessed with liposomes labelled with carboxyfluore-
scein (CF) covalently linked to the lipid bilayer. Subsequently,
the uptake and photoactivity of m-THPC were defined by deli-
vering the drug via FA-targeted or un-targeted liposomes to FR-
positive KB cells and FR-negative A549 cells.
Experimental
Materials
DPPC [1,2-dipalmitoyl-sn-glycero-3-phosphocholine], DPPG
[1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol], DOPE [1,2-dio-
leoyl-sn-glycero-3-phosphoethanolamine], mPEG-750-DSPE
[N-(carbonyl-methoxypolyethyleneglycol 750)-1,2 distearoyl-
sn-glycero-3-phosphoethanolamine], and mPEG-5000-DSPE
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[N-(carbonyl-methoxypolyethyleneglycol 5000)-1,2 distearoyl-sn-
glycero-3-phosphoethanolamine] were purchased from
Genzyme Pharmaceuticals (Liestal, Switzerland) while FA-5000-
PEG-DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
FA(polyethylene glycol)-5000) and DOPE-CF [1,2-dioleoyl-sn-
glycero-3-phosphoethanolamine-N-(carboxyfluorescein)] were
purchased from Avanti Polar (Alabaster, AL, USA). Temoporfin
(m-THPC) [3,3′,3′′,3′′′-(2,3-dihydroporphyrin-5,10,15,20-tetrayl)-
tetraphenol] and liposomal formulations of m-THPC were pro-
vided by Biolitec Research GmbH (Jena, Germany). The CellTi-
ter 96® Aqueous One Solution Cell Proliferation Assay (MTS)
was from Promega Co. (Madison, WI, USA). Solvents and com-
mercially available reagents were used as received.
Preparation and characterization of liposomal formulations
All liposomal formulations were prepared by the conventional
film method followed by extrusion. In Table 1, we report the
list and the composition of the different preparations con-
sidered in this study. For liposomes containing m-THPC
(Fospeg), a chloroform solution of m-THPC and phospholipids
(DPPC, DPPG, DOPE, mPEG-750-DSPE, mPEG-5000-DSPE and
FA-5000-PEG-DSPE when required) was evaporated and the
lipid film was hydrated by adding 10 mM histidine buffer,
pH 6.5, with 5% (w/w) glucose for 30 min. Afterwards the lipo-
some dispersion was extruded through polycarbonate mem-
branes with pore sizes between 100 and 400 nm using an
EmulsiFlex-C5® or LiposoFast-extruder®. Carboxyfluorescein
doped liposomes (CF-liposomes), with phospholipid compo-
sitions as Fospeg, were prepared by adding DOPE-CF to the
mixture of phospholipids. Liposomal suspensions were charac-
terised by photon correlation spectroscopy (PCS) with a Zetasi-
zer Nano S90 from Malvern Instruments GmbH (Herrenberg,
Germany), by differential scanning calorimetry with a Pyris 1
instrument (Perkin Elmer, MA, USA) and by cryo-transmission
electron microscopy with a Philips CM 120 instrument (Eind-
hoven, The Netherlands). m-THPC and CF concentrations were
determined by UV-Vis absorption spectroscopy.
Cell cultures
A549 cells derived from a human lung carcinoma do not
express FR, while KB cells, derived via HeLa contamination,
express high levels of FR. Both cell lines were obtained from
American Type Culture Collection (ATCC, Rockville, MD, USA).
These cell lines were maintained at 37 °C in a humidified
atmosphere containing 5% CO2. A549 cells were cultured in
F-12K medium supplemented with 10% heat-inactivated
foetal bovine serum (FBS, Life Technologies, Milan, Italy),
38 units ml−1 streptomycin and 100 units ml−1 penicillin G
(Sigma-Aldrich, St. Louis, MO, USA). KB cells were grown in
modified Eagle’s medium (MEM, Life Technologies, Milan,
Italy) and supplemented with 38 units ml−1 streptomycin and
100 units ml−1 penicillin G and 10% FBS.
Cellular uptake of FA-targeted and un-targeted CF-liposomes
Preliminary uptake experiments were carried out with FA-
targeted and un-targeted CF-doped liposomes to assess the
involvement of FR in the uptake of the targeted liposomes. In
these liposomes the release of the fluorescent probe is avoided
by its covalent binding to phospholipids and therefore they
can be safely used for monitoring cellular entry and localis-
ation of liposomes. KB and A549 cells (105) were seeded in
35 mm diameter tissue culture dishes containing 2 ml of FA-
deficient RPMI medium (Life Technologies, Milan, Italy). After
24 h at 37 °C, the cells had reached the exponential phase of
growth and were incubated for 5 h with increasing concen-
trations of liposomes in a culture medium supplemented with
3% FBS or for different time periods (from 1 to 24 h) with a
liposome concentration equivalent to 11 μg ml−1 of phospholi-
pids. At the end of the incubation time the cell monolayers
were washed and detached from the plates with trypsin (Life
Technologies, Milan, Italy). Cells were centrifuged and re-sus-
pended in versene before measuring CF fluorescence by flow
cytometry using a BD FACSCanto™ II instrument (Becton
Dickinson, San Jose, CA, USA). The blue laser at 488 nm was
used as an excitation source and FITC channel was selected for
the detection of the CF fluorescence. Ten thousand events/
samples were acquired and analyzed with the FACSDiva soft-
ware. Competition experiments with 1 mM free folic acid
(Sigma-Aldrich, St. Louis, MO, USA) were carried out incubat-
ing the cells for 1 h prior to the addition of liposomes in order
to saturate FRs present on the cell surface.
Cellular uptake of FA-targeted and un-targeted Fospeg for-
mulations was determined by using incubation protocols as
described for CF-liposomes and measuring m-THPC fluore-
scence (PerCP channel of the flow cytometry) after 3 or 24 h of
incubation. The influence of serum proteins on the uptake of
targeted Fospeg was evaluated after 1 h of cell incubation in a
medium supplemented with 0, 3 or 10% FBS.
Table 1 Composition of the Fospeg liposomal formulations
Formulation DPPC DPPG mPEG-750-DSPE mPEG-5000-DSPE Folate-PEG5000-DSPE DOPE DOPE-CF m-THPC
FA-targeted CF-liposomes 18 2 4 — 1 — 1 —
Un-targeted CF-liposomes 18 2 4 1 — — 1 —
FA-Fospeg 18 2 4 — 1 1 — 1.5
Un-targeted Fospeg 18 2 4 1 — 1 — 1.5
Values are expressed in mg ml−1 of the preparation. The watery phase in all formulations is 10 mM histidine buffer with 5% of glucose. The
concentrations of mPEG-750-DSPE correspond to 8 mol% while mPEG-5000-DSPE or folate-PEG5000-DSPE (if present) corresponds to 0.5 mol%
of the total phospholipids.
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Confocal microscopy
KB cells incubated with FA-targeted or un-targeted CF-labelled
liposomes were visualized with a Leica SP5 confocal laser scan-
ning microscope (Leica Microsystems Srl, Milan, Italy) and the
images were analyzed with the ImageJ software. Twenty-four
hours before the experiments, 2 × 105 cells per sample were
seeded in 35 mm diameter tissue culture dishes containing a
glass cover slip. Cells were incubated for 5 h with CF-labelled
liposomes (11 μg ml−1 phospholipids) diluted in a medium
supplemented with 3% FBS. At the end of the incubation time,
cells were washed twice with PBS and fixed with 4% paraform-
aldehyde in PBS at 37 °C for 15 min. The fixed cells were
washed again three times with PBS in order to remove excess
formaldehyde. Cells were counterstained with 2 μg ml−1 DAPI
(4,6-diamidino-2-fenilindole) in antifade solution (Vectashield,
Vector Laboratories, Burlingame, CA, USA) and glass cover
slips were mounted.
Phototoxicity of m-THPC delivered by FA-targeted or un-
targeted liposomes (Fospeg)
The in vitro photodynamic efficiency of FA-targeted and un-
targeted Fospeg was evaluated in cells incubated with lipo-
somes for 3 h. KB and A549 cells were seeded in 96-well plates
(3000 cells per well) 24 h before starting the incubation. Cells
were incubated in the dark with increasing and not toxic con-
centrations of m-THPC (0.1 to 2 μM), delivered as Fospeg in a
culture medium supplemented with 3% FBS. At the end of the
incubation time, cells were washed twice with PBS with Ca2+
and Mg2+, and irradiated in PBS with 0.8 J cm−2 of red light
(600–700 nm) emitted from a Waldmann PDT 1200 lamp
(Waldmann Medizintechnik, Villingen-Schwenningen,
Germany). The fluence rate at the level of the cell monolayer
was 12 mW cm−2 as measured with a radiometer IL 1700
(International Light, Newburyport, MA, USA). Immediately
after irradiation the cells were brought back to the incubator
after replacement of PBS with fresh medium containing 10%
FBS and cell viability was measured with the MTS test after an
additional 24 h. For the MTS test the cell medium was
replaced with 100 μl of a serum-free medium and 20 μl of Cell-
Titer 96® Reagent and the wells were incubated for 1.5 h at
37 °C. The absorbance at 492 nm was measured with a Biotrak
II (GE Healthcare, Piscataway, NJ, USA) plate reader and the
viability of the treated cells was expressed as the percentage of
the absorbance of the control cells that was taken as 100%
viability.
Dose–response curves were determined as a function of the
light dose (from 0 to 2.4 J cm−2) for KB cells incubated for 3 h
with 3 selected doses of FA-targeted and un-targeted Fospeg
corresponding to m-THPC concentrations of 0.5, 0.75, 1 μM.
Statistical analysis
The Primer software for biostatistics (McGraw-Hill, Columbus,
OH, USA) was used for statistical analysis of the data. The data
are expressed as means ± standard deviations (SD) of at least 3
experiments. The differences between groups were evaluated
with the Student’s t-test and considered significant for
p < 0.05.
Results
Characterization of liposomal formulations
The composition of the formulations used in the present work
is reported in Table 1. The mean particle size (PCS z-average)
and the polydispersity indices (PDI) were measured directly
after liposome extrusion. CF-doped liposomes had a PCS
z-average between 97 and 117 nm whereas the PDI was
between 0.077 and 0.160. Fospeg formulations had a PCS
z-average between 105 and 122 nm whereas the PDI was lower,
between 0.061 and 0.056, indicating a very narrow size distri-
bution. Cryo-transmission electron microscopy images of a FA-
targeted Fospeg formulation confirmed the monodispersity of
liposome suspensions and indicated that no micellar struc-
tures were detectable (Fig. 1A). Each preparation of FA-targeted
liposomes was analysed by column chromatography to test if
free FA was present in the suspension. The analysis showed
that free FA was not detectable and confirmed the validity of
the used production procedure (Fig. 1B). CF-labelled lipo-
somes as well as liposomes in Fospeg were PEGylated on the
surface because they contained 8 mol% of PEG750 and
0.5 mol% of PEG5000 or FA-PEG5000, respectively, in the un-
targeted and targeted versions. The liposomes were found to
be stable with respect to size and optical appearance over the
storage time of 6 months.
Uptake of FA-targeted and un-targeted CF-liposomes
It was already reported that in the presence of serum proteins
an important fraction of m-THPC is released from non-
PEGylated (Foslip®) and PEGylated (Fospeg®) liposomes.30,41,42
Therefore to study the receptor-mediated uptake and to follow
the cell internalization of the FA-targeted liposomes, we pre-
pared CF-doped liposomes in which the fluorescent tracer was
covalently linked to one phospholipid of the bilayer
(DOPE-CF). The time-dependent and concentration-dependent
uptake of FA-targeted and un-targeted CF-liposomes
was measured by flow cytometry in KB and A549 cells. The
time-dependent uptake was measured with a CIF-liposome
Fig. 1 (A) Cryotransmission electron microscopy image of a representative FA-
targeted Fospeg formulation. (B) Column chromatography analysis of free folic
acid in a folate-decorated liposome sample, indicating the absence of released
targeting molecules.
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concentration of 11 μg ml−1 of phospholipid; that with Fospeg
corresponds to a m-THPC concentration of 1 μM, frequently
used in in vitro uptake and phototoxicity studies. The time-
dependent studies showed that in KB cells liposome internaliz-
ation was very fast, especially for FA-targeted liposomes,
during the first 5 h and then tended to a plateau (Fig. 2). The
highest ratio (1.94) for FA-targeted vs. un-targeted liposomes
was measured after 1 h, it remained around 1.8 until 5 h and
decreased to 1.2 at 24 h very likely because of a higher contri-
bution of non-specific uptake. In A549 cells, the uptake was
slower and was still slightly increasing at 24 h.
The concentration-dependent uptake was measured at 5 h,
the incubation time approaching maximum uptake and ratio
of targeted vs. un-targeted (Fig. 2). As reported in Fig. 3A, in
KB cells the uptake of FA-targeted liposomes was about twice
that of the un-targeted counterpart (average ratio of FA-
targeted vs. un-targeted is 1.8). In A549 cells, the uptake of
both targeted and un-targeted liposomes was lower than in KB
cells but also in these FR negative cells the uptake of targeted
liposomes was slightly higher than that of the un-targeted
ones. However, the higher ratio of uptake between targeted
and un-targeted liposomes in KB with respect to A549 cells
suggested some involvement of FR and therefore competition
experiments were carried out to confirm this hypothesis. In
cells pre-incubated for 1 h with 1 mM free FA before liposome
addition, we actually measured a significant reduction of
uptake of the FA-targeted liposomes in KB cells (Fig. 3B) while
the uptake of un-targeted liposomes was almost unaffected.
The inhibitory effect of 1 mM FA was very similar for the two
tested liposome concentrations of 11 and 16.5 μg ml−1 phos-
pholipids, suggesting no dependency on liposome concen-
tration at least in this range. In A549 cells the preincubation
with 1 mM FA decreased to a lesser extent the uptake of tar-
geted and un-targeted liposomes. Nevertheless, in KB cells
1 mM FA did not inhibit the uptake of the FA-targeted lipo-
somes to the level of the un-targeted ones, while 1 mM FA
almost totally inhibited the uptake of a simple FA-FITC conju-
gate (Fig. S1†). The latter observation suggested that 1 mM FA
was sufficient to saturate all FRs on the surface of KB cells.
Confocal microscopy studies
In order to confirm the cellular uptake of CF-liposomes
measured with flow cytometry, KB cells were incubated with
11 μg ml−1 of CF-liposomes for 5 h and analysed by confocal
microscopy. Both targeted and un-targeted liposomes were
internalized as shown by the CF green fluorescence localised
in the cytoplasm of the cells. As expected, the fluorescence
signal in cells incubated with FA-targeted liposomes (Fig. 4A)
Fig. 2 Time-dependent uptake of FA-targeted or un-targeted CF-labelled lipo-
somes in KB and A549 cells. Liposome concentration was equivalent to
11 μg ml−1 of phospholipid and uptake was measured by flow cytometry at
different times up to 24 h of cell incubation. Data are means ± SD (n = 3).
Fig. 3 Flow cytometry measurements of CF-labelled liposome uptake in KB (FR-positive) and A549 (FR-negative) cells. (A) Cells were incubated for 5 h with increas-
ing concentrations of FA-targeted or un-targeted liposomes. (B) Competition experiment: cells were pre-treated (1 h) with 1 mM free folic acid and then incubated
for 5 h with CF-labelled liposomes. Data are means ± SD (n = 3). *p < 0.005; **p < 0.001 with respect to the corresponding sample not pre-incubated with 1 mM FA
(Student’s t-test).
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was higher with respect to that of cells incubated with the un-
targeted liposomes (Fig. 4B). Moreover, it appeared that the
fluorescence intensity of targeted liposomes was very high only
in some cells of the sample whereas in the case of the un-
targeted ones the distribution appeared more homogeneous.
This may be related to different levels of expression of FR on
KB cells. The fluorescence signals in A549 cells were very low
and the differential uptake between targeted and un-targeted
liposomes was not appreciable (images not shown).
Uptake of FA-targeted and un-targeted Fospeg
Based on the results of the CF-liposomes, we evaluated the
uptake of increasing concentrations of m-THPC loaded in lipo-
somes (Fospeg) of the same phospholipid composition, after 3
and 24 h of incubation. The long incubation of 24 h was
selected because it was frequently used by us21,30 and other
authors34 for similar studies, while the incubation of 3 h
approached the time of maximum liposome uptake (Fig. 2)
and was sufficiently short to ensure that a large fraction of
m-THPC had not escaped the liposomes before being interna-
lised by the cells. As reported in Fig. 5A, after 3 h of incu-
bation, the mean fluorescence intensity of cells incubated with
FA-Fospeg was higher than that of the cells incubated with un-
targeted Fospeg. In KB cells the ratio of FA-targeted vs. un-
targeted Fospeg was significantly higher than in A549 cells
(e.g. 1.94 vs. 1.34 for 0.5 μM m-THPC). In A549 cells the uptake
of FA-targeted Fospeg was not significantly (p > 0.05) higher
than that of the un-targeted Fospeg. When the incubation
time was prolonged to 24 h, the mean fluorescence intensity of
the cells was very similar for both the targeted and un-targeted
Fospeg and the cell lines (Fig. 5B).
It is well known that serum proteins compete with the cells
for the binding of m-THPC42 and decrease the cell photosensi-
tizer uptake. We checked whether serum proteins could affect
differently the internalisation of targeted and un-targeted
Fospeg and their FR-mediated or non-specific mechanism of
entry. Thus, the uptake of the Fospeg formulations was evalu-
ated after 1 h of cell incubation in a medium supplemented
with 0, 3 or 10% FBS (Table 2). As expected, in both types of
Fig. 4 Confocal microscopy images of KB cells incubated for 5 h with FA-
targeted (A) or un-targeted (B) carboxyfluorescein doped liposomes at a
concentration of 11 μg ml−1 of phospholipids.
Fig. 5 Cellular uptake of FA-targeted and un-targeted m-THPC loaded liposomes (Fospeg). KB and A549 cells were incubated for (A) 3 h or (B) 24 h with increasing
doses of Fospeg. Data are means ± SD (n = 3). *p < 0.05; **p < 0.005 with respect to un-targeted Fospeg (Student’s t-test).
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cells and for both targeted and un-targeted Fospeg formu-
lations, the increasing percentage of FBS decreased the uptake
of m-THPC. However, it is worth noting that in KB cells the
uptake of m-THPC was inhibited less when delivered by tar-
geted instead of un-targeted Fospeg and when compared to
A549 cells. As a consequence in A549 cells the ratio of FA-
targeted vs. un-targeted Fospeg remained around 1 in all
tested serum conditions while in KB cells the ratio increased
with the increasing percentage of FBS.
Phototoxicity of FA-targeted and un-targeted Fospeg
The in vitro phototoxicity of m-THPC delivered with the Fospeg
formulations was evaluated in cells incubated for 3 h with
increasing concentrations of the photosensitizer and irradiated
with 0.8 J cm−2 of red light. Photosensitisation studies were
carried out only with the 3 h incubation because at this time
enhanced uptake of m-THPC delivered with targeted Fospeg
was measured. In line with this, in KB cells, the photo-killing
efficiency of FA-targeted Fospeg was approximately 1.5-fold
higher with respect to un-targeted Fospeg (Fig. 6A) as deduced
also from the IC50 values of 0.81 and 1.17 μM, respectively, of
FA-targeted and un-targeted Fospeg. Indeed, in A549 cells the
cytotoxicity was lower and similar for both Fospeg
formulations and the m-THPC concentration decreasing the
cell viability by 50% was higher than 2 μM (Fig. 6B).
From the dose–response curves of Fig. 6 it appears that the
best selectivity in killing KB cells was achieved with m-THPC
concentrations in the range 0.5–1 μM. For such a reason, KB
cells were incubated with 0.5, 0.75, and 1 μM m-THPC Fospeg
formulations and then irradiated with increasing doses of
light (0–2.4 J cm−2) (Fig. 7). For each m-THPC concentration,
targeted and un-targeted Fospeg induced a light-dose-depen-
dent decrease of cell viability that was, however, more severe
with FA-Fospeg especially at low light doses (0.4–1.2 J cm−2).
In all cases, dark incubation alone (0 J cm−2) induced no
detectable decrease of cell viability, indicating that both
Fospeg formulations were not cytotoxic in the absence of
light.
Discussion
Specific delivery of photosensitizers to tumour cells is one of
the most important challenges of PDT and nanotechnologies
appear to offer great opportunities for reaching this goal. Thus
we explored the possibility of obtaining selective delivery of
Table 2 Uptake of 1 μM m-THPC delivered to KB and A549 cells with FA-targeted or un-targeted liposomes diluted in a culture medium supplement with different
percentage of serum. The values represent the mean fluorescence intensity (a.u.) of m-THPC internalized by the cells as measured by flow cytometry after 1 h of
incubation. Values ± SD from three independent experiments
KB cells A549 cells
Serum concentration (%) FA-Fospeg Un-targeted Fospeg Ratio FA-Fospeg Un-targeted Fospeg Ratio
0 1005.00 ± 127.05 771.00 ± 12.77 1.3 754 ± 14.47 719.33 ± 95.13 1.04
3 707.33 ± 77.47 390.67 ± 39.51 1.81 382 ± 72.81 406.33 ± 30.35 0.94
10 515.00 ± 24.27 249.00 ± 17.35 2.09 281.33 ± 28.04 266 ± 19.70 1.05
Fig. 6 In vitro phototoxicity of KB (A) and A549 (B) cells incubated for 3 h with increasing doses of FA-targeted or un-targeted Fospeg and irradiated with
0.8 J cm−2 of red light (600–700 nm). Cell viability was measured with the MTS test 24 h after irradiation and expressed as mean percentage ± SD (n = 9) with
respect to untreated and un-irradiated control cells. *p < 0.05 and **p < 0.001 significantly different from FA-targeted Fospeg values (Student’s t-test).
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m-THPC to cancer cells by using PEGylated liposomes targeted
with folic acid, since FR is overexpressed in many types of
human tumours.43
Our in vitro work included two steps: in the first one, FA-
targeted and un-targeted CF-labelled liposomes were used to
assess FR involvement in the nanocarrier uptake; in the
second step, we studied delivery and phototoxicity of m-THPC
entrapped in FA-liposomes.
The liposomes used in the formulations are “stealth” since
they contain 8 mol% of phospholipid PEGylated with PEG750
while the FA molecule is coupled to a PEG5000 chain. It was
already shown that in the construction of targeted nanovehi-
cles the length of the PEG chain used for the coupling of the
targeting agent (PEG spacer) is crucial and a compromise
must be found with the lengths of the PEG chains forming the
coating. Lee and Low44 studied the influence of the PEG
spacer in calcein loaded liposomes and found that if FA was
directly linked to the amino group of phospholipids
(no spacer), liposomes were not taken up by KB cells while the
addition of a PEG spacer permitted efficient uptake of the lipo-
somes. The nature and the length of the spacer were shown to
play a role also in the FR-mediated uptake of FA-conjugated
PSs and quantum dots.34,39
Based on this, we synthesized two formulations of FA-
targeted CF-liposomes coated with PEG750 in which PEG2000
or PEG5000 was used as a spacer to expose the FA molecules
on the surface of liposomes. Intracellular uptake studies
demonstrated the uselessness of PEG2000 as a spacer for FA
since no increased uptake was measured for this type of lipo-
somes in KB cells incubated for 5 h (data not shown). In con-
trast, the coupling of FA to PEG5000 produced a 2-fold
increase of the uptake of the targeted with respect to the un-
targeted liposomes in KB cells (Fig. 3A). The higher uptake of
FA-liposomes in FR-positive cells was also appreciated by the
confocal microscopy analysis carried out after 5 h of
incubation (Fig. 4). Our findings are in agreement with those
of Yamada et al.45 who studied the in vitro and in vivo cellular
uptake of doxorubicin delivered by FA-liposomal formulation
and found the highest uptake for FA-PEG5000 liposomes with
respect to FA-PEG3400 or FA-PEG2000 liposomes. Thus, it
appears that the longer PEG chains favour FR-mediated lipo-
some internalization.
We found that the uptake of FA-targeted was higher with
respect to the un-targeted liposomes also in A549 cells which
are negative for the expression of FR (Fig. 3A). This result may
indicate that the coupling of FA molecules induces changes of
the liposome surface favouring un-specific internalization.
This effect is very likely mediated by the association of extra-
cellular and serum components on the surface of FA-targeted
liposomes.46 Thus, when the incubation is carried out in the
presence of serum, as in our experiments, the association of
proteins favoured by the FA molecules might lead to the for-
mation of complexes that are easily internalized by the cells.
Nevertheless, the involvement of FR-mediated endocytosis in
the uptake of FA-liposomes in KB cells was confirmed with
competition experiments (Fig. 3B). In these cells, the pre-incu-
bation with 1 mM free FA determined a significant decrease of
the internalization of FA-liposomes and did not affect the
internalization of un-targeted nanocarriers. However, 1 mM FA
did not reduce the uptake of FA-liposomes to the level of the
un-targeted liposomes as found by Kawano and Maitani47 who
studied the specific internalization of FA-targeted liposomes
loaded with doxorubicin in the same cellular system. There-
fore, based on the competition experiment we deduced that
only a small fraction (about 15%) of FA-targeted liposomes
entered the cells via FR-mediated endocytosis while nonspeci-
fic endocytosis seems to be the predominant mechanism of
uptake. Some improvements with regard to the specific uptake
are very likely obtained by reducing the numbers of FA mole-
cules conjugated to the liposomes.47,48
Fig. 7 Light-dose-dependent photo-killing of KB cells incubated for 3 h with selected doses of FA-targeted (A) or un-targeted (B) Fospeg and then irradiated with
increasing doses of red light. Cell viability was measured with the MTS test 24 h after irradiation and expressed as mean percentage ± SD (n = 9) with respect to
untreated control cells.
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The experiments on the time-dependent internalization of
liposomes, up to 24 h, in KB cells showed that the differential
uptake of FA-targeted vs. un-targeted liposomes reached the
maximum (1.94) after 1 h and decreased (1.2) after 24 h
(Fig. 2). Notwithstanding the mild gain of intracellular uptake
of CF-liposomes targeted with FA, we evaluated the uptake of
m-THPC delivered with liposomes of the same composition.
A significantly higher uptake of m-THPC delivered with
FA-Fospeg with respect to un-targeted Fospeg was observed
only in KB cells after a short incubation time (3 h) (Fig. 5A). In
the Fospeg formulations m-THPC is not covalently linked to
phospholipids but only physically entrapped into the bilayer;
therefore, drug release can occur in the presence of serum pro-
teins. The kinetics of redistribution of m-THPC from Foslip®
(non-PEGylated m-THPC liposomes) or Fospeg® to biological
substrates were well characterised by Reshetov and co-
workers.40,41 In particular, they found that in the presence of
5% serum, m-THPC release from Fospeg® showed two phase
kinetics: a fast one with more than 20% released in the first
minutes of incubation and a slow one (from 30 minutes
onward) in which the release is less consistent with a
maximum of about 70%. In the Fospeg® formulations used by
Reshetov PEG2000 was used for the coating while in our case
PEG750 was used. Nevertheless, the photosensitizer release
from our targeted liposomes must be considered already after
few minutes of incubation in a medium added with the
serum. The cell fluorescence signals measured by flow cytome-
try derive from m-THPC molecules entering the cells still
entrapped in liposomes as well as those associated with serum
proteins as a consequence of premature release from lipo-
somes. In all cases, higher (∼2-fold) m-THPC fluorescence
signals were measured after 3 h of incubation of KB cells with
FA-Fospeg with respect to un-targeted Fospeg, showing some
contribution of FR-mediated endocytosis. A similar increase of
m-THPC fluorescence was found in KB cells incubated, under
conditions comparable to ours, with FA-conjugated polymeric
micelles as PS nanocarriers.20 The enhancement of PS uptake
mediated by the FR receptor was higher when using simple
FA–PS conjugates34,36 and this is very likely explained with a
different ability of FA to bind its receptor as can be expected by
changing the nature of its cargo (a simple PS molecule or a
nanoparticle). In all cases, it is worth noting that in A549 cells
m-THPC uptake for FA-Fospeg and un-targeted Fospeg was
very similar to that of un-targeted Fospeg in KB cells. This is
different from the results obtained with the CF-labelled lipo-
somes (Fig. 3A) and confirmed the hypothesis that an import-
ant fraction of m-THPC molecules enter the cells with a
mechanism not involving liposomes. After 24 h of incubation,
no significantly different uptake of m-THPC was measured
between the two cell lines and the two formulations (Fig. 5B),
in agreement with the release of most of the drug molecules
from liposomes and the decreased contribution of FR-
mediated endocytosis already highlighted for FA-targeted CF-
liposomes (Fig. 2).
The influence of serum protein concentration on the
specific uptake of m-THPC was evaluated by increasing the
percentage of FBS during liposome incubation (Table 2). In a
serum-free medium m-THPC delivered with FA-Fospeg entered
the cells only by a specific and non-specific endocytosis of
liposomes. Therefore, in this condition the fraction of liposo-
mal m-THPC taken up by FR-mediated endocytosis can be
better appreciated. From the data of Table 2, it appears that
serum proteins inhibited more the non-specific with respect to
the FR-mediated uptake of m-THPC because only in KB cells
and using FA-Fospeg, 3% and 10% FBS inhibited m-THPC
uptake by about 30% and 50%, respectively, with respect to the
uptake in the absence of serum. In all other conditions, inhi-
bition of m-THPC uptake accounted for about 50% and 65%
respectively for 3% and 10% FBS. As a consequence, the ratio
of m-THPC uptake in FR-positive cells increased with the
increasing serum percentage while it remained constant in FR-
negative cells.
The more selective m-THPC uptake obtained with FA-
liposomes translated to higher photo-induced toxicity in cells
incubated with Fospeg formulations for 3 h and then irra-
diated with 0.8 J cm−2 of light (Fig. 6). The decrease of viability
of KB cells was approx. 1.5 times more if m-THPC was deliv-
ered with FA-targeted with respect to un-targeted liposomes,
while in A549 cells the mortality was not appreciably influ-
enced by the Fospeg formulations. Hence, the contribution of
FR-mediated endocytosis of FA-targeted liposomes yielded
enhanced phototoxicity (∼30%) with equal concentrations of
m-THPC administered to FR-expressing cells. The enhance-
ment of phototoxicity afforded by the conjugation of Fospeg
to FA is lower than expected but not very different from
that observed in KB cells with FA-conjugated liposomes
loaded with a tetrasulphonated phthalocyanine37 and with FA-
conjugated quantum dots39 in comparison with their un-
targeted counterparts. Our results are also in line with those
of García-Diaz49 et al., reporting modest enhancement of
internalization of the PS ZnTPP and phototoxicity in FR-
positive HeLa cells with FA-targeted liposomes. Similarly to us
they concluded that FA-liposomes are mainly internalized by
non-specific endocytosis.
While the biodistribution, selectivity of uptake and PDT
efficiency of FA-Fospeg in vivo need to be defined, we can
speculate that, in spite of limited selectivity emerging from
our in vitro data, FA-Fospeg would favourably affect the
outcome of PDT in FR-overexpressing tumours. Bovis et al.31
have clearly shown that un-targeted Fospeg® accumulates
rapidly and efficiently in the MC28 fibrosarcoma. Fospeg®
uptake in tumour increased about 3-fold compared to Foscan®
with a maximal tumour to skin ratio of 6 (vs. 1.4 of Foscan®)
at 6 h after injection. Overall, the data indicated that for clini-
cal PDT a shorter drug light interval and a lower dose of
m-THPC in Fospeg® can be adopted over those currently used
for Foscan®. The tumour to skin ratio of un-targeted Fospeg®
is comparable to that reported for a m-THPC-like PS conju-
gated to folate and tested in KB tumour25 and is higher than
that of m-THPC delivered with FA-conjugated polymeric
micelles.20 Conjugation with FA should not affect negatively
the pharmacokinetic properties and bioavailability of Fospeg;
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instead, a further improvement is expected since the targeted
formulation slightly favours cellular internalisation of
m-THPC. Because of the prolonged circulation of Fospeg in the
bloodstream, the damage to the vasculature largely contribute
to the PDT-induced tumour damage.31 The FA-Fospeg favour-
ing the cellular internalisation of the PS might increase the
contribution of the direct tumour cell damage and therefore
the tumour response to PDT.
Conclusions
We have reported that the selectivity of m-THPC uptake and
phototoxicity in FR-expressing cells can be improved by deli-
vering the photosensitising drug via FA-targeted Fospeg.
However, our results show modest selectivity of uptake of FA-
liposomes and suggest that non-specific endocytosis remains
the prevailing mechanism of cell internalisation also for the
targeted nanocarriers. In spite of the modest contribution of
the specific uptake on the total of m-THPC uptake, in FR-posi-
tive KB cells, the photo-killing effect produced with FA-Fospeg
was 1.5 times stronger when compared to un-targeted Fospeg.
The limited selectivity of the uptake of m-THPC delivered by
FA-liposomes is explained with the modest contribution of FR-
mediated endocytosis to the overall liposome internalisation
and premature escape of the drug from liposomes in the pres-
ence of serum proteins. It appears that the attachment of FA to
PEG diminishes by 5–10-fold the extent of binding of FA to its
receptor.46 In addition the presence of the PEG corona on the
liposome surface, while conferring stealth properties to the
particles and prolonging their systemic circulation in vivo,
interferes with the targeting effect of FA.46,50 Recently, it has
been suggested that a FA-poly(L-lysine) conjugate might be
more promising than FA–PEG–lipid as a coating and coupling
element in the development of liposomal formulations for
targeting FR.51 Therefore, additional investigations can further
optimise the targeting of liposomal nanocarriers and fully
exploit the potential of FA as a targeting agent for cancer cells.
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In vitro and in vivo characterization of 
temoporfin-loaded PEGylated PLGA nanoparticles 
for use in photodynamic therapy
Photodynamic therapy (PDT) is a promising 
treatment for cancer, its aim being to specifically 
destroy the malignant tissue [1,2]. To be effec-
tive, PDT requires a photosensitizer (PS) that 
accumulates preferentially in malignant tissue, 
nonthermal visible light and molecular oxygen. 
Upon absorption of photons, the PS is activated 
and can undergo two different types of reactions, 
one producing oxygen radicals and the other, sin-
glet oxygen. These reactive oxygen species can 
induce damage in malignant and nonmalignant 
cells alike, depending on the PS distribution [3,4].
Meta-tetra(hydroxyphenyl)chlorin (mTHPC, 
temoporfin) is a highly potent second generation 
PS [5]. After systemic administration, the distri-
bution of temoporfin between the tumor and the 
skin, the tumor to skin ratio, is significantly better 
than that obtained with previous PSs (e.g., hema-
toporphyrin derivates and photofrin), resulting 
in reduced side effects [6]. Temoporfin-mediated 
PDT has been shown to be an effective treatment 
for head and neck cancer [7], early stage oral squa-
mous cell carcinoma [8] and prostate cancer [9]. A 
solution of temoporfin in ethanol and propylene 
glycol (Foscan®, Biolitec AG [Jena, Germany]) 
has been approved in the EU, Norway and Iceland 
as a local therapy for the palliative treatment of 
patients with advanced head and neck cancer who 
have failed prior therapies and are unsuitable for 
radiotherapy, surgery or systemic chemotherapy.
Bioavailability and biodistribution of PSs can 
be improved by nanoparticulate delivery systems 
such as liposomes and polymer particulate car-
riers [10]. These nanoscale delivery systems are 
capable of accumulating in tumor tissues due to 
the phenomenon known as the enhanced per-
meability and retention effect, or by targeting 
ligands designed to selectively bind over-expressed 
tumor-associated antigens [11]. Biodegradable 
poly-(d,l-lactide-co-glycolide) (PLGA) nanopar-
ticles (NPs) constitute a delivery system that can 
be loaded with a variety of therapeutic agents, 
including low-molecular-weight drugs, as well 
as macromolecules such as proteins and plasmid 
DNA [12]. They are degraded to biocompatible, 
nontoxic products that are removed from the 
body by physio logical pathways and clearance 
mechanisms. By changing the composition of 
the copolymeric system, it is possible to regulate 
the rate of degradation and the pore size, conse-
quently releasing incorporated therapeutic mol-
ecules. Owing to excellent biocompatibility and 
bio degradability, the PLGA co-polymer has been 
approved by the US FDA [13] and has received 
wide attention as a promising biomaterial for the 
formulation of NPs for delivery of anti-tumor 
agents including PSs [14–17].
However, systemic use of NPs, including 
PLGA NPs, is limited due to their rapid opso-
nization and removal from the body by the 
Aims: In this study we evaluated temoporfin-loaded polyethylene glycol (PEG) poly-(D,L-lactide-co-glycolide) 
(PLGA) nanoparticles (NPs) as a new formulation for potential use in cancer treatment. Materials & methods: 
NPs were characterized for their photophysical properties, temoporfin release, cellular uptake and intracellular 
localization, and dark and photocytotoxicities of temoporfin by using A549, MCF10A neoT and U937 cell lines. 
In vivo imaging was performed on athymic nude-Foxn1 mice. Results: Temoporfin was highly aggregated 
within the NPs and the release of temoporfin monomers was faster from PEGylated PLGA NPs than from 
non-PEGylated ones. PEGylation significantly reduced the cellular uptake of NPs by the differentiated 
promonocytic U937 cells, revealing the stealth properties of the delivery system. Dark cytotoxicity of temoporfin 
delivered by NPs was less than that of free temoporfin in standard solution (Foscan®, Biolitec AG [Jena, 
Germany]), whereas phototoxicity was not reduced. Temoporfin delivered to mice by PEGylated PLGA NPs 
exhibits therapeutically favorable tissue distribution. Conclusion: These encouraging results show promise in 
using PEGylated PLGA NPs for improving the delivery of photosensitizers for photodynamic therapy.
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mononuclear phagocytic system. Several meth-
ods for modifying or masking the NP surface 
have been developed that allow NPs to tempo-
rarily evade recognition by the mononuclear 
phagocytic system and reach the target site. The 
most commonly used method for development 
of what are known as stealth NPs is to bind poly-
ethylene glycol (PEG) chains to the NP surface 
[18]. PEGylated PLGA NPs have been shown to 
be retained in the blood significantly longer than 
the bare PLGA NPs [19,20].
The aim of this study was to prepare a PLGA 
NP delivery system loaded with the PS temo-
porfin to be used in PDT. PLGA NPs were opti-
mized with respect to their average particle size, 
surface charge, drug loading and degradation 
rate. Furthermore, the effect of PEGylation on 
cell internalization, intracellular distribution and 
cell viability was evaluated in vitro in different 
cell lines. Dark cytotoxicity and photocytotoxic-
ity of temoporfin-loaded PEGylated PLGA NPs 
were determined and compared with those of 
free temoporfin in a standard solution (Foscan). 
Finally, the performance of all three formula-
tions (Foscan, PEGylated and non-PEGylated 
PLGA NPs) has been characterized in vivo using 
fluorescence-based imaging.
Materials & methods
?? Materials
Temoporfin (3,3 ,´3´´ ,3´´ -´(2,3-dihydroporphy-
rin-5,10,15,20-tetrayl)tetraphenol) was provided 
by Biolitec AG (Jena, Germany) and dissolved in 
ethanol and propylene glycol – standard solution 
(Foscan). Resomers RG 503H and RGP d 50155 
were obtained from Boehringer (Ingelheim, 
Germany), poloxamer 188 (Lutrol F68) and 
dimethyl sulfoxide (DMSO) were supplied by 
Sigma-Aldrich (MO, USA).
?? Cell lines
The human-transformed breast MCF10A neoT 
cell line was provided by Bonnie F Sloane 
(Wayne State University, MI, USA). The cells 
were cultured in DMEM/F12 (1:1) medium 
(Gibco, Invitrogen, CA, USA) supplemented 
with 5% fetal bovine serum (FBS), 1 μg/ml 
insulin (?), 0.5 μg/ml hydrocortisone (?), 
50 ng/ml EGF (?), 2 mM l-glutamine and 
antibiotics (38 units/ml streptomycin and 
100 units/ml penicillin G). Human promono-
cytic cell line U937 (CRL-1593.2; ATCC, VA, 
USA) was grown in Advanced RPMI 1640 
(Gibco, Invitrogen) supplemented with 2 mM 
l-glutamine, antibiotics (38 units/ml strep-
tomycin and 100 units/ml penicillin G) and 
10% FBS. Human lung carcinoma A549 cells 
(CCL-185, ATCC, MA, USA) were cultured in 
F-12K medium supplemented with 10% FBS 
(Gibco, Invitrogen), 2 mM l-glutamine, 2.5 g/l 
sodium bicarbonate, 38 units/ml streptomycin 
and 100 units/ml penicillin G (?). HCT116-
luc is a human colorectal adenocarcinoma cell 
line stably transfected with firefly luciferase 
gene (Caliper, MA, USA). HCT116-luc cells 
were cultured in Advanced RPMI 1640 (Gibco, 
Invitrogen) supplemented with 2 mM l-gluta-
mine, antibiotics (38 units/ml streptomycin and 
100 units/ml penicillin G) and 10% FBS.
?? Preparation of temoporfin-loaded 
PLGA & PEGylated PLGA NPs
PLGA and PEGylated PLGA NPs were prepared 
by a modified nanoprecipitation method [21]. In 
short, 45 mg of PLGA (Resomer RG 503H) 
and 5 mg of temoporfin were dissolved in 1 ml 
acetone and the solution was slowly injected into 
50 ml of 0.25% (weight/volume) poloxamer 188 
water solution with moderate magnetic stirring. 
The resulting NP dispersion was stirred for 
15 min at room temperature and then centri-
fuged at 15,000 rpm for 15 min to separate NPs 
from nonincorporated temoporfin and excess 
stabilizer. Subsequently, the NPs were washed 
with 20 ml of distilled water, centrifuged at 
15,000 rpm for 15 min, and then dispersed in 
10 ml of 5% (weight/volume) aqueous treha-
lose solution. The NPs were freeze-dried at room 
temperature and 0.090 mbar for 24 h (Christ 
Beta 18–K, Germany). PEGylated NPs were pre-
pared by the same procedure, the only difference 
being the polymer composition. The weight ratio 
of PLGA (Resomer RG 503H) and PEG PLGA 
(Resomer RGP d 50155) used for preparation of 
PEGylated NPs was 1:1.
?? Characterization of NPs
The mean particle diameter and width of the 
particle distribution (polydispersity index) 
were determined by photon correlation spec-
troscopy using a Zetasizer Nano ZS (Malvern 
Instruments, Worcestershire, UK). Particle 
charge was quantified as ?-potential by laser 
Doppler anemometry using a Zetasizer Nano ZS 
(Malvern). Freeze-dried NPs were dispersed in 
10% FBS solution in phosphate buffered saline 
(PBS) prior to measurement. All measurements 
were made in triplicate.
The total amount of temoporfin entrapped 
in NPs was measured by fluorescence spec-
troscopy after complete dissolution of the NPs 
in DMSO. The temoporfin f luorescence (? 
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excitation 423 nm, ? emission 652 nm) was 
recorded on a Tecan Safire2 and compared with 
the corresponding standard curve.
?? Photophysical characterization
The measurements of absorption spectra, flu-
orescence emission spectra and fluorescence 
lifetimes are shown in SUPPLEMENTARY MATERIAL, 
see online: www.futuremedicine.com/doi/
suppl/10.2217/NNM.11.130.
?? Release of temoporfin from NPs
PEGylated and bare freeze-dried PLGA NPs 
loaded with temoporfin were dispersed in PBS 
containing 10% FBS. The samples were incu-
bated at 37°C (to mimic cell culture condi-
tions) for 1–24 h then centrifuged for 20 min at 
50,000 × g using a Thermo Scientific Sorvall® 
WX100 ultracentrifuge with rotor F50L-
24 × 1.5 ml. After ultracentrifugation, the 
supernatants were removed and DMSO was 
added to dissolve the temoporfin-loaded NPs. 
Temoporfin fluorescence (? excitation 423 nm, 
? emission 652 nm) was recorded on Tecan 
Safire® and compared with the corresponding 
standard curve.
?? Cellular uptake of temoporfin
A549 and MCF10A neoT cells (1 × 105) were 
seeded in 24-well culture plates with appropriate 
medium and grown to confluence. U937 (4 × 105 
cells/ml of medium) were differentiated with 
50 nM phorbol 12-myristate 13-acetate (Sigma, 
MO, USA) for 24 h to induce macrophage-like 
properties and attached on a polystyrene plate 
[22]. Cells were washed with PBS and incubated 
for 4 h and 24 h with 0.5 or 1 μM temoporfin, 
respectively, delivered by NPs in culture medium 
supplemented with 10% FBS. Cells were then 
washed twice with PBS to remove NPs not inter-
nalized by the cells, detached from plates and 
immediately analyzed by flow cytometry (4-h 
and 24-h time points). Additional samples were 
washed and incubated in NP-free medium for an 
additional 20 h or 24 h (4 + 20 h and 24 + 24 h 
time points). The mean fluorescence intensity 
(MFI) of a population of 1 × 104 cells was deter-
mined using a FACSCalibur (Becton Dickinson, 
CA, USA). An argon ion laser at 488 nm was 
used for excitation, and fluorescence emission 
was measured at 670 nm (FL-3 detector).
?? Intracellular localization of 
temoporfin
The intracellular localization of temoporfin 
delivered by PEGylated PLGA NPs was assessed 
by fluorescence microscopy, taking advantage of 
temoporfin’s red fluorescence. For these experi-
ments 3 × 104 MCF10A neoT cells were seeded 
in a 24-well cell culture plate containing glass 
coverslides. After 1, 3, 6 and 10 h incubation, 
cells were washed using PBS and then fixed 
with 4% paraformaldehyde in PBS (pH 7.4) 
for 30 min. After washing with PBS, ProLong 
Antifade kit (Gibco, Invitrogen) was mounted 
on dried coverslides and allowed to dry overnight 
at 4°C. Labeling of cells with markers of subcel-
lular structures was performed separately. For 
labeling of the Golgi apparatus, cells were fixed 
with 4% paraformaldehyde in PBS (pH 7.4) for 
30 min and permeabilized with 0.1% Triton 
X-100 in PBS (pH 7.4) for 10 min. Nonspecific 
staining was blocked with 3% BSA in PBS (pH 
7.4). The Golgi was labeled with primary rabbit 
polyclonal anti-GM130 antibody (Sigma) with 
a working concentration of 0.4 μg/ml in 3% 
BSA in PBS. After 2 h of incubation, cells were 
washed three-times with PBS and incubated with 
Alexa 488-labeled donkey anti-rabbit (2:1000, 
Molecular Probes®, Invitrogen) antibodies for 
2 h. After washing with PBS, ProLong Antifade 
kit was mounted on dried coverslides and allow 
to dry overnight at 4°C. Endosomal and lyso-
somal labeling were performed using Organelle 
Lights™ Endosomes and Lysosomes (Gibco, 
Invitrogen), following the manufacturer’s pro-
tocol. Fluorescence microscopy was performed 
at room temperature using an Olympus IX/81 
inverted fluorescence microscope equipped with 
a Dapi/FITC/TxRed filter set (E0435016) and 
immersion oil was used as imaging medium. 
Images were analyzed using CellR Imaging 
software.
?? Dark cytotoxicity studies
The dark cytotoxicity of temoporfin-loaded 
PEG-PLGA NPs was evaluated in A549 cells 
using the MTS test (Promega Co., WI, USA) 
and compared with that of temoporfin in stan-
dard solution (Foscan). Cytotoxicity of empty 
PEGylated NPs was evaluated with both the 
MTS test and lactate dehydrogenase (LDH) 
assays. For both tests, A549 cells were seeded 
in 96-well plates (3 × 103 cells/well) in culture 
medium supplemented with 10% FBS. After 
24 h, cells were incubated with fresh medium 
containing 3% FBS and increasing concentra-
tions of empty or temoporfin-loaded PEG-PLGA 
NPs or Foscan. The cells were incubated in the 
dark for 24 h and cell viability was then mea-
sured with the MTS test, as well as after an addi-
tional 24 h during which the cells were kept in 
71
???????????????? Rojnik, Kocbek, Moret et al.
Nanomedicine (2012) 7(5)666 future science group
temoporfin-free medium containing 10% FBS 
in the dark (24 + 24 h). For the MTS assay, the 
cell medium was replaced with 100 μl of serum-
free medium and 20 μl of CellTiter 96® Reagent 
(Promega Co.) and the wells were incubated for 
1.5 h at 37°C. The absorbance at 492 nm was 
measured with a Biotrack II (GE Healthcare, 
Little Chalfont, UK) visible plate reader, and the 
survival of the treated cells expressed as a percent-
age of the absorbance of the untreated control, 
which was set to 100%. The activity of the LDH 
released in the culture medium during incuba-
tion of the cells with empty PEG-PLGA NPs for 
24 h was measured according to the manufac-
turer’s instructions (Promega Co.). This, and the 
activity of the total cellular LDH content, were 
measured in order to calculate the percentage of 
enzyme released during the treatment.
?? Photocytotoxicity studies (PDT) 
in vitro
The phototoxic effects of temoporfin loaded 
in PEG-PLGA NPs or dissolved in the stan-
dard solution (Foscan) were evaluated using 
carcinoma A549 cells. Cells were seeded in 
96-well plates and incubated for 24 h at 37°C 
in the dark with temoporfin concentrations 
from 0.25–1.5 μM, which were not toxic with-
out light activation. After incubation, the cells 
were washed twice with PBS containing Ca2+ 
and Mg2+, and irradiated in PBS with 0.24 J/
cm2 of red light (600–700 nm) emitted from 
a Waldmann PDT 1200 lamp (Waldmann 
Medizintechnik, Schwenningen, Germany). 
The fluence rate at the level of the cell mono-
layer was 12 mW/cm2 as measured with a radi-
ometer IL 1700 (International Light, MA, USA). 
Immediately after irradiation, PBS was replaced 
with fresh medium containing 10% FBS and the 
cells were incubated in the dark at 37°C. Cell 
viability was determined with the MTS test after 
an additional 24 h. Using the same protocols, 
irradiation experiments were also performed with 
cells incubated with empty PEG-PLGA NPs at 
doses equivalent to those loaded with temopor-
fin, to exclude any light-induced toxic effect in 
the presence of the nanovehicle alone.
?? HCT116-luc xenograft mouse model
Animal experiments were approved by the local 
Committee for Research and Animal Ethics in 
compliance with the law on experimental ani-
mals. Ten-week-old male Hsd:Athymic nude-
Foxn1 mice were purchased from Harlan (Horst, 
The Netherlands). Mice were housed in indi-
vidually ventilated cages and fed ad libitum with 
an alfalfa-free diet and sterilized water. Twelve 
mice were subcutaneously inoculated with 
5 × 106 HCT-116-luc cells in 100 μl PBS supple-
mented with matrigel (1:1). Tumor growth was 
monitored by bioluminescence imaging.
?? Bioluminescence & fluorescence 
imaging
Bioluminescence imaging was performed using 
the IVIS® Spectrum Imaging System (Xenogen, 
Table 1. Particle size, polydispersity index and ?-potential of temoporfin-loaded poly-(D,L-lactide-co-glycolide) 
and polyethylene glycol–poly-(D,L-lactide-co-glycolide) nanoparticles.
Formulation Particle size (nm) PI ?-potential (mV) Temoporfin loading  
(%, weight/weight)
PLGA NPs 179.0 ± 0.3 0.27 ± 0.01 -5.5 ± 0.4 6.90
PEG-PLGA NPs 144.7 ± 2.0 0.13 ± 0.01 -2.5 ± 1.1 6.70
NP: Nanoparticle; PEG: Polyethylene glycol; PI: Polydispersity index; PLGA: Poly-(D,L-lactide-co-glycolide). 
Table 2. Fluorescence lifetimes of PEGylated and non-PEGylated poly-(D,L-lactide-
co-glycolide) nanoparticles in phosphate-buffered saline or dimethyl sulfoxide, 
together with pre-exponential factors.
Formulation ?1 (ns) A1 (%) ?2 (ns) A2 (%)
PLGA in PBS 6.2 67 2.3 32
PEG-PLGA in PBS 3.2 27 1.4 73
Temoporfin in DMSO 9.6 100 – –
PLGA in DMSO 9.5 100 – –
PEG–PLGA in DMSO 9.5 100 – –
???Fluorescence lifetime;?A: Pre-exponential factor; DMSO: Dimethyl sulfoxide; PBS: Phosphate-buffered saline; 
PEG: Polyethylene glycol; PLGA: Poly-(D,L-lactide-co-glycolide).
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CA, USA) every other day until day 10, after 
which imaging was performed daily. Ten min-
utes prior to imaging, animals were injected 
intraperitoneally with d-luciferin (25 mg/ml; 
Xenogen). Imaging of animals was performed 
under general anesthesia (2.5% isoflurane in 
oxygen). First, a gray-scale reference photo 
was taken of the animal from the lateral side. 
Bioluminescence images were acquired using the 
following settings: integration time 1 s; binning 
factor 8; field of view 21.2; and f/stop 1 open 
filter. Living Image 3.1 software (Xenogen) was 
used for data analysis and to create a pseudo-color 
image representing light intensity (blue: low 
intensity; red: high intensity). Bioluminescence 
images were quantified in radiance (photons/s/
cm2/sr) for reliable comparisons between the 
various images.
After reaching a tumor size of 0.5 cm3, cor-
responding to radiation of 109 photons/s/cm2/sr, 
mice were assigned randomly into four groups of 
three animals each. In each group, animals were 
injected in the penile vein with 100 μl PBS or 
100 μl of a specified temoporfin formulation. A 
total of 0.3 mg of temoporfin/kg bodyweight was 
used to ensure a detectable fluorescence signal 
in a new in vivo imaging model. Animals were 
injected with PBS (group 1), Foscan (group 2), 
PLGA NPs (group 3) and PEGylated PLGA NPs 
(group 4).
After injection, fluorescence imaging was per-
formed every 24 h for 4 days using the following 
settings: integration time 1 s; binning factor 8; 
field of view 21.2; f/stop 2; lamp level high; exci-
tation filter 430 nm; and emission filter 660 nm. 
After imaging at t = 96 h, the animals were ter-
minated. Subsequently, tumor, liver, spleen, 
kidney, muscle, lungs, heart, bladder, skin and 
colon were surgically procured. Fluorescence 
was quantified in the harvested tumors and the 
separate organs.
?? Statistical analysis
The SPSS PC software (Release 13.0) was used 
for the statistical analysis of all of the data. The 
differences between the groups were evaluated 
using Student’s t-test. p < 0.05 was considered 
to be statistically significant.
Results
?? Preparation & characterization of 
temoporfin-loaded NPs
Polymeric NPs loaded with temoporfin were 
formed by the nanoprecipitation method and 
their physicochemical parameters, such as mean 
diameter, size distribution and ?-potential, were 
determined (TABLE 1). The ?-potential was signifi-
cantly more negative for PLGA NPs compared 
with PEGylated PLGA NPs (p < 0.05), indi-
cating the presence of a larger number of free 
carboxyl groups on the PLGA NP surface than 
on the PEGylated PLGA NPs, which, in addi-
tion, have uncharged PEG chains on their sur-
face. The particle size of PLGA NPs was larger 
than that of PEGylated PLGA NPs, probably 
due to the incorporation of more hydrophilic 
PEG chains in the hydrophobic PLGA poly-
mer. Covalently linked hydrophilic PEG blocks 
changed physicochemical properties of PLGA 
polymer enabling formation of smaller particles. 
Both NP formulations showed low polydisper-
sity index and low negative surface charge. Low 
surface charge of NPs indicates low stability, 
resulting in aggregation and sedimentation of 
NPs from the aqueous dispersion. Therefore, to 
obtain long-term stable NP samples, the disper-
sions were freeze-dried and NPs were redispersed 
in suitable medium prior to the in vitro or in vivo 
experiments.
?? Fluorescence properties of 
temoporfin-loaded NPs
The fluorescence emission spectra and lifetimes 
were recorded for NP stock solutions diluted in 
PBS (pH 7.4), in comparison to the same sample 
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Figure 1. The release of temoporfin from polyethylene glycol-poly-(D,L-
lactide-co-glycolide) and poly-(D,L-lactide-co-glycolide) nanoparticles. The 
percentage of loaded temoporfin left in NPs after 1, 2, 3, 4, 6, 10 and 24 h 
incubation in phosphate-buffered saline with 10% fetal bovine serum. Temoporfin 
retained in NPs was measured after ultracentrifugation and dissolution of NPs in 
dimethyl sulfoxide. 
NP: Nanoparticle; PEG: Polyethylene glycol; PLGA: Poly-(D,L-lactide-co-glycolide).
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Figure 2. Cellular uptake of temoporfin-loaded nanoparticles. Uptake of temoporfin-loaded 
PEGylated and non-PEGylated PLGA nanoparticles by (A) MCF10A neoT, (B) A549 and (C) 
differentiated U937 cells. Cells were treated with 0.5 or 1 μM temoporfin delivered by nanoparticles 
for 4 and 24 h. After incubation, the cells were washed and fresh nanoparticle-free medium was 
added for an additional 20 h (4 + 20 h) and 24 h (24 + 24 h). 
MFI: Mean fluorescence intensity; PEG: Polyethylene glycol; PLGA: Poly-(D,L-lactide-co-glycolide).
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dissolved in DMSO at an equivalent temoporfin 
concentration. SUPPLEMENTARY FIGURE 1 shows the flu-
orescence emission spectra recorded for the NP 
solutions diluted at the same concentrations in 
PBS versus DMSO. For both the PEGylated and 
non-PEGylated PLGA NPs, much lower fluo-
rescence intensities were noted for the PBS solu-
tions compared to DMSO solutions, by factors 
of 21 and 11, respectively. Likewise, a significant 
change in fluorescence lifetimes was observed 
between the two solvents, as shown in TABLE 2. In 
DMSO, mono-exponential decays with identi-
cal lifetimes (within experimental error) were 
observed for all samples. In PBS, multiexponen-
tial decays with significantly shorter lifetimes 
were observed for both the PEGylated and 
non-PEGylated NPs in comparison to DMSO 
solutions of the NPs. Using bi-exponential fit-
ting, the lifetimes of the PEGylated NPs in PBS 
(3.2 and 1.4 ns) were shorter than for the non-
PEGylated NPs. Temoporfin itself is insoluble 
in PBS and so no lifetime data are given.
?? Release of temoporfin from the NPs
Temoporfin is noncovalently entrapped inside 
the copolymeric matrix and partially bound 
to the NP surface, and therefore its binding to 
serum proteins is possible only after its release 
from the NPs. Temoporfin still present in NPs 
was separated from the released temoporfin 
by ultracentrifugation and quantified. Results 
showed sustained release of temoporfin from 
PLGA NPs. After 1 h no significant change 
was observed, whereas after 24 h 68 ± 1% of 
temoporfin was still present in NPs (t = 0 vs 
24 h; p < 0.001) (FIGURE 1). PEGylated PLGA 
NPs showed faster release of the drug immedi-
ately after incubation with serum proteins, after 
1 h incubation 62 ± 2% of the temoporfin was 
present in NPs (t = 0 vs 1 h; p < 0.05). Release 
then became slower, with 45% of temoporfin 
still present in NPs after 24 h (t = 0 vs 24 h; 
p < 0.001).
?? Cellular uptake of temoporfin-
loaded NPs
Cellular uptake of temoporfin-loaded NPs was 
evaluated by flow cytometry in A549, MCF10A 
neoT and differentiated U937 cells at four time 
points (FIGURE 2). MCF10A neoT cells internalized 
larger amounts of drug than the other cell lines, 
especially following delivery with PLGA NPs 
(p < 0.05). Moreover, the uptake of temoporfin 
was significantly increased (p < 0.05) when deliv-
ered by PLGA NPs compared with PEGylated 
PLGA NPs in all cell lines at 4 and 24 h.
Differences between the single time points 
were the most obvious at 24 and 24 + 24 h. The 
MFI of temoporfin in U937 cells at 24 + 24 h was 
greater than at the 24 h time point (p < 0.01), 
except in the case of the epithelial cell lines A549 
and MCF10A neoT, most probably because the 
differentiated U937 cells are not able to prolifer-
ate. Another major difference between A549 and 
MCF10A neoT cells and promonocytic U937 
cells concerns the internalization rate of PLGA 
NPs. The MFI of temoporfin in U937 cells was 
almost identical at 4 + 20 h and 24 h (p > 0.05), 
while in the epithelial cell lines a significant dif-
ference was observed between these two time 
points (p < 0.001).
The data obtained from experiments with 
U937 cells can be useful in clarifying the fate 
of PLGA NPs after their cellular uptake. An 
increase in temoporfin MFI was observed in 
U937 cells, even after cell washing with PBS 
and incubation in NP-free medium (4 + 20 h, 
24 + 24 h time points), indicating continuous 
intracellular degradation of the PLGA matrix. 
Furthermore, the degradation of PEGylated 
NPs was significantly lower than that of PLGA 
NPs in all the selected cell lines.
Internalization of temoporfin-loaded NPs 
depends on the PEGylation of the NPs. The 
ratio between the MFI for PLGA NPs and 
PEGylated PLGA NPs (PLGA/PEG-PLGA 
ratio) [23] clearly shows a lower uptake of 
PEGylated PLGA NPs than the non-PEGylated 
version in all the tested cell lines after 4 and 
24 h of incubation (FIGURE 3). U937 cells exhibit 
the highest MFI PLGA/PEG-PLGA ratio 
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Figure 3. The effect of PEGylation on the cellular uptake of nanoparticles. 
Ratio of the mean fluorescence intensities of PLGA nanoparticles (NPs) and 
PEGylated PLGA NPs (PLGA/PEG-PLGA ratio) indicating the stealth properties of 
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PEG: Polyethylene glycol; PLGA: Poly-(D,L-lactide-co-glycolide).
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after 4 h of incubation (p < 0.05), followed by 
MCF10A neoT cells, while the ratio is barely 
above one for A549 cells. After 24 h of incuba-
tion, the PLGA/PEG-PLGA ratio decreases in 
U937 cells (p < 0.01), while in A549 (p < 0.001) 
and MCF10A neoT (p < 0.05) cells the ratio 
increases significantly compared with the 4-h 
time point.
?? Intracellular localization of 
temoporfin-loaded PEGylated 
PLGA NPs
Localization of temoporfin-loaded PEGylated 
PLGA NPs in MCF10A neoT cells was visual-
ized using fluorescence microscopy after 1, 3, 
6 and 10 h incubation. After 1 h of incubation, 
the red fluorescence corresponding to the inter-
nalized temoporfin was distributed throughout 
the cell cytoplasm (FIGURE 4). However, it was 
more intense in regions corresponding to the 
endoplasmic reticulum and Golgi apparatus, 
as previously reported [24]. On incubation of 
cells for 3, 6 and 10 h, increasing numbers of 
red spots appeared, corresponding to accumu-
lated temoporfin or temoporfin-loaded NPs in 
lysosomal–endosomal compartments. Similar 
intracellular localization was reported for 
PLGA NPs [25].
?? Dark cytotoxicity of empty & 
temoporfin-loaded PEGylated 
PLGA NPs
Empty PEGylated PLGA NPs did not affect 
the survival of A549 cells exposed to NP con-
centrations up to 100 μg/ml for 24 h, much 
higher than those used to deliver the highest 
temoporfin concentration of 5 μM used in our 
experiments. The MTS assay showed that the 
number of metabolically active cells at 24 and 
24 + 24 h after exposure to NPs was not reduced 
relative to controls (FIGURE 5A). The biocompat-
ibility of the empty nanocarrier was confirmed 
by the LDH assay, which showed no increase 
in the cytosolic enzyme in the medium of cells 
exposed to NPs. Only 6.2 ± 1.1% of LDH was 
measured in the culture medium of A549 cells 
exposed to 100 μg/ml of empty PEGylated 
NPs, which was not different from the 7.8 ± 1% 
measured in untreated cells. 
The dark cytotoxicity of temoporfin in con-
centrations up to 5 μM loaded in PEGylated 
PLGA NPs was evaluated and compared with 
temoporfin delivered as Foscan in the standard 
solution (FIGURE 5B). The MTS assay showed no 
decrease in survival of A549 cells at the end 
of the 24 h incubation with temoporfin-loaded 
PEGylated PLGA NPs. However, a decrease in 
Figure 4. Localization of temoporfin-loaded PEGylated poly-(D,L-lactide-co-glycolide) 
nanoparticles in MCF10A neoT cells (red fluorescence). Cells were incubated with 50 μg /ml of 
nanoparticles in cell medium supplemented with 10% fetal bovine serum for 1, 3, 6 and 10 h (left 
panel). Separately, Golgi (A) was labeled with anti-GM130 antibody (Sigma, MO, USA) using Alexa 
488-labeled donkey anti-rabbit (Gibco, Invitrogen, CA, USA) IgG as secondary antibody. Endosomes 
(B) and lysosomes (C) were labeled with Organelle Lights™ (Molecular Probes, Invitrogen). Scale bars 
represent 20 μm.
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cell survival was observed with temoporfin at 
concentrations above 3 μM after 24 h of NP 
exposure and the additional 24 h of cell incu-
bation in NP-free medium (24 + 24 h). In any 
case, the dark toxicity of temoporfin delivered 
as Foscan was much greater than that of temo-
porfin delivered by PEGylated PLGA NPs at 
both investigated time points. At concentrations 
above 2 μM Foscan was highly cytotoxic and the 
cell survival was reduced to 10–20% at 5 μM. 
Concentrations of 0.5 and 1 ?M temoporfin 
used in other experiments are therefore below 
the threshold of dark toxicity of all temoporfin 
formulations.
?? Phototoxicity studies of empty & 
temoporfin-loaded PEGylated 
PLGA NPs
Phototoxicity studies were carried out with A549 
cells preincubated with empty PEGylated PLGA 
NPs, temoporfin-loaded PEGylated PLGA NPs 
and with Foscan standard solution. The cells, 
preincubated for 24 h in the dark, were irradi-
ated with a light dose of 0.24 J/cm2. As shown in 
FIGURE 6, the reduction in cell survival measured 
24 h after irradiation was dependent on temo-
porfin dose, but was similar for both temoporfin 
formulations. To assess whether the comparable 
phototoxic effect correlated with a similar intra-
cellular drug concentration at the time of irra-
diation, the amount of temoporfin internalized 
by the cells was determined by flow cytometry. 
Surprisingly, the results showed that the cellu-
lar uptake of free temoporfin was significantly 
higher than when delivered by PEGylated PLGA 
NPs. In fact, by expressing the uptake as the 
ratio between the MFI for Foscan standard solu-
tion and temoporfin loaded in PEGylated PLGA 
NPs, we found ratio values of 2.2 and 2.3 for 0.5 
and 1 μM temoporfin, respectively.
The empty PEGylated PLGA NPs exhib-
ited no cytotoxic effects on cells after irradia-
tion, confirming that they are photochemically 
inert and, therefore, any contribution of the 
drug delivery system to the phototoxic effect of 
temoporfin-loaded PEGylated PLGA NPs can 
be ruled out. 
?? In vivo distribution of temoporfin
Total body fluorescence of mice (FIGURE 7) indi-
cates no significant difference between temopor-
fin-loaded PLGA and PEGylated PLGA NPs at 
24h postinjection. At this time point, the fluo-
rescence was significantly lower (p < 0.01) for 
Figure 5. Dark cytotoxicity of empty and temoporfin-loaded PEGylated poly-(D,L-lactide-co-glycolide) nanoparticles in A549 
cells. (A) Viability of cells incubated in the dark with increasing doses of empty nanoparticles for 24 h (24 h) and for 24 h and an 
additional 24 h in NP-free medium (24 + 24 h). (B) Dark cytotoxicity of temoporfin-loaded NPs compared with that of temoporfin in the 
standard solution (Foscan®, Biolitec AG [Jena, Germany]) after 24 h or 24 + 24 h of incubation. Viabilities are expressed as mean 
percentages ± standard deviation (n = 9) relative to control cells.
*p < 0.001 vs controls (t-test). 
NP: Nanoparticle; PEG: Polyethylene glycol; PLGA: Poly-(D,L-lactide-co-glycolide).
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both nanoparticulate systems than for Foscan, 
and remained so until the end of the experiment 
at 96 h postinjection. Overall body fluorescence 
showed time-dependent increases for both PLGA 
NPs and PEGylated PLGA NPs during a 96 h 
follow-up (FIGURE 8). Mouse organs were harvested 
96 h postintraperitoneal injection of temoporfin 
formulations, and scanned for temoporfin fluo-
rescence (FIGURE 9). The data have been normalized 
using the IVIS imaging software. Fluorescence 
of each tissue sample taken is indicated as a per-
centage of the sum of fluorescence of all organs 
evaluated, which was set at 100%. The highest 
levels for all three formulations were observed in 
the skin, followed by tumor and bladder tissue. 
However, different levels can partially be due to 
different optical properties of tissues. In all the 
tissues, the fluorescence of temoporfin was higher 
when delivered by PEGylated PLGA NPs than 
by PLGA NPs, although the difference was not 
statistically significant. Interestingly, delivery 
of temoporfin to colon tissue was higher with 
PEGylated and PLGA NPs than Foscan (Foscan 
to PLGA NPs; p = 0.007; Foscan to PEGylated 
PLGA NPs; p = 0.058). In lung tissue, the 
concentration of temoporfin was higher when 
delivered by PLGA NPs than Foscan and 
PEGylated PLGA NPs (Foscan to PLGA NPs; 
p = 0.006; PLGA NPs to PEGylated PLGA NPs; 
p = 0.038). The skin uptake of the drug, which 
results in skin photosensitivity, appeared lower 
for the NPs; however, this was not significantly 
different from Foscan, as shown in FIGURE 9.
Discussion
The use of NPs as drug delivery systems can sig-
nificantly improve the distribution of the PS for 
PDT and the efficacy of the treatment in cancer 
patients. In this study, we formulated PLGA NPs 
with incorporated PS temoporfin. The average 
particle size of 150 nm enables NP accumulation 
at the tumor site by the enhanced permeability 
and retention effect [26] and their internalization 
in tumor cells. PEG chains bound to the surface 
of PLGA NPs did not significantly change the 
physical properties of the delivery system; how-
ever, PEGylation may prolong the retention time 
in the blood stream. The PEG chains prevent 
the adhesion of opsonins present in the blood 
serum to the NPs surface, making the surface 
of the NP unrecognizable by the mononuclear 
phagocyte system [18].
In the present study, we showed that PEGylation 
of PLGA NPs did not significantly affect the 
loading of temoporfin to the polymeric matrix. 
The monomeric form of porphyrin-based PSs, 
including temoporfin, is well known to possess 
more advantageous fluorescence properties (in 
terms of longer fluorescence lifetimes) and higher 
triplet state yields, and thus higher photodynamic 
efficiency than the aggregates [27]. PSs entrapped 
inside PLGA NPs were suggested to form aggre-
gates that dissociate to monomeric forms after 
their release from the NPs and transfer to plasma 
proteins [16]. Furthermore, the PS release from 
NPs and its activity were shown to be controlled 
by the NP size, composition and surface proper-
ties [28]. The fluorescence emission and lifetime 
data shown in SUPPLEMENTARY FIGURE 1 & TABLE 2 indicate 
that temoporfin fluorescence is strongly quenched 
in NPs, in comparison to monomeric temoporfin. 
This comparison was achieved by dissolving the 
NPs in DMSO to induce release of the temopor-
fin in monomeric form, which resulted in a large 
increase in fluorescence intensity and lifetime. 
These results are consistent with the occurrence 
of fluorescence self-quenching due to aggrega-
tion of the temoporfin within the intact NPs. 
The degree of quenching appeared to be greater 
for the PEGylated NPs, despite the comparable 
temoporfin loading, which could be explained by 
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their smaller size resulting in a higher local temo-
pofin concentration and thus greater propensity 
for aggregation. Similar fluorescence quenching 
effects are observed for temoporfin incorporated 
in liposomal membranes where the fluorescence 
lifetime was reduced to 1 ns, which was attributed 
to aggregation [28–30]. The other technique we 
could use would be absorption spectroscopy, but 
the spectral differences between the monomeric 
and dimerized forms are less easy to interpret.
It was shown that temoporfin can readily be 
released from PLGA NPs when reaching tumors 
and it was demonstrated that it is able to asso-
ciate with various serum protein fractions [31,32]. 
Therefore, we may expect that, when delivered 
to the site of action, temoporfin is monomer-
ized, a form that is preferable for effective PDT. 
When PLGA NPs were resuspended in cell cul-
ture medium containing serum proteins, most of 
the temoporfin remained entrapped inside NPs 
after 1 h of incubation and was released at the 
rate of degradation of the polymer. On the other 
hand, more than 30% (weight/weight) of temo-
porfin was immediately released from PEGylated 
PLGA NPs after incubation in medium contain-
ing serum proteins. This burst release could be a 
consequence of the temoporfin fraction that was 
adsorbed on the NP surface and released imme-
diately to the medium due to incompatibility 
with the hydrophilic PEG chains on the surface 
of PEGylated PLGA NPs. The difference in release 
profiles of temoporfin from these two delivery sys-
tems could also result in different time courses of 
temoporfin-dependent total body fluorescence in 
mice. Again, temoporfin released from PLGA NPs 
revealed a continuous increase until reaching the 
96-h time point, whereas peak temoporfin release 
from PEGylated PLGA NPs was at 48 h (FIGURE 8).
The availability and photo-activity of the 
intracellular temoporfin delivered by PEGylated 
PLGA NPs is dependent on its monomerization, 
which follows the degradation of the polymer 
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Figure 7. Total body fluorescence of mice 24 h postinjection with phosphate-buffered 
saline (control), Foscan® (Biolitec AG [Jena, Germany]), poly-(D,L-lactide-co-glycolide) 
nanoparticles and PEGylated poly-(D,L-lactide-co-glycolide) nanoparticles loaded with 
temoporfin. The total body fluorescence values are presented in upper inserts and the fluorescence 
localized to tumors in lower inserts. 
PEG: Polyethylene glycol; PLGA: Poly-(D,L-lactide-co-glycolide).
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and the release of the temoporfin from NPs. The 
dissociation may occur before or after the cel-
lular uptake of NPs, and temoporfin released 
from NPs prior to internalization may also 
contribute to intracellular activity, if internal-
ized. On the other hand, cell division continu-
ously decreases the intracellular concentration 
of temoporfin [24]. We have shown that the 
intracellular monomerization of temoporfin 
delivered by PLGA NPs is a preferred process 
in all cell lines studied. During the first 24 h of 
incubation, temoporfin fluorescence increased. 
The effect was lower because of cell division, 
in particular in MCF10A neoT and A549 cells, 
whereas in differentiated U937 cells the fluores-
cence increased, even up to 24 + 24 h (FIGURE 2). 
The PEGylation of NPs significantly decreased 
the rate of temoporfin intracellular mono-
merization, probably due to its faster release 
into the cell medium, lower internalization or 
slower intracellular degradation of PEGylated 
PLGA NPs. The effect of PEGylation on cel-
lular uptake can be deduced by evaluating 
the PLGA/PEG-PLGA ratio (FIGURE 3). In the 
first 4 h of incubation, the internalization of 
PEGylated PLGA NPs was significantly slower 
than that of PLGA NPs. The difference was par-
ticularly evident in U937 cells, indicating the 
ability of PEGylation to confer stealth proper-
ties on PLGA NPs, at least against this type of 
immune cell. This effect was less evident after 
24 h incubation of cells with temoporfin-loaded 
NPs, probably due to the different extra- and 
intracellular release profiles of temoporfin from 
PEGylated and PLGA NPs. These results are 
consistent with previous studies reporting that 
PEGylation of PLGA NPs affects the uptake 
by monocytes during short incubation times, 
whereas prolonged incubation diminished the 
effect of PEGylation [23].
The subcellular localization of the PS is 
one of the key factors governing the outcome 
of PDT, since it determines the primary sites 
of photoinduced damage [33]. The preferential 
sites of accumulation of temoporfin delivered 
as Foscan were the endoplasmic reticulum and 
Golgi apparatus, probably as a consequence of 
its internalization in a complex with serum pro-
teins [24,34]. On the other hand, PLGA NPs are 
internalized by specific endocytotic processes, 
mostly through a clathrin-dependent pathway, 
targeting endosomal–lysosomal compartments 
[35,36]. Our results of temoporfin intracellular 
localization suggest two mechanisms of cell 
internalization when PEGylated PLGA NPs 
were used as a delivery system. First, temoporfin 
released from NPs prior to cell internalization 
binds to serum proteins and follows the same 
route as the internalization of temoporfin deliv-
ered as Foscan, accumulating in the Golgi appa-
ratus and endoplasmic reticulum. By contrast, 
temoporfin incorporated in NPs is taken up by 
clathrin dependent endocytosis and is triggered 
to the endosomal and lysosomal compartments.
The PLGA copolymer is not cytotoxic [37,38] 
and the same holds for PLGA NPs in concentra-
tions up to 5 mg/ml in A549 cells [36]. Similarly, 
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in the same cell line, we detected no cytotoxicity 
for empty PEGylated PLGA NPs at concentra-
tions up to 0.1 mg/ml, both in the dark and 
after illumination with red light (FIGURES 5 & 6). 
Temoporfin-loaded PEGylated NPs showed a 
moderate dark cytotoxicity which was, however, 
significantly lower than that of temoporfin as 
Foscan (FIGURE 5). Thus, the incorporation of 
temoporfin into a nanocarrier reduces its dark 
cytotoxicity. Similarly, the dark cytotoxicity 
of temoporfin was demonstrated to be lower 
when loaded in PEGylated liposomes (Fospeg®, 
Biolitec AG) than in Foscan [39].
The photodynamic effectiveness of temopor-
fin delivered by PEGylated NPs was assessed 
by irradiation of A549 cells with red light 
(600–700 nm) and compared to that of temo-
porfin as Foscan. The in vitro phototoxic effect 
of the two formulations was similar, although 
the intracellular availability of temoporfin, as 
determined by flow cytometry, in cells incu-
bated with temoporf in-loaded PEGylated 
NPs, was approximately 50% that of the cells 
incubated with Foscan. However, temoporfin 
delivered by PEGylated NPs can be completely 
converted to very photoactive monomers, 
which may compensate for the reduction in 
the uptake. Our result is consistent with those 
obtained by other groups, where incorporation 
of PS in PLGA NPs has been shown to enhance 
the photodynamic activity of the PS and give 
improved phototoxicity results compared with 
the free PS [16,40].
The distribution of temoporfin applied to 
mice loaded either in NPs or as Foscan was 
compared by fluorescence-based imaging. As 
expected, 24 h postinjection the total body 
fluorescence of temoporfin delivered by NPs 
was significantly lower than that delivered by 
Foscan, which can be accounted for by the 
delayed release of temoporfin from the PLGA 
matrix. At 96 h postinjection, the total body flu-
orescence reached steady levels for both NP for-
mulations, indicating that, in this time period, 
most of the temoporfin was released from the 
PLGA NPs. The tissue distribution of temo-
porfin differed little between the delivery sys-
tems (FIGURE 9). The skin and the tumor uptake 
indicate that temoporfin loaded to PEGylated 
PLGA NPs results in a higher tumor-to-skin 
ratio than Foscan or PLGA NPs, thus limiting 
the side effects of the treatment [6]. Moreover, 
PEGylated PLGA NPs show decreased delivery 
of temoporfin into the lungs and colon than 
PLGA NPs, which could further reduce side 
effects in healthy tissues.
Conclusion
A stealth, biodegradable nanosystem has been 
developed for the systemic delivery and pro-
longed intracellular release of photodynamic 
agents for PDT. We demonstrated higher in vitro 
phototherapeutic effectiveness of temoporfin 
delivered by PEGylated NPs than in standard 
solution (Foscan). PEGylation significantly 
reduced the cellular uptake of NPs, especially 
by the differentiated promonocytic U937 cells, 
revealing the stealth properties of the delivery 
system. Importantly, the dark cytotoxicity of 
temoporfin in the PLGA formulation is sub-
stantially lower than that of Foscan, with the 
consequence that fewer side effects of PDT are 
envisaged by delivering temoporfin in PLGA 
NPs. Finally, temoporfin delivered in vivo by 
PEGylated PLGA NPs exhibits favorable tissue 
distribution to be used in PDT. The selectiv-
ity of the delivery system, and hence of PDT, 
could be further improved by binding biological 
molecules that specifically recognize tumor cells.
Future perspective
Toxicity of anti-tumor drugs should be limited to 
tumor cells and tissues with low adverse effects 
on other organs. PEGylated PLGA NPs enable 
more specific targeting of the PS temoporfin to 
tumor cells than the standard solution of temo-
porfin and may improve PDT of cancer patients. 
However, for effective tumor targeting, the 
nanoparticulate delivery system has to contain 
surface-bound ligands that specifically recognize 
tumor-associated molecules. Second, the process 
of preparation of temoporfin-loaded PEGylated 
PLGA NPs needs to be optimized in order to 
improve the stability and to prevent aggrega-
tion and sedimentation of NPs when dispersed 
in serum-like media. Finally, additional in vivo 
studies, testing the phototoxic effect of temopor-
fin are needed to confirm the advantage of new 
temoporfin formulation over existing studies.
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Abstract 
PEGylated and non-PEGylated ORMOSIL nanoparticles 
prepared by microemulsion condensation of vinyltriethoxy-
silane (VTES) were investigated in detail for their micro-
structure and ability to deliver photoactive agents. With 
respect to pure silica nanoparticles, organic modification 
substantially changes the microstructure and the surface 
properties. This in turn leads to a modulation of both the 
photophysical properties of embedded photosensitizers and 
the interaction of the nanoparticles with biological entities as 
serum proteins. The flexibility of the synthetic procedure 
allows the rapid preparation and screening of multifunctional 
nanosystems for photodynamic (PDT) therapy. Selective 
targeting of model cancer cells was tested by using folate, 
integrin specific RGD peptide and anti-EGFR antibodies. 
Data suggest the interference of the stealth-conferring layer 
(PEG) with small targeting agents, but not with bulky 
antibodies. Moreover, we showed that selective photokilling 
of tumour cells may be limited even in the case of efficient 
targeting because of intrinsic transport limitations of active 
cellular uptake mechanisms or suboptimum localization. 
Introduction 
Over the last few years, silica nanoparticles have attracted a great 
deal of interest as materials for biomedical applications.1 At first 
glance, this may appear quite surprising. Unlike other 
nanomaterials, silica nanoparticles do not have any nanosize-
related properties, nor are they easily biodegraded.2 So, what 
makes silica nanoparticles so attractive? The answer lies in their 
highly cross-linked polymeric nature. Being of polymeric 
structure they can accommodate in their interior (either in the 
silica matrix or within pores) active molecules, such as drugs, 
dyes and photosensitizers.3 The loading capacity of silica 
nanoparticles is hence much higher than that achievable with 
other nanomaterials which allow only surface grafting, and this 
enables their use for drug delivery applications. On the other 
hand, their highly cross-linked nature renders silica nanoparticles 
much more rigid than other polymeric nanoparticles. This makes 
it possible to process them into very complex structures, 
including mesoporous particles,1c,4 nanoshells5 and multi-shell 
particles.3,6 Such versatility has opened the way to the realization 
of several sophisticated systems, such as gated porous particles 
for controlled release,1a,f multimodal imaging and delivery 
agents,1 chemical sensors.7 Notably, silica does not need to be 
made only by silicon oxide. Using organosilane precursors in the 
formation of the silica network, organically modified silica 
(ORMOSIL) materials can be obtained.8 Here, the possibilities 
for tuning the nanoparticles properties, either of the surface and
Scheme 1. One-pot synthesis of doped, PEGylated and functional ORMOSIL nanoparticles. Any of the components indicated in the caption, with the 
exception of the surfactant may be omitted to prepare nanoparticles with different features.
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of the bulk phase, or by changing the nature of the organic moiety 
introduced, are very broad. A class of ORMOSIL nanoparticles 
that has recently emerged as an attractive candidate for 
nanomedicine applications comprises those prepared by the base-
catalyzed condensation of vinyl-triethoxysilane (VTES, chart 1) 
in aqueous surfactant solutions.  
This synthetic protocol was first proposed by P. N. Prasad and 
co-workers in 2003 for the development of photosensitizer 
delivery agents in photodynamic therapy (PDT).9 This approach 
enabled a series of very elegant advances stemming from the 
original photosensitizer loaded particles,10 including two-photon 
excitation of the photosensitizer through Förster energy transfer 
from a co-included antenna11 and matrix enhancement of the 
singlet oxygen production quantum yield.12 Applications for 
fluorescent probes,13 encapsulation of other nanoparticles,14 DNA 
transfection15 and targeted delivery16 were also reported. 
Advantages of such ORMOSIL nanoparticles are many. Firstly, 
the use of the organosilane precursor provides a low polarity 
interior that favours the inclusion of hydrophobic molecules but 
does not prevent their release in biological fluids.17 Secondly, the 
properties of both the bulk material and probably also of the 
particles surface may be tailored, as mentioned earlier, by the use 
of different organosilane precursors. But the most relevant feature 
is brought about by the microemulsion polymerization protocol 
used for their preparation. In fact, not only does the surfactant 
aggregate act as a nanocontainer where the organosilane 
polymerization is confined, but it can also play the role of a 
template, where it pre-organizes the nanoparticle components 
placing them precisely in the site they are needed to perform their 
function. Hence, as demonstrated by Prasad and also by us, dye-
doped surface functionalized nanoparticles can be prepared by a 
one pot-procedure.16,18 Indeed, we recently showed, by taking full 
advantage of such an approach, that densely PEGylated 
nanoparticles can be prepared18 and that such a dense coating 
reduces the toxic19 and pro-coagulant20 properties of particles 
themselves and avoids capture by immune system cells.18 While 
these findings further amplify the interest in nanomedicine 
applications of ORMOSIL nanoparticles, their structure and 
characteristics have yet to be fully investigated. By a detailed 
investigation of the chemical, structural and biological properties 
of PEGylated and non-PEGylated ORMOSIL nanoparticles made 
with VTES, we have acquired herein a deeper comprehension of 
their properties and potential for applications. 
Results and Discussion 
Chemical microstructure and surface properties 
The synthesis of the VTES-ORMOSIL nanoparticles (Scheme 1) 
may be regarded as a variation of the well-known Stöber 
procedure,21involving the ammonia-catalysed polymerization of 
alkoxysilane precursors in ethanol. The main difference here is 
that the reactions occur in water and in the presence of a 
surfactant (AOT, Tween, Brij) that controls the growth of the
Figure 1. ATR-IR Spectra of lyophilized ORMOSIL nanoparticles (blue) 
and PEGylated ORMOSIL nanoparticles (green). 
nanoparticles. Such modifications of the use of an organosilane 
precursor may influence the nanoparticles microscopic structure. 
With this view, we prepared VTES nanoparticles with a diameter 
of 50 nm using the Brij surfactant for spectroscopic 
characterization. The ATR-IR spectrum (Figure 1, blue) contains 
all the main features of VTES-containing materials.22 The most 
intensive band, at about 1100 cm-1 is due to the asymmetric 
stretching of the Si–O–Si bridges, and, as usually found for 
ORMOSIL materials, splits into two separate bands at 1040 (TO 
mode) and 1110 (LO mode) cm-1. Interestingly, the position of 
these signals is 20-40 nm red-shifted with respect to the usual 
values found in VTES containing sol-gel films prepared by acid 
catalysis,22 possibly indicating a highly porous structure of the 
nanoparticles. The symmetric stretching of the same silicon–
oxygen bridges is responsible of the band at about 760 cm-1. The 
sharp signals at 1409 (in plane CH2 bending) and 1602 (C=C 
stretching) cm-1 arise from the vibrations of the vinyl groups. On 
the other hand, the sharp signal at 966 cm-1, is likely the result of 
the overlap of the signals arising from Si-OH stretching and vinyl 
CH2 wagging. 
More detailed structural information is obtained by MAS solid 
state NMR. 13C NMR (Figure 2a, blue) confirmed the complete 
hydrolysis of the alkoxysilane precursor since no signals related 
to the ethoxy moieties are visible in the spectrum. The two-broad 
signals at 145 and 135 ppm arise from the two carbon atoms of 
the vinyl residue. On the other hand, a series of sharp signals is 
visible between 80 and 20 ppm, which corresponds very well to 
the Brij surfactant. We were not able to remove the surfactant 
signals either by extensive ultrafiltration or Soxlet extraction with 
ethanol, indicating that it is likely physically entrapped in the 
ORMOSIL matrix. The 29Si spectrum (Figure 2b, blue) shows 
two signals at -77 and -68 ppm, arising respectively from fully 
condensed T3 and partially condensed T2 silicon atoms.  
Integration of the signals indicates that T2 atoms are only 10% of  
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Figure 2. 29Si MAS (a) and 13C MAS solid state NMR of lyophilized 
ORMOSIL nanoparticles (blue) and PEGylated ORMOSIL nanoparticles 
(green). C=C indicates the vinylic carbons and C-O the carbons bound 
oxygen of the PEG polymer.  to The symmetric signals (*) at 70 and 170 
ppm in the 29Si spectrum are spinning bands. 
the total, indicating a highly condensed structure. When 
compared with pure silica nanoparticles, the VTES ORMOSIL 
particles reveal interesting differences. Early studies by van 
Blaaderen indicated that silica nanoparticles prepared either via 
the Stöber protocol (TEOS condensation in ethanol) or via the 
micro-emulsion protocol (TEOS condensation in 
water/cyclohexane microemulsion) are characterized by 
incomplete hydrolysis of the precursor alkoxysilanes and much 
less condensed structure (67 and 55% of fully condensed Q4
silicon atoms, respectively).23 Only the commercial Ludox 
particles, that are prepared by condensation of silicates in water, 
present a similarly highly condensed structure, with 85% of Q4
silicon atoms.23
The degree of hydrolysis and condensation, however, does not 
influence surface charge, which is one of the most important 
features of nanoparticles for biomedical applications since it 
determines their stability in high ionic strength biological fluids 
and ability to interact with cells. Z-potential measurements 
performed in PBS buffer at pH 7.4 yielded the values of -5.9, -
18.3 and -15.6 mV respectively for ORMOSIL, Stöber and Ludox 
particles (50 nm diameter). Hence, surface charge is not 
proportional to the amount of Si-OH groups present on the 
particles, which is greater in Stöber particles and smaller in 
ORMOSIL and Ludox. Van Blaaderen calculations reveal that 
surface silanols account for a very small fraction (2,5% for 50 nm  
Figure 3. Comassie Blue stained SDS-PAGE analysis of nanoparticle-
bound human plasma proteins. 
diameter nanoparticles) of the total silicon atoms.23 Hence, even 
in the most condensed particles the amount of silanols detected 
by 29Si MAS NMR groups largely exceed that necessary for a full 
surface coverage. This explains why Stöber and Ludox particles 
have similar Z-potential values notwithstanding the large 
difference in number of silanols. Once all the available sites on 
the surface are occupied, silanols in excess must locate in the 
nanoparticles interior not affecting the overall surface charge. 
Hence, in the case of ORMOSIL particles, the less-negative Z-
potential could be explained by postulating that several vinyl 
moieties are exposed on surface instead of OH groups, and this 
reduces the overall surface charge. The consequences of such a 
relevant difference in the surface chemical structure should be 
observed not only on the Z-potential values but also on the 
interaction with serum proteins, which is fundamental in 
determining the biological fate of the nanoparticles.24 To test this 
hypothesis the patterns of protein adsorbed on ORMOSIL and 
Ludox particles, after 3 hours incubation at 37°C in human 
plasma, were identified by SDS-PAGE and mass spectroscopy 
(figure 3). Interestingly, both ORMOSIL and Ludox particles 
recruit few and quite different plasma proteins, with Ludox 
interacting preferentially with Immunoglobuline-G (IgG), 
Histidine Rich Glycoprotein (HRG), Human Serum Albumin 
(HSA) and apolipoproteins ApoA-I, ApoA-II, and ApoC-III, 
while ORMOSIL exhibit higher affinity for ApoA-IV, ApoE, 
ApoJ and ApoA-I. Hence, the reduction of the surface charge 
(which still remains negative) and the exposure of vinyl residues 
results in a shift of preference from soluble IgG, HSA and HRG 
proteins to more hydrophobic lipoproteins. We previously 
observed that hydrophobic photosensitizers entrapped in the 
ORMOSIL where rapidly released from the nanoparticles when 
incubated with serum.17b The high preference for recruiting 
lipoproteins, which are known carriers of hydrophobic species, 
could account for this observation. 
As we have shown earlier, addition of an amphiphilic 
trialkoxysilane PEG derivative to the reaction mixture, as 1 in 
Chart 1, results in the formation of densely PEGylated 
nanoparticles.18 PEGylation produces only minor modifications 
on the IR spectrum (Figure 1, green) where a broadening of the 
signals in the 1000-1200 cm-1 range, due to the superimposition 
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Chart 1. Alkoxysilane derivatives used in this work. 
of the PEG signals, is the main difference observed. PEG features 
are also visible in the 13C MAS solid state NMR signal at 71 ppm, 
arising from the methylenes of the polyethylene oxide chain 
(Figure 2b, green). Analysis of this spectrum also reveals the 
absence of residual surfactant in these samples, in contrast with 
the non-PEGylated ORMOSIL nanoparticles (Figure 2b, blue). 
This suggests that the presence of the amphiphilic silane prevents 
the surfactant from remaining physically entrapped in the 
ORMOSIL matrix, hence favouring its removal. TGA analysis 
(ESI) reveals that the dense coat of PEG-2000 accounts 
respectively for 67, 38 and 25% of NPs weight for nanoparticles 
with 20, 55 and 70 nm diameters. Such figures lead to estimate a 
surface density of 1-2 PEG molecules per nm2.
Finally, 29Si-NMR indicates a smaller degree of condensation of 
the silicon atoms, with the amount of partially condensed T2
atoms raised here to 34%. However, both the surface coating with 
PEG and again the presence of a larger amount of silanol groups 
in the ORMOSIL matrix appear not to affect the overall surface 
charge, the Z-potential (in PBS buffer, pH 7.4) being −4.3 mV, 
only slightly different form that of the “naked” ORMOSIL 
particles. 
Photochemical properties of embedded photosensitizers 
Having such a strong influence on the surface properties of the 
nanoparticles, the presence of the vinyl groups is expected to 
affect also the interior silica matrix and as a consequence the 
properties of embedded dyes. This aspect is particularly relevant 
for one of the most promising application of VTES-ORMOSIL 
nanoparticles, namely the anticancer modality called 
photodynamic therapy (PDT). In this approach, a 
photosensitizing molecule should be selectively delivered inside 
the tumour and produce, upon activation with light, cytotoxic 
reactive oxygen species (ROS) that kill the tumour cells. 
Remarkably, the photosensitizer does not need to be released 
from the carrier to exert its phototoxic effect and therefore it can 
be embedded in the nanoparticles without the need of devising 
effective release mechanisms. However, the essential requirement 
is that the embedded photosensitizer maintains its photophysical 
properties and hence its ability to generate ROS, in particular 
singlet oxygen.
To investigate this point, we initially prepared both Stöber silica 
nanoparticles and VTES-ORMOSIL nanoparticles (both 
PEGylated and not) doped with the alkoxysilane porphyrin 
derivative 3 (we selected this molecule because most of the 
photosensitizers used in clinic are porphyrins or chlorins) and 
investigated the photophysical properties of the embedded dye. 
Inspection of the fluorescence lifetime data reported in Table 1 
reveals that all the nanoparticles-embedded dyes (Entries 2-4) 
show biexponential decays with a long component (~10 ns) that 
is very similar to the life-time of 3 in ethanol (Entry 1) and a 
short component (~3 ns) which presumably arise from poorly 
emissive porphyrin aggregates. However, while the short 
component is minor in the ORMOSIL particles, it is predominant 
in the Stöber particles (Entry 2), where this behaviour is 
accompanied by a broadening of the porphyrin Soret band in the 
UV-Vis spectrum (ESI). This suggests that the more polar 
environment provided by silica matrix with respect to that of 
ORMOSIL favours the formation of weakly fluorescent dye 
aggregates inside the particles, which are known to be ineffective 
as photosensitizers.25 Fluorescence self-quenching through 
interaction of adjacent photosensitiser moieties results in lower 
triplet state and singlet oxygen yields, and this interaction should
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Table 1. Photophysical properties (fluorescence lifetimes (?) and their 
amplitudes (A), and singlet oxygen quantum yields (??) of 
photosensitizers embedded in silica (Stöber) and ORMOSIL (OS) 
nanoparticles.a,b
Entry Dye Np Solvent ?1/ns (A1) ?2/ns (A2) ??e?
1 3 - EtOH 9.5 (100) -
2 3 Stoberc H2O 9.6 (55) 2.3 (45) -
3 3 OSc H2O 11.2 (91) 3.0 (9) -
4 3 OS/PEGc H2O 12.1 (85) 4.7 (15) -
5 mTHPC - MeOH 8.4 (100) - 0.71
6 4 - MeOH 8.4 (100) - 0.67
7 4 OS/PEGd MeOH 8.5 (91) 0.8 (9) -
8 4 OS/PEG MeOH 8.6 (94) 1.0 (6) 0.55
9 4 OS/PEG MeOH/H2O 9.7 (90) 1.7 (10) -
10 4 OS/PEG H2O 9.9 (83) 0.8 (17) 0.53
11 5 - MeOH 8.3 (100) - 0.65
12 5 OS/PEGd MeOH 8.7 (78) 3.4 (22) 0.55
13 5 OS/PEG MeOH 8.4 (88) 1.2 (12) 0.58
14 5 OS/PEG MeOH/H2O 9.9 (52) 0.8 (48) -
15 5 OS/PEG H2O 10.0 (18) 0.7 (82) 0.10
a Nanoparticles diameter 20 nm and average photosensitizer loading 1.5% 
w/w unless otherwise stated. bErrors within 5%. c0.3% w/w 
photosensitizer loading. d 90 nm diameter. e ???measured in MeOD except 
Entries 10 and 15, which were carried out in D2O. 
therefore be minimised as far as possible. The less polar 
environment provided by the ORMOSIL matrix hence appears to 
be ideal for accommodating photosensitizer molecules with 
retention of their optimal photophysical properties. 
More insight on this respect was obtained by studying the 
photochemistry of ORMOSIL nanoparticles containing the 
alkoxysilane derivatives 4 and 5 of the commercial 
photosensitizer mTHPC (Chart 1). Likewise in the previous case 
fluorescence decay profiles are biexponential, with the long 
component (~8-9 ns) similar to that of the free dye in methanol 
and a short component (~0.5-1 ns). mTHPC in MeOD 
(“monomeric mTHPC”) exhibited a ?? of 0.71, which is in 
agreement with the literature.26
In methanol, either mono- and tetra-functionalization of the 
parent mTHPC does not significantly alter the photophysical 
properties of the derivatives (Entries 5, 6 and 11). The singlet 
oxygen yields measured for mTHPC in MeOD are in good 
agreement with other studies.26 Also embedding in the 
ORMOSIL matrix does not alter the photosensitizer properties 
(Entries 7-8, 12-13). In fact, in all these cases very similar 
emission lifetimes are observed with a major long-lived 
component and a minor short component. However, the situation 
drastically changes when moving to solvents with higher polarity 
(1:1 methanol/H2O, H2O). In the particles doped with 4 the long 
component remains predominant with only a slight increase of 
the short-lived one in more polar solvents (Entries 8-10). 
However, in the particles doped with 5, the amplitude of the short 
component is substantially increased in water so that it becomes 
the dominant decay component. The fluorescence emission 
intensity is also substantially quenched compared to methanol 
(Entries 13-15). The behaviour of the emission quantum yield 
parallels that of the singlet oxygen quantum yield (measured by 
singlet oxygen phosphorescence at 1270 nm). Singlet oxygen 
production of nanoparticles doped by both the dye in methanol 
and by dye 4 in deuterated water are very similar to that of 
mTHPC in deuterated methanol, on the other hand, singlet 
oxygen production by 5-doped nanoparticles in deuterated water 
is much lower (Entry 15). 
The peculiar behaviour of the embedded dye 5 is not due to 
aggregation since it is not loading-dependent (not shown). In this 
case we propose that the penetration of water and resulting H-
bonding inside the nanoparticle may lead to distortion of the 
tetra-coordinated chlorin macrocycle since it is rigidly attached to 
the silica matrix and cannot compensate by conformational 
realignment, unlike the mono-coordinated chlorin which is able 
to rotate. Distortion in the macrocycle planarity is well known to 
increase the rate of internal conversion resulting in quenching of 
its emission and singlet oxygen production.27
Targeting of the ORMOSIL nanoparticles 
As we earlier demonstrated, functional groups for conjugation of 
the nanoparticles to targeting species can be introduced in the 
coating layer by simply adding a second PEG-trialcoxysilane
derivative bearing a reactive terminal group (Scheme 1).18 To 
further explore such possibility we prepared several batches of 4-
doped ORMOSIL nanoparticles targeted with different bioactive 
molecules, such as folic acid, biotin, the cyclic(RGD) peptide and 
the antibody Cetuximab (Chart 2). The nanoparticles were 
prepared in different sizes (20-100 nm) by adding to the reaction 
mixture different amounts of PEG derivatives 1 and 2 (1-30%). In 
the case of folic acid and biotin, which can be directly linked to 
the nanoparticles amino groups via the formation of an amide 
bond, targeting was performed by directly adding O-
hydroxysuccinimmide ester derivatives of the targeting agents to 
the reaction mixture before the purification (Scheme 1). In this 
way, dye-doped, PEGylated and targeted nanoparticles could be 
prepared by a simple one-pot procedure. The grafting of folate 
and biotin to the nanoparticles was demonstrated by the presence 
of the characteristic spectral features of this molecule in the UV-
Vis spectrum in the case of the first, and by the HABA-Avidin 
and the EZview Red Streptavidin Affinity Gel tests for the second 
(see ESI). 
On the contrary, the cyclic(RGD) peptide, which targets the ?v?3
integrin associated to tumor neovasculature (Chart 2), and the 
Cetuximab antibody, recognizing the Epithelial Growth Factor 
receptor (EGFR) overexpressed in many tumours, were 
conveniently conjugated to the nanoparticles by taking advantage 
of thiols group inserted in the derivatives (i.e. in the case of 
Cetuximab thiols group were introduced by reaction with 2-
iminothiolane). This required the conversion of the terminal 
amine groups of the nanoparticles into thiol-reactive maleimide 
groups via the reaction with the commercial MBS crosslinker 
(Chart 2). Subsequent reactions with the cyclic(RGD), the 
inactive analogue cyclic(RAD) and iminothiolane modified 
Cetuximab antibody provided the targeted nanoparticles. In this 
case, due to the sensitivity of the maleimide group to 
nucleophiles, and to prevent unwanted conjugation between the 
targeting peptide and unreacted MBS, we preferred to perform 
the conjugation with a three step procedure involving 
nanoparticles purification after each step (Chart 2). Antibody  
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Chart 2. Targeting agents used and scheme for the post-synthetic functionalization of 1/2-coated nanoparticles with the peptides and antibodies (TAG).
conjugation was confirmed by Western Blot analysis (see ESI).
Cellular uptake and targeting
In order to investigate the ability of the PEGylated ORMOSIL 
nanoparticles to enter cancer and healthy cells, free mTHPC and 
4-doped nanoparticles (90 nm diameter) were incubated, at the 
same dye concentration, with human lung carcinoma cells A549 
and normal lung fibroblasts CCD-34Lu for 24 h at 37 °C in 
culture medium supplemented with 3% fetal calf serum (FCS). 
The dye uptake was measured by flow cytometry (FACS)
experiments using the fluorescence emission of the chlorins 
associated to the cells. As expected, the cellular uptake of the 
drug by both the cancer (Figure 4) and healthy cells (ESI, Figure 
S10) is greatly reduced by the embedding in the PEGylated 
nanoparticles, with the uptake of the photosensitizer being only 
about 5% of that measured when the free dye is incubated with 
the cells.
These results are important because they clearly indicate that the 
use of the PEGylated nanoparticles as a carrier for the 
0
1x104
2x104
3x104
4x104
5x104
6x104
7x104
1.751.510.750.5
m
T
H
PC
 fl
uo
re
sc
en
ce
 (a
.u
.)
mTHPC (?M)
0.25
Figure 4. Flow cytometry measurements of mTHPC and derivative 
4uptake in A549 cells incubated for 24 h with increasing concentration 
of free mTHPC (white) or 4-doped PEG-ORMOSIL nanoparticles (grey).
photosensitizer should minimize unwanted uptake by healthy 
tissues and by consequence reduce the unwanted systemic 
toxicity of the therapy. On the other hand, this ability to escape 
cell capture makes conjugation with targeting agents necessary in 
order to trigger active uptake mechanisms and ensure that the 
photosensitizer is delivered to the target cells. We hence 
investigated the “in vitro” uptake of folate-, RGD- and 
Cetuximab-conjugated nanoparticles using cell lines over-
expressing the targets recognized by each vehicle moieties. The 
results obtained are quite different with the three guided-
nanosystems. 
In the case of folate, KB cells overexpressing and A549 cells not 
expressing the folate receptor were used. The presence of the 
folate in the nanoparticles coating results in (see ESI): i) 
decreased uptake with respect to nanoparticles coated with only 
PEG; ii) no difference in the uptake of folate-nanoparticles 
between KB and A549 cells (not shown) and; iii) no inhibition of 
the uptake of folate-targeted nanoparticles in KB cells 
preincubated with 1 mM free folic acid to saturate the receptor 
and prevent the internalization of the nanoparticles through the 
receptor-driven specific endocytosis. Such behavior is not 
affected by the size of the nanoparticles or by the thickness of the 
PEG coating or the length of the PEG functioning as a linker for 
folate. 
Different results were obtained with the RGD-targeted 
nanoparticles incubated with HUVEC cells overexpressing the 
integrin ?v?3 receptors for RGD. We evaluated the efficiency of 
the targeting agent on the same cell line by comparing the uptake 
of the RGD-targeted nanoparticles with that of identical particles 
(prepared from the same original batch) targeted with the RAD 
peptide, where the substitution of the central glycine with an 
alanine prevents the recognition by the integrins. Inspection of 
the results reported in Figure 5 provides evidence of higher 
uptake of the RGD-conjugated nanoparticles with respect to the 
RAD-conjugated ones. The uptake improves by increasing the 
amount of RGD peptides present in the nanoparticles coating 
layer form 15 to 30%, while uptake slightly decreases using 
smaller nanoparticles (40 nm diameter). The different behaviour 
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Figure 5. Flow cytometry measurements of mTHPC derivative 4 uptake
in HUVEC cells incubated for 3 or 24 h with 4-doped PEG-ORMOSIL 
nanoparticles of different size and conjugated with RGD and RAD 
peptides in different amounts.
between the two small-molecule targeting agents is not 
unprecedented in PLGA nanoparticles and was attributed to poor 
surface exposure of the hydrophobic folate moiety.28 Moreover, it
has been recently reported that a dense PEG layer coating silica 
nanoparticles can effectively capture and incorporate organic 
dyes from water solution.29 It can hence be expected that the long 
PEG3300 linker, bearing the targeting agent, folds allowing to the 
folate moiety to hide in the PEG layer. In support of this view, 
some of us recently found that only liposomes with a degree of 
PEGylation not higher than 8% folate conjugation slightly 
improved the selectivity of mTHPC uptake in KB cells.30
Furthermore, the decreasing uptake of folate ORMOSIL 
nanoparticles with the increasing of the folate percentage might 
indicate changes of the surface properties that make cell 
internalization less efficient. The zwitterionic RGD peptide is 
much more hydrophilic than folate and hence it likely less 
attracted by the PEG pseudophase, therefore remaining available 
for the interaction with the cellular receptor. 
Such a picture is confirmed by the results obtained with the 4-
doped nanoparticles conjugated with the antibody Cetuximab 
(Figure 6). Here the size of the targeting agent (i.e. the average
size of an antibody is 15×8×4 nm31) is such that the interference 
of the PEG coating with its binding efficiency appear to be 
unlikely. In fact, internalization of targeted nanoparticles at 37°C,
measured on the A431 cells overexpressing the EGF receptor, is
impressive. The uptake of the conjugated nanoparticle is at least 
20-fold greater than that of the unconjugated or BSA-conjugates 
(prepared as negative control systems). The specific uptake of 
Cetuximab-guided nanoparticles on A431 cells was confirmed by 
competition experiments performed co-incubating cells, at 37°C, 
with increased concentrations of free Cetuximab (Figure 7). In
fact the co-incubation of targeted nanoparticles with free 
Cetuximab reduces the nanoparticle uptake of about 93%, 
whereas no decrease of nanosystem uptake is observed for BSA-
conjugated control particles in the same conditions (see ESI).
Further assays were performed to obtain more insight on the 
internalization mechanism. First the dependence of the uptake by
the amounts of Cetuximab or BSA-conjugated nanoparticles
Figure 6. Differential uptake of 4-doped PEG-ORMOSIL nanoparticles 
unconjugated (NPs alone), or conjugated with Cetuximab and BSA on 
A431 cells. Cells were incubated with nanoparticles at1 ?M concentration 
of dye 4 for 90 minutes at 37°C, nanoparticle uptake was analyzed by 
flow cytometry.
added was investigated (see ESI) and demonstrates that the 
internalization mechanism of the antibody-guided nanovectors is 
saturable. In fact, the amount of taken-up nanoparticles does not 
increases linearly with the amount of nanoparticles added and 
appears to reach a plateau for nanoparticles concentrations of 320 
?g/mL (corresponding to a dye concentration of 4 ?M). Such 
behavior suggests that, once all the EGF receptors available on 
the surface of the cells are bound to antibodies conjugated with 
the nanoparticles, further increments of the nanoparticles 
concentrations do not result in increased uptake, as expected for a 
receptor mediated internalization mechanism. Indeed the BSA-
conjugated nanoparticle uptake appears to follow a different trend 
with a linear concentration-dependent increase of the uptake in 
the interval studied. 
The same picture emerged from time-dependant analysis 
performed using in this case three different cell lines (see ESI):
Figure 7. Displacement of the uptake of 4-doped PEG-ORMOSIL
nanoparticle conjugate with Cetuximab on A431 cells by free Cetuximab. 
Cells were incubated with nanoparticles at 0.25 ?M concentration of dye
4 and increasing concentrations of free Cetuximab for 90 minutes at 
37°C, nanoparticle uptake was analysed by FACS.
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Figure 8. Nanoparticles induced down-regulation (measured as amount of 
cell bound FITC-labelled anti EGFR antibody) of EGF receptor in 
different cell lines. Cells were incubated in DMEM 10% FCS with 
different concentrations of Cetuximab (?) or BSA (?) conjugated 
nanoparticles for two hours at 37°C; washed and analysed by FACS. Note 
the different signal intensities in the three cell lines, proportional to 
plasma membrane EGFR amounts. 
normal HeLa cells, expressing basal amounts of plasma 
membrane located EGFR, a derived HeLa cell lines, permanently 
transfected to express higher levels of surface EGFR (4-5 folds 
the parental HeLa cell line) and the above mentioned A431 cells, 
expressing a high amount of EGFR (10-13 folds in the plasma 
membrane compared to HeLa cells). As expected, Cetuximab-
conjugated nanoparticle uptake is not linear with incubation time 
and reaches a saturation level after about 2 hours with all the cell 
lines. Moreover, the amount of nanoparticles taken up at 
saturation is directly correlated with the extent of EGFR 
expression levels, with A431 and transfected HeLa internalizing 
upon prolonged incubation an amount of nanoparticles about 20- 
and 4-fold larger than normal HeLa. On the other hand, non-
specific uptake of BSA-conjugated nanoparticles appears to occur 
with a slower and cell line-independent kinetic that does not 
reach saturation values in the time span explored. As a 
consequence, maximum preferential uptake is observed for short 
incubation times. 
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Figure 9. Colocalization of Cetuximab and dye 4 upon incubation of 
EGFR positive A431 cells, EGFR over-expressing HeLa and parental 
HeLa (having reduced EGFR levels) with Cetuximab conjugated 4-doped 
ORMOSIL nanoparticle at 1 μM mTHPC concentration for two hours at 
37°C. Green signal is Cetuximab distribution, red one is mTHPC. Arrows 
point the colocalisation of Cetuximab and mTHPC.
The specific interaction of the nanoparticles with EGFR, 
followed by internalisation of the resulting complex, was clearly
documented by further experiments in which the amount of 
surface receptors was quantified by FACS after incubation with 
nanoparticles using a fluorescein-conjugated Cetuximab as a 
label (Figure 8). Indeed, Cetuximab-conjugated nanoparticles, but 
not BSA-conjugated ones, down regulate EGFRs in all cell types, 
suggesting, in agreement with confocal microscopy (see infra),
that Cetuximab-nanoparticles complexes with EGFRs, formed on 
the plasma membrane, are internalised in endosomes and this 
leads to a decrease of the amount of receptor on the cell surface.
EGFR down regulation is complete at very low nanoparticle 
concentrations (50 ?g/mL for A431 cells, corresponding to a 4
concentration of 0.62?M). Confocal microscopy analysis
experiments (Figure 9) enabled localisation of both nanoparticle-
linked Cetuximab (by staining with a fluorescein labelled anti-
human antibody) and of the nanoparticle-linked dye 4. The 
experiment confirmed that the nanoparticles bind more 
effectively to cells overexpressing the EGFR, with localized 
emission of dye 4 suggesting endosomial localization, while the 
high degree of colocalization of Cetuximab and 4 indicates that 
the nanoparticles maintain their integrity upon internalization.
Taken together, all these experiments confirm an active uptake 
mechanism, where the targeted nanoparticles bind to the EGF 
receptors available on the cell surface and are internalized by 
endocytosis. On the other hand, untargeted nanoparticles are 
taken up by a slow and non saturable passive mechanism. Hence, 
optimal selectivity can be achieved for relatively low doses and 
incubation times.
Finally from the perspective of future “in vivo” evaluations, we 
investigated the serum stability of our protein conjugated-
nanosystems. The nanoparticles functionality, assessed as binding 
and uptake capabilities on A431 cells, decreases of less than 20% 
when the incubation of Cetuximab-conjugated nanoparticles was 
performed in 100% of serum (i.e. 90 minutes at 37°C). The good 
serum stability was also confirmed when longer incubation times 
were applied (i.e. 32% of functionality was preserved after 16 hrs 
of serum pre-treatment, data not shown).
PDT experiments
The phototoxicity of 4 delivered by nanoparticles was determined 
both in the case of RGD- and Cetuximab-conjugated 
nanoparticles. In the case of RGD nanoparticles, a significant 
reduction of the cell viability was found after irradiation of the 
cells incubated with the 4-loaded nanoparticles, demonstrating 
the photokilling activity of the dye embedded in the 
nanoparticles. Disappointingly, the dose-response curve obtained 
by treatment of the HUVEC cells with RGD-conjugated
nanoparticles was in any case perfectly superimposed (see ESI) to 
that of RAD-conjugated nanoparticles. A possible explanation of 
such a behaviour is based on the findings of Allen and co-
workers that suggest that RGD, but not RAD, partially protect the 
cells from PDT induced death by exerting an anti-oxidant and/or 
anti-apoptotic effect.32
Better results were obtained with the Cetuximab-conjugated 
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nanoparticles (Figure 10), but only when prolonged (6 hours) 
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legend: A) Cells were incubated for 6 hours at 37°C in DMEM 10%  FCS with a concentration of Erbitux-NPs corresponding 
to the indicated concentrations of mTHPC, washed with PBS and irradiated or not for 10 minutes at room temperature (60 mWatts/cm
2
)
with a Waldmann Meidizintechnik PDT 1200 apparatus. After placing cells in culture medium again for 24 hours,   cells viability was determined as MTS assay
and expressed as percent of non-irradiated samples at the same NPs doses. Dark toxicity in these conditions was < 3 % with respect to cells not treated
with any agonist. Positive controls (not shown) were cells treated with 0.1 ?M free mTHPC in the same conditions, 
corresponding to a 16 folds higher loading of the photosensitiser leading to > 95 % cell killing after irradiation. B) Ratio values of percentage of dead cells after treatment with Erbitux-NPs and irradiation 
with respect  dead cells after treatment with BSA-NPs and irradiation. The numbers  in square brackets indicate the absolute percentage of killing in A431 cells in each condition.
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Figure 10. Photokilling efficiency of Cetuximab- and BSA-conjugated 4-
loaded PEG-ORMOSIL nanoparticles upon incubation for 6 hours with 
different cell li es and light xp sure. A) Amount of cells kil ed with 
respect to the controls at increasing nanoparticle doses. B) Ratio of 
photokilling activity between targeted and control nanoparticles on the 
different cell lines as a function of the dose administered. 
incubation times where applied. As revealed from figure 10A, 
absolute photokilling efficiency does not correlate with uptake in 
the different cell lines, likely as a result of a different ability of 
the cell line to resist to cytotoxicity of generated ROS. However,
when the attention is focused on the difference between the 
activity of the targeted and untargeted nanoparticles with each 
cell line, it appears evident as the Cetuximab-conjugated 
nanoparticles are substantially more efficient in photokilling 
A431 cells (up to 8-fold) than the BSA-conjugated counterparts 
when delivered at doses well below the EGF receptors saturation 
level. This difference rapidly decreases when the nanoparticles 
dose is increased, possibly because the non-specific uptake of the 
untargeted particles becomes more relevant with respect to the 
receptor-mediated uptake at this prolonged incubation times, or 
when cells express a lower (HeLa-EGFR, 40% of EGFR with 
respect to A431) or negligible (HeLa) amount of EGF receptor. 
Shorter incubation times at low doses led to negligible 
photokilling. As a matter of fact, when compared with free 
mTHPC delivered as standard formulation, Cetuximab-
conjugated nanoparticles are still less efficient in producing 
phototoxicity. The photochemical investigations reported in the 
previous paragraph exclude the possibility that such a result 
arises from a lower efficiency of singlet oxygen production by the 
nanoparticle-embedded photosensitizer. On the other hand,
unfavourable localization of the nanoparticles inside the cells 
could result into a lower cytotoxic activity of the singlet oxygen 
produced. In fact, it is well-known that mTHPC mainly localises 
in the Golgi apparatus and the endoplasmic reticulum, while we 
have showed here that 4-loaded Cetuximab-conjugated 
nanoparticles are found essentially in endosomal vesicles.
Conclusions
In summary, the results reported provide interesting insight on 
how to optimise the properties of VTES-ORMOSIL nanoparticles 
for biomedical applications, and in particular for targeted therapy.
Being designed to operate in a very complex environment such as 
a living organism, such nanoparticles require a precise design 
which in turn needs detailed chemical and structural 
characterization. The first feature that emerges is the flexibility of 
the synthetic procedure, which enables the one-pot preparation of 
nanoparticles loaded with the active agent, PEGylated and either 
targeted or ready for post-targeting. However, realization of such 
a multifunctional entity requires taking into account all the 
possible interactions between the components. The organosilica 
matrix provides a low polarity environment that preserves the 
photochemical properties of the embedded photosensitizer while 
maintaining water accessibility, but excessive rigidity of the 
framework, as here in the case of tetrasilane derivative 5, may 
result in an unanticipated perturbation to the photophysical 
properties in aqueous solution leading to a reduced singlet 
oxygen yield. Dense PEGylation minimizes toxicity and RES 
capture, but also uptake by cells. This enables higher selectivity 
with active targeting strategies, as we demonstrated using the 
Cetuximab targeting agent. On the other hand, the possibility of 
adverse interactions between the targeting molecules and the 
stealth-conferring layer to which they are grafted, as here in the 
case of folate, must be taken in to account and prevented.
Another important feature is the interaction with proteins, which 
is fundamental in determining the final fate of a nanoparticle 
following administration. The results reported herein suggest that 
not only we can prevent such interactions, as is well known, by 
coating the particles with PEG or other hydrophilic molecules, 
but also we can select the interacting proteins by finely tuning the
surfaces properties, as here shown in the case of VTES and 
Stöber particles.
Finally, we explored the crucial point of selective targeting and 
the importance of the subcellular fate of the nanoparticles. The 
results we report on RGD and Cetuximab-conjugated 
nanoparticles clearly show that increased uptake arising from 
efficient targeting is not sufficient to ensure higher therapeutic 
efficiency. In particular data obtained with Cetuximab were very 
informative, since they clearly indicate that differential binding to 
tumor model cells of nanoparticles and hence of mTHPC loading 
may be achieved only at doses of ligand-linked nanoparticles that 
do not saturate the internalization mechanism. Once these
specific sites are saturated, non-specific and non-saturable
binding sites become more relevant upon increasing the applied 
nanoparticle concentrations. The resulting paradox is that 
selective photokilling was only achieved under conditions of 
partial killing efficacy. Moreover, subcellular localization may 
also play an important role in explaining the correlation between 
uptake and PDT efficacy, since the amount of photosensitizer 
internalized could not be a good parameter to evaluate the real 
amount of effective photosensitizer, i.e. the fraction localized at 
critical sites more susceptible to generated ROS.
These observations may lead to the development of new 
strategies to improve the intrinsic efficacy of the nanoparticles-
carried photosensitizer inside the cell, a parameter that, in the 
end, appears to be the most critical and limiting to gain effective 
neoplastic cell disruption. The implementation of active release 
mechanisms or the addition of other chemical determinants to the 
nanoparticle coating layer capable of re-directing them to more 
sensitive intracellular sites/organelles, or helping their 
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translocation to the cell cytoplasm, could provide solutions to this 
problem. All this information provides a useful framework in the 
development of new nanosystems for tumor therapy. 
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1. Experimental procedures.
Instrumentation. Ultrafiltration of the nanoparticles was carried out using a 75 ml Amicon
Ultrafiltration Cell, Millipore using a cellulose membrane with a cut-off of 10,000 Da.  
UV-Vis absorption spectra were measured in water on a Perkin-Elmer Lambda 45 UV-Vis 
spectrophotometer with 1 cm path length quartz cuvettes. 
Fluorescence spectra were measured in water on a Perkin-Elmer LS-50B fluorimeter with 1 cm path 
length quartz cuvettes. Infrared spectra were recorded on a Nicolet 5700 FT-IR instrument.
NMR spectra in the solution state were recorded on a Bruker Avance (250 MHz 1H frequency) or 
on a Bruker AC-300 (300 MHz 1H frequency). NMR spectra in the solid state were collected on a 
Varian 400 equipped with a narrow bore, triple resonance T3 MAS probe spinning 4 mm rotors and 
operating at 1H, 29Si and 13C frequencies of 400.36, 79.51 and 100.68 MHz, respectively. The 
nominal temperature of the probe was always set to 298 K. 13C CP-MAS spectra were acquired at 5 
kHz MAS with 1200 scans and a repetition delay up to 3 s. The contact time for CP was 2 ms, and 
an acquisition time of 50 ms was used. 29Si spectra were obtained at 5 kHz MAS with a basic pulse-
acquire sequence (2048 scans) and a recycle delay of 60 s. The chemical shifts were referenced 
externally against the 13CH2 resonance observed for adamantane at 38.48 ppm (for 13C) or against 
the signal of Q8M8 (for 29Si).
The hydrodynamic particle size (Dynamic Light Scattering, DLS) and Z-potential were measured 
with a Malvern Zetasizer Nano-S equipped with a HeNe laser (633nm) and a Peltier thermostatic 
system. Measurements were performed at 25 °C in water or PBS buffer at pH 7.0.
Transmission electron microscopy (TEM) was recorded on a Jeol 300PX instrument. One drop of 
sample was placed on the sample grid and the solvent was allowed to evaporate. 
Thermogravimetric analysis (TGA) was run on 5 mg lyophilized nanoparticle samples using a SDT-
2960 model TA instrument from 30 to 1,200 °C under a continuous air flow.
Solvents and reagents. Solvents were of analytical reagent grade, laboratory reagent grade or 
HPLC grade. Water was purified using a Milli-Q  water purification system. High surface area 
hydrophobic Bio-Beads  SM were obtained from Bio-Rad and used according to instructions of the 
supplier. Haba-Avidin Test and EZview Red Streptavidin Affinity Gel were obtained by Aldrich 
and used according to the manufacturer instructions. 2-(4-chlorosulfonylphenyl)ethyltrimethoxy
silane (50 % solution in dichloromethane) was obtained by ACROS. 5-(4-Aminophenyl)-10,15,20-
triphenyl-porphyrin was purchased by Porphyrins Systems. Cyclo[RGDfK(AcSCH2CO)] and 
cyclo[RGDfK(AcSCH2CO)] where obtained by Peptides International. 5,10,15,20-tetra(3-
hydroxyphenyl)-(2,3-dihydro)porphyrin (mTHPC, temoporfin) was gently provided by Biolitec.
Derivatives 1, 2, Folate-OSu, Biotin-OSu were prepared as previously reported. All the other 
reagents were used as received from Sigma-Aldrich.
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2. Synthesis of derivatives 3-5. 
2.1 Synthesis N-[3-(triethoxysilyl)propyl]-N'-[4-(10,15,20-triphenylporphin-5-yl)phenyl]-urea (3).
In a sealed tube, 50 mg (0.08 mmol) of 5-(4-aminophenyl)-10,15,20-triphenylporphyrin and 198 μL
(0.8 mmol) of 3-(trimethoxysilyl)propyl isocyanate are dissolved in 6 mL of dry acetonitrile and the 
reaction mixture is heated at 90°C for 24 hours. The reaction is followed by TLC (eluent: Petroleum 
Ether/EtOAc = 2:1, Rf = 0.22). The solvent is removed and the solid obtained is redissolved in 2 
mL of CH2Cl2 and precipitated in 60 mL of n-hexane. The product is recovered by centrifugation at 
4,000 g for 20 minutes. The procedure is repeated 3 times providing after drying 52 mg of a violet 
powder (yield 74%). 
1H-NMR (250 MHz, CDCl3): δ -2.78 (s, 2H, NH), 0.77 (t, 2H, J = 7.5 Hz, SiCH2), 1.27 (t, 9H, J = 7 
Hz, CH3CH2O), 1.80 (qn, 2H, J = 7.5 Hz, SiCH2CH2), 3.88 (q, 6H, J = 7.5 Hz, CH3CH2O), 7.73 (m, 
11H, ArH), 8.18 (m, 8H, ArH), 8.87 (m, 8H, ArH).
ESI-MS: m/z calcd. for C54H53N6O4Si [M + H]+: 877.4; found: 876.9 (100%).
2.2 Synthesis of N-[3-(triethoxysilyl)propyl]-O-[4-(10,15,20-tri(3-hydroxyphenyl)-(2,3-dihydro)
porphin-5-yl) phenyl]-carbamate (4).
In a small conical vial, 17 mg (0.025 mmol) of mTHPC, 15.4  L (0.062 mmol) of 3-
(trimethoxysilyl)propyl isocyanate and 8.6 μL (0.062 mmol) of triethylamine are dissolved in 100 
μL of dry THF. The reaction is followed by TLC (eluent EtPet: iPrOH = 3:1, Rf mTHPC-Si = 0.3, Rf 
mTHPC-2Si = 0.4, Rf mTHPC-3Si = 0.5). The solvent is evaporated and the product is used without other 
purifications.
ESI-MS: m/z calcd. for C54H54N5O8Si [M mTHPC-Si + H]+: 928.4; found: 928.7 (100%),
C64H75N6O12Si2 [M mTHPC-2Si + H]+: 1175.5; found: 1175.8 (30%).
UV-vis (toluene): λmax (nm) 420, 518, 545, 601, 654.
2.3 Synthesis of 5,10,15,20-tetra(3-(N-(triethoxysilylpropyl)carbamate)phenyl)-(2,3-dihydro)
porphyrin (5).
In a small conical vial, 17 mg (0.025 mmol) of mTHPC, 24.7 μL (0.1 mmol) of 3-
(trimethoxysilyl)propyl isocyanate and 13.8 μL (0.1 mmol) of triethylamine are dissolved in 100 μL
of dry THF. The reaction is followed by TLC (eluent EtPet: iPrOH = 3:1, Rf mTHPC-3Si = 0.5, Rf 
mTHPC-4Si = 0.6). The solvent is evaporated and the product is used without other purifications.
ESI-MS: m/z calcd. for C74H96N7O16Si3 [M mTHPC-3Si + H]+: 1422.6; found: 1422.7 (100%),
C84H117N8O20Si4 [M mTHPC-3Si + H]+: 1669.7; found: 1669.8 (20%).
UV-vis (toluene): λmax (nm) 420, 518, 545, 601, 654.
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3. Synthesis and purification of the nanoparticles.
3.1 Stöber nanoparticles.
To a thermostated vessel charged with 3 (4 mg, 0.005 mmol) and ethanol (20 mL), 100 μL (0.45 
mmol) of TEOS were added under stirring at 25 °C. Subsequently, 1 mL of a 14.8 M aqueous 
solution of ammonia was added to initiate the polymerization. After 16 hours, the solution was 
diluted to 80 mL with ethanol and concentrated to the original volume by ultrafiltration (Amicon 
stirred cell) through a regenerated cellulose membrane (cut-off 10 kDa) under nitrogen pressure (4 
bar). The procedure was repeated five times with ethanol and 7 times with Milli-Q water. The 
resulting solution was filtered through a 0.22 μm cellulose acetate membrane.
3.2 VTES nanoparticles (OS). 
Brij 35 (90 mg, 75 μmol, 15 mM) was dissolved under stirring in 5 ml of water at 25°C into a 
thermostated reaction vessel. Subsequently, 150 L (1.64 μmol) of n-butanol, 25 μL (10 mM 
DMSO solution) of 3 and VTES (45 mg, 0.24 mmol) were added. The mixture was vigorously 
stirred for 30 min (very important) and then 10 L of a 14.8 M aqueous solution of ammonia were 
added to initiate the polymerization. After 2 hours, the solution was transferred into an Amicon 
stirred cell and extensively ultrafiltrated with 1.5 L of Milli-Q water, using a regenerated cellulose 
membrane (cut-off size 10 kD). The nanoparticles suspension was then collected and filtered 
through a 0.22 μm cellulose acetate filter.
3.3 PEGylated VTES nanoparticles (OS/PEG).
The appropriate amount of Brij 35 (see the following table), 1 (15.2 μmol, 3 mM), n-butanol (150 
L, 1.64 μmol) and, when required, 3, 4 or 5 (10 mM DMSO solution, 10 to 130 μL) were 
dissolved under stirring in 5 mL of water into a thermostated reaction vessel. The temperature was 
adjusted according to the following table and the desired amount of VTES was added: 
The mixture was vigorously stirred for 30 min (very important) and then 10 L of a 14.8 M aqueous 
solution of ammonia were added. The mixture was further stirred for 2 hours at constant 
temperature. Then 14.3 mg of Bio-Beads SM per mg of surfactant were added and the suspension
was gently stirred for 3 hours. The beads were filtered off with filter paper and the filtrate diluted to 
15 mL with Milli-Q water and concentrated to 0.5 mL by ultrafiltration with Amicon Ultra-15 
Centrifugal Filter Units (cut-off 10 kDa) at 4,000 g. The procedure (dilution-concentration) was 
NP Final Size (nm) T (°C) Brij35 (mM) VTES (mM)
OS/PEG 20 25 15 50
OS/PEG 50 30 5 50
OS/PEG 90 30 5 100
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repeated seven times. The resulting solution was diluted to the original volume and filtered through 
a 0.22 μm cellulose acetate filter. 
When required to prepare amine/OS/PEG nanoparticles, part of 1 was replaced with 2 (0.1 to 30 %
in moles) to provide amine groups in the PEG. Some examples are given in the following table. 
Note 1: The amino-PEG derivative 2, in DMSO solution, must be added to the reaction mixture just before 
the addition of ammonia. 
Note 2. 20-nm VTES nanoparticles can be synthesized at 30°C using Tween 80 (33 mg, 25 μmol, 5 mM) in 
place of Brij 35, in this case n-buthanol is not needed. 
3.3.1 Folate and Biotin conjugated nanoparticles.
To a preparation of crude (unpurified) amine/OS/PEG (as described in the previous paragraph)
Folate-OSu or Biotin-OSu dissolved in DMSO (20 equivalents with respect to the amount of 2 used
in the synthesis of the nanoparticles) were added and the mixture was further stirred at 25 °C for 16
h. Then 14.3 mg of Bio-Beads SM per mg of surfactant were added and the mixture was further 
gently stirred for 3 hours. The beads were filtered off with filter paper and the filtrate diluted to 15 
mL with Milli-Q water and concentrated to 0.5 mL by ultrafiltration with Amicon Ultra-15 
Centrifugal Filter Units (cut-off 10 kDa) at 4,000 g. The procedure was repeated seven times for 
biotin-conjugated nanoparticles and 10 times for folate-conjugate nanoparticles. The resulting 
solution was diluted to the original volume and filtered through a 0.22 μm cellulose acetate filter.
3.3.2 RGD and RAD conjugated nanoparticles.
Into a thermostated reaction vessel, PBS-10x (0.5 mL) was added to a purified preparation of 
amine/OS/PEG nanoparticles (5 mL). The pH was adjusted to 7.2, then MBS (20 equivalents with 
respect to the amount of 2 used for the synthesis of the nanoparticles) was added and the mixture 
was stirred at 30 °C for 16 h. The mixture was then filtered through a 0.45 μm cellulose acetate 
filter, the filtrate was diluted to 15 mL with Milli-Q water and concentrated to 0.5 mL by 
ultrafiltration with an Amicon Ultra-15 Centrifugal Filter Unit (cut-off 10 kDa) at 4,000 g. The 
procedure was repeated seven times. The resulting solution was diluted to the original volume (5.5 
mL) and filtered through a 0.22 μm cellulose acetate membrane. HEPES buffer (5 mM, 0.5mL) was 
added and the pH was adjusted to 7. Then, the solution was split in three fractions of 2 mL each.
NP Final 
Size (nm)
T (°C) Brij35 (mM) 1 (μmol) 2 (μmol) VTES (mM)
OS/PEG (1% 2) 100 30 5 15.0 0.15 100
OS/PEG (10% 2) 100 30 5 13.7 1.5 100
OS/PEG (30% 2) 100 30 5 10.7 4.5 100
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RGD or RAD peptides (1 equivalent with respect to the amount of 2 used in the synthesis of the 
nanoparticles) were deacetylated in 0.1 mL of an HEPES (17 mM)/NH2OH.HCl (17 mM)/ EDTA 
(10 mM) buffer (pH 7.2) for 1 h at room temperature. Then, the resulting RGD/RAD solution (0.1 
mL) was added to one of the nanoparticles aliquots (2 mL). The solutions were stirred overnight at 
RT. The solution was then diluted to 15 mL with Milli-Q water and concentrated to 0.5 mL by 
ultrafiltration with an Amicon Ultra-15 Centrifugal Filter Unit (cut-off 10 kDa) at 4,000 g. The 
procedure was repeated seven times. The resulting solution was diluted to the original volume and 
filtered through a 0.22 μm cellulose acetate filter. 
3.3.3 Cetuximab and Bovine Serum Albumin (BSA) conjugated nanoparticles.
For the conjugation of these proteins to the nanoparticle surface we decided to derivatize the PEG-
amino groups with the cross-linker MBS using the same procedures described for the conjugation of 
RGD and RAD peptides, whereas the proteins (i.e. Cetuximab and BSA) were functionalized by 2-
iminothiolane (2-IT) reaction that modified the NH2 of lysine introducing new free sulfhydryl 
groups. Briefly, the protein functionalization was performed o/n at 4°C, the reaction blocked with 
glycine 0.2 M for 20 minutes at r.t. and finally the derivatized proteins were purified by gel 
filtration on PD10 columns (Sephadex G-25M, GE Healthcare) in order to remove the excess of 2-
IT. The number of introduced SH groups were calculated using the Ellman’s assay; the NP-protein 
conjugation was performed o/n at 30°C and then a dialysis step was performed for 24 hr at r.t. in 
PBS EDTA 10 mM.
At last nanoconjugates were purified from the unreacted reagent by a first step of centrifugation at 
100,000 g for 45 minutes and a second step of size exclusion chromatography on HiLoad 16/60 
column (Superdex 75 prep grade, GE Healthcare) using a FPLC apparatus (Biologic Workstation, 
Bio-Rad). The purified fractions were concentrated by centrifugation. 
103
S 7
4. Characterization of the nanoparticles.
4.1 TEM analysis.
Figure S1. TEM images of OS/PEG nanoparticles with different sizes: 20 nm (A, B), 55 nm (C, 
E), 70 nm (D), 90 nm (F).  
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C
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4.2 DLS analysis 
Diameter (nm)
A B C
Figure S2. DLS analysis of OS/PEG nanoparticles with different sizes: 20 nm (A), 55 nm (B), 90
nm (C).
4.3 UV-Vis and Fluorescence analysis.
Figure S3. UV-Vis spectrum of 20-nm diameter Stöber (red) and OS (blue) nanoparticles doped 
with dye 3 (water, 25 °C). See Table 1, entries 2 and 3.
Wavelength (nm)
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Figure S4. UV-Vis absorption (purple) and emission (blue) spectrum of 90-nm diameter OS/PEG
nanoparticles doped with dye 4 (water, 25 °C). See Table 1, entry 7.
Figure S5. UV-Vis spectrum of 90-nm diameter amine/OS/PEG nanoparticles doped with dye 4
and targeted with folic acid (blue, water, 25 °C) and of folic acid (magenta, water, 25 °C).
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4.4 TGA analysis.
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Figure S6. Thermogravimetric (TGA) profiles in air of OS/PEG nanoparticles of different sizes: 
red: 20 nm diameter; green: 55 nm diameter; blue: 70 nm diameter.
Weight fraction of the ORMOSIL cores was calculated by assuming that the residue at 900° is silica 
(SiO2) and adding the corresponding weight of the vinyl groups. Weight of a single ORMOSIL core 
was calculated from the particles diameter using an estimated density of 1.5 g/cm3, as
vinyltriethoxysilane ORMOSIL nanoparticles are considered (see ref. 9) to be less dense than pure 
silica ones (2.0 g/cm3). PEG surface density is then easily calculated on the basis of geometrical 
considerations.
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4.5 Avidin tests.
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Figure S7. HABA/AVIDIN test on 90-nm diameter amine/OS/PEG nanoparticles doped with dye 
4 and targeted with biotin. The test is based on the displacement of the HABA dye bound to avidin 
by biotin. The displacement causes a decrease in the absorption of the HABA dye at 500 nm that 
allow to measure the amount of biotin present in the sample analyzed.
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Figure S8. EZviewTM Red Streptavidin Affinity Gel test on 90-nm diameter amine/OS/PEG
nanoparticles doped with dye 4 and targeted with biotin. The test is based on streptavidin coated 
agarose beads, the nanoparticles are incubated with the beads for 1 hour and the beads are then
removed, the difference in the absorbance before and after the beads incubation confirm the 
conjugation of the particles with the biotin.
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4.6 Western blot analysis of Cetuximab-conjugated nanoparticles.
Figure S9. Western blot analysis to confirm the antibody conjugation to the nanoparticles. 
Cetuximab-conjugated NPs (lane 1) and Cetuximab (lane 2) were separated by SDS-PAGE under 
non reducing condition and after the transfer onto a membrane of nitrocellulose the antibodies were 
stained using an anti-human antibody conjugated to HRP. Chemiluminescent signals, developed 
using ECL substrate, were detected by photographic films. 
109
S 13
5. Photophysical studies.
5.1 Absorbance and Fluorescence Measurements.
Absorbance spectra were measured using a Perkin-Elmer (Beaconsfield, UK) Lambda 25 UV/Vis 
spectrometer with 1 cm path length quartz cuvette. Fluorescence spectra were measured using a 
Perkin-Elmer LS50-B spectrofluorimeter equipped with a bifurcated fiber-optic probe. 
5.2 Fluorescence Lifetime Measurements. 
Fluorescence lifetimes were measured using time correlated single photon counting (TCSPC). 
Dilute solutions were prepared with the dye concentration at 0.5 μM and placed in a 1 cm path 
length quartz cuvette. A pulsed laser diode module (90 picosecond pulse duration) was used to 
excite the samples at 405 nm at a 5MHz repetition rate (EPL-405, Edinburgh Instruments Ltd., 
UK). The fluorescence was detected using a fast multialkali photomultiplier module (model H5773-
04, Hamamatusu Photonics K.K., Japan) via a longpass filter (OG510, Schott, UK) and a 
monochromator (model M300, Bentham Instrument Ltd, UK). A Lyot depolarizer (Thorlabs Ltd, 
UK) was incorporated to minimize any polarisation anisotropy artefacts. TCSPC was carried out 
using a PC-mounted TCSPC board (TimeHarp, Picoquant GmbH, Germany) and lifetimes were 
derived using Fluofit software (PicoQuant GmbH, Germany). The Instrument Response Function 
(IRF) was obtained from a non-fluorescent scattering Ludox® solution (Sigmal-Aldrich, 
Gillingham, UK). Optimum fitting with minimization of the residuals was confirmed using a Chi-
squared value χ2< 1.4. 
5.3 Singlet Oxygen Measurements. 
The singlet oxygen phosphorescence at 1270 nm was detected using time-resolved photon counting 
from air-equilibrated, deuterated aqueous or methanolic solutions in quartz cuvettes. For detection 
in the near-IR, a thermoelectrically cooled photomultiplier (model H10330-45, Hamamatsu 
Photonics Ltd, UK) was used, and emission was collected via a series of lenses from the cuvette in 
combination with a long-pass and a band-pass filter centered at 1270 nm (BK Interferenzoptik 
Electronik, Germany). The solutions were excited using a 532 nm Nd:YAG laser (Lumanova 
GmbH, Germany) with the beam axis aligned orthogonally to the collection optics. The laser was 
pulsed at a repetition rate of 3 kHz and a pulse length of 3 ns, giving a mean power of 8 mW, and a 
fast photodiode (1 ns rise time, Becker-Hickl, Berlin, Germany) was used to synchronize the laser 
pulse with the photon counting detection system. A series of neutral density filters was used to 
attenuate the laser power. The photon counting equipment consisted of a PC-mounted multiscaler 
board (model MSA-300, Becker-Hickl, Germany) and a pre-amplifier (Becker-Hickl, Germany) 
which gave a resolution of 5 ns per channel. Time-resolved phosphorescence measurements were 
accumulated by the multiscaler board. The traces were analysed using FluoFit software (PicoQuant 
GmbH, Germany) to extract the singlet oxygen decay lifetime. To calculate the quantum yield, 
Rose Bengal was used as the standard which has singlet oxygen yields of 0.76 in D2O and 0.79 in 
MeOD (R. W. Redmond, and J. N. Gamlin, “A compilation of singlet oxygen yields from 
biologically relevant molecules” Photochem. Photobiol. 1999, 70, 391-475). The concentrations 
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were adjusted to give the same absorbance at 532 nm, and to analyze the time-resolved data we 
used the standard zero-intercept method. 
6. Protein binding studies. 
6.1 Nanoparticles incubation with human plasma. 
Venous blood was taken from healthy volunteers and immediately anticoagulated with 3.8% 
trisodium citrate (9 vol blood + 1 vol citrate). Plateled poor plasma (PPP) was obtained by 
centrifuging blood at 2,000 g for 10 min, without use of a brake. Plasma aliquots were frozen in 
liquid nitrogen and stored at -20°C until time of use. Before use, plasma was thawed and 
centrifuged at 16000 g at 4°C for 20 min, to eliminate any precipitate. Then, it was diluted in PBS 
EDTA 1 mM pH 7.4 at a final concentration of 24% (v/v), filtered through a 0.22 μM filter and 
incubated with PBS (ctrl) and 2 mg of ORMOSIL or Ludox® nanoparticles for 1 hour at 37°C 
under gentle stirring. Then, nanoparticles were recovered by ultracentrifuging at 100,000 g for 1 h 
at 4°C, using a XL-70 Ultracentrifuge (Beckman), and washed twice with PBS EDTA 1 mM pH 
7.4. 
6.2 Identification of plasma proteins adsorbed to nanoparticles surface.
The pellet of nanoparticles was dissolved in 150 μl of non-reducing sample buffer (50 mM Tris HCl 
pH 6.8, 2% SDS, 0.06% bromophenol blue, 6% glycerol) plus protease inhibitors cocktail (Sigma 
Aldrich), heated at 95°C for 5 min and loaded on a 12% (v/v) SDS-PAGE. After protein staining 
with colloidal Comassie G-250, bands of interest were excised and analyzed by mass spectrometry.  
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7. Biological studies 
7.1 Cell culture and incubation experiments. 
A549 (human lung carcinoma cells), CCD-34Lu (human normal lung fibroblasts), KB (folate 
receptor positive cells derived via HeLa contamination), HeLa (human malignant cervical cells 
expressing low amounts of EGF receptor), A431 (human epidermoid carcinoma cells, expressing 
high amounts of EGF receptor) and HUVEC (human umbilical vein endothelial cells, 
overexpressing ανß3 integrin) cell lines were obtained from American Type Culture Collection 
(ATCC, Rockville, USA). The cells were maintained at 37 °C in a humidified atmosphere 
containing 5% CO2 and 90% of humidity. A549 were cultured in F-12K medium containing 2 mM 
L-glutamine and 2.5 g/L sodium bicarbonate; CCD-34Lu, HeLa and A431 were cultured in 
Dulbecco Modified Eagle’s Medium (DMEM) containing 3.7 g/L sodium bicarbonate, 4.5 g/L 
glucose and supplemented with 0.1 mM MEM non essential amino acids and 0.02 M HEPES while 
KB were cultured in Modified Eagle’s Medium (MEM). All the media were supplemented with 
10% heat-inactivated foetal bovine serum (FBS) (Invitrogen, NY, USA) and antibiotics (38 
units/mL streptomycin and 100 units/mL penicillin G (Sigma-Aldrich, St Louis, MO, USA). 
HUVEC cells were cultured in Medium-200 supplemented with antibiotics and with the Low Serum 
Supplement Kit (Invitrogen) having a final FBS concentration of 2%. To obtain stabilized EGFR-
expressing HeLa cells (HeLa EGFR +), 3x106 cells were transfected with 30 μg of pBABE-EGFR 
plasmid (Addgene) by means of electroporation treatment (250 V, 950 μF) in 0.45 cm 
electroporation cuvettes (Gene Pulser, Bio-Rad); after two days, transfected cells were diluted and 
selected in 2 μg/ml puromycin-containing medium (Sigma). 
In all the experiments, the cells (A549, CCD-34Lu, KB, A431, HeLa and HeLa EGFR +) were 
seeded and maintained for 24 h in culture medium supplemented with 10% FBS (complete medium) 
before starting the treatment; then, the medium was replaced with fresh medium containing 3% 
FBS, in which free mTHPC or nanoparticle suspensions were freshly diluted. For HUVEC cells no 
additional serum was used nor for the seed nor for the treatments. 
7.2 Cellular uptake of mTHPC in standard solvent or loaded in ORMOSIL/PEG 
nanoparticles.
A549 and CCD-34Lu cells (105) were seeded in 2 mL of complete medium in 35 mm diameter 
tissue culture dishes. After 24 h, the cells were incubated with increasing concentrations (0.25-1.75
μM) of mTHPC, delivered by standard solvent (Foscan®, ethanol/poly(ethylene glycol) 400/water; 
20:30:50, by vol.) or by OS/PEG nanoparticles in the form of dye 4, (Table 1). After 24 h of 
incubation, the cells were washed twice with 2 mL of versene, detached with 500 μL of trypsin 
(Invitrogen) that was neutralized with the addition of 200 μL of FBS. Cells were centrifuged and 
resuspended in versene before measuring mTHPC fluorescence by flow cytometry with a BD 
FACSCantoTM II (Becton Dickinson, San Jose, California, USA). The blue laser at 488 nm was 
used as excitation source and wavelengths longer than 670 nm (PerCP channel) were used for the 
detection of the mTHPC fluorescence. Ten thousand events/sample were acquired and analyzed 
with the FACSDiva Software.
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Figure S10. Flow cytometry measurements of mTHPC and derivative 4 uptake in CCD-34Lu 
normal cells incubated for 24 h with increasing concentration of free mTHPC (white) or 4-doped 
OS/PEG nanoparticles (grey).
7.3 Specific uptake of mTHPC (dye 4) loaded in targeted ORMOSIL/PEG nanoparticles.
Folate-targeted nanoparticles. 105 KB cells were seeded in 2 mL of folate-deficient RPMI medium 
and 24 h after the seeding were incubated for 5 h with increasing concentration (0.005-1 μM) of 
mTHPC (dye 4, Table 1) in folate-targeted (0.1 or 1% folate) or un-targeted (0% folate) OS/PEG
nanoparticles. After incubation time, the cells were washed, detached from the plates and analyzed 
by flow cytometry to measure mTHPC fluorescence as described above. Competition experiments 
with 1 mM of free folic acid (Sigma-Aldrich) were carried out incubating the cells for 1 h prior the 
addition of NPs in order to saturate folate receptors present on KB cell surface.
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Figure S11. Flow cytometry measurements of mTHPC derivative 4 uptake in folate receptor 
positive KB cells incubated for 5 h with increasing concentration of 4-doped OS/PEG nanoparticles 
conjugated with folate in different amounts (light grey: 0%, grey: 0.1%, dark grey 1% PEG3300-
folate/PEG2000).
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RGD-targeted nanoparticles. 50,000 HUVEC cells were seeded in 500 μl of M-200 medium in 24-
well plates. After 24 h, the cells were incubated with 0.1 or 1 μM mTHPC (dye 4, Table 1) loaded 
in RGD-NPs or RAD-NPs for 3 or 24 h. After incubation, the cells were washed twice with 500 μl 
of versene, detached with 200 μL of trypsin and neutralized with 100 μL of FBS before flow 
cytometry analysis (see text). 
Cetuximab-targeted nanoparticles. To analyze the cellular uptake 100,000 A431 cells were seeded 
in 500 μl of DMEM medium in 24-well plates. After 24 h, the cells were incubated with 1 μM 
mTHPC (dye 4, Table 1) loaded in Cetuximab-NPs, NPs-alone or BSA-NPs for 90 minutes at 37°C; 
finally, the cells were washed twice with 500 μl of versene, detached with 200 μL of trypsin and 
neutralized with 100 μL of FBS before flow cytometry analysis. For competition experiments 
Cetuximab and BSA-NPs were mixed with a molar excess of free Cetuximab before the incubation 
with the cells. In order to investigate if the uptake is dose-dependent, A431 cells were incubated 
with increasing amounts of mTHPC (dye 4, Table 1) loaded on Cetuximab-NPs or BSA-NPs for 90 
minutes at 37°C and then analyzed by flow cytometry. Finally to evaluate the serum stability, 
Cetuximab-NPs or BSA-NPs were incubated for 90 minutes at 37°C with increasing concentrations 
of serum (i.e. ranging from 10% to 100%) before to assess their functionality in uptake experiments 
on A431 cells. 
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Figure S12. Displacement of the uptake of Cetuximab or BSA-4 doped OS/PEG on A431 cells by 
free Cetuximab. Live adherent cells were incubated with a fixed NP concentration (concentration of 
0.25 μM in dye 4) and with or without an excess of free Cetuximab (20 μg of antibody) for 90 
minutes at 37°C. After washings, detachment from the well and a further washing step cells were 
analyzed by flow cytometry measuring the dye 4 fluorescence (APC channel). 
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Figure S13. Differential uptake of Cetuximab-NPs ( ) and BSA-NPs (?) on A431 cells. Live 
adherent cells were incubated with increasing concentrations (concentration ranging from 0.25 to 4 
μM in dye 4) of 4-doped OS/PEG for 90 minutes at 37°C. After washings, detachment from the 
well and a further washing step, cells were analyzed by flow cytometry measuring the dye 4
fluorescence (APC channel). 
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Figure S14. Serum stability of Cetuximab-NPs and BSA-NPs. After a pre-incubation of NP batches 
in serum at 37°C for 90 minutes, the NP functionality was assessed measuring the uptake on A431 
cells. Briefly, serum-treated NPs were incubated on A431 cells for 90 minutes at 37°C; after 
washings, detachment from the well and a further washing step cells were analyzed by flow 
cytometry measuring the dye 4 fluorescence (APC channel). 
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Figure S15. Time-dependant uptake of Cetuximab- and BSA- conjugated nanoparticles with 
different cell lines. EGFR positive A431 cells, EGFR over-expressing HeLa and parental HeLa, 
having reduced EGFR levels, were incubated at 37°C for different times (up to 3 hours) with a 
concentration of Cetuximab-NPs corresponding to 1 μM mTHPC. Cells were then washed and 
directly analyzed by FACS.
7.4 Measurement of EGFR down regulation induced by Cetuximab-conjugates NPs.
The day before the experiment 1x105 A431, HeLa and HeLa EGFR + cells were seeded on 24 wells
plastic plates (Falcon). The day of the experiment, cells were incubated for two hours with different 
concentrations of Cetuximab or BSA-conjugated NPs (up to 50 μg/ml) at 37°C, then they were 
washed, trypsinized and stained with a FITC-conjugated anti-EGFR antibody (Abcam) for 30 
minutes at 4°C. After washing, cells were analyzed by FACS, acquiring 10,000 events for each 
sample.
7.5 Confocal analysis of A431, HeLa and HeLa cells incubated with Cetuximab-conjugated 
NPs.
The day before the experiment, cells (1x105) were seeded on cover glasses; after 24 hours they were 
treated for two hours at 37°C with an amount of nanoparticles corresponding to 1 μM mTHPC, 
washed, fixed with 2% paraformaldehyde (Sigma) in PBS for 20 minutes at room temperature, 
permeabilized with 0.2% Triton X-100 (Sigma) for 10 minutes at 4°; cells were then washed and 
saturated with 1% BSA in PBS for 1 hour at room temperature; Cetuximab conjugated to NPs was 
then stained with a FITC-conjugated anti-IgG antibody (Millipore) for 1 hour at 4°C. After three 
washings coverslips were mounted in mounting medium (KPL) and were analyzed with a confocal 
microscope (SP2 Leica), using 488 nm and 630 nm excitation sources. Images have been acquired 
with the different fluorescence filters, representative pictures were collected as Tiff files and 
processed with standard imaging programs (Photoshop and Image J).
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7.6 Photokilling experiments. 
8x103 A431, HeLa and HeLa EGFR cells were seeded on 96 wells plastic plates (Falcon) and after 
24 hours were treated with different amount of Cetuximab- or BSA-conjugated NPs for 6 hours at 
37°C. Cells were then washed in PBS and irradiated or not with a red light (Waldmann 
Meidizintechnik PDT 1200, 60 mW/cm2) for 10 minutes (36 J/cm2) at room temperature. Fresh 
culture medium was added and after 24 hour cell viability was assessed by MTS assay (Promega), 
following manufacturer instructions. 
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Figure S16. Phototoxicity in HUVEC cells after exposure to different preparations of RGD- or 
RAD conjugated 4-doped OS/PEG nanoparticles. Cells were irradiated with 2.4 J/cm2 of red light 
(Waldmann, 600-700 nm, 12 mW/cm2) after 24 h incubation with increasing doses of mTHPC in 
RGD targeted NPs or RAD conjugated NPs as untargeted control. Cell viability was measured 24 h 
post-irradiation by MTS assay and expressed as mean percentage ± S.D. with respect to not 
incubated but irradiated, control cells.
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PEGylation of ORMOSIL nanoparticles abolishes the 
toxicity toward some lung cells but not alveolar type II 
epithelial cells in vitro 
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Abstract
Background: The development of novel nanocarriers for drug delivery needs to be accompanied by detailed cytotoxicity 
studies to guarantee a safe medical use. PEGylated ORganically MOdified SILica (ORMOSIL) nanoparticles (NPs) appear 
promising for improving drug delivery to cancer cells but a detailed toxicity profile is not yet available. Therefore the 
responses of human normal and cancer cells of the lung to ORMOSIL NP exposure were studied with the aim to determine 
the effect of PEGylation on NP cytotoxicity. 
Results: The exposure to non-PEG NPs caused a concentration-dependent decreased of viability of all types of cells. On the 
contrary PEG NPs-caused plasma membrane damage and death only in carcinoma alveolar type II A549 cells while had no 
effects on CCD-34Lu normal fibroblasts. The similar uptake of NPs in these cells promoted ROS production; superoxide 
dismutase and catalase reduced ROS levels but did not protect A549 cells from death, suggesting that the oxidative stress was 
not the main determinant of cytotoxicity. Gene expression analysis showed that only in A549 cells genes involved in 
inflammation, signal transduction, cell death were differentially expressed, while CCD-34Lu did not modulate significantly 
transcription, after NP exposure. PEG-NPs localized in the lamellar bodies of A549 cells, reduced the production of 
surfactant proteins and very likely interfered with the pulmonary surfactant system, peculiar of alveolar epithelial type II cells 
of which A549 represent a model. 
Conclusions: PEGylation did not abolish the cytotoxicity of ORMOSIL NPs toward A549 cells while they were not toxic 
toward the other lung cells. The death of A549 cells occurred very likely via necrosis and was consequent to impaired 
functioning of surfactant machinery determined by the interaction of the NPs with the surfactant film. Our in vitro results 
highlight the importance of identifying the characteristics that make the cells sensitive or resistant to stress or damages 
caused during exposure to nanomaterial.
Keywords: cytotoxicity, ORMOSIL nanoparticles, PEGylation, plasma membrane permeabilization, reactive oxygen 
species, inflammation, gene expression profiles, pulmonary surfactants, lamellar bodies.
Background
In the recent years there have been tremendous progresses in 
the synthesis of nanosized materials with controlled structures 
and functions [1-3]. Such nanomaterials are particularly 
attractive for biomedical applications especially because they 
can be exploited as carriers of therapeutic and diagnostic agents 
[4-6]. It is hence expected that properly engineered 
nanomaterials will provide powerful tools in the management 
of many types of important diseases, such as cancer. At the 
same time, some concern exists about their possible toxic 
effects [7]. Because of their large surface area, nanoparticles 
(NPs) exhibit high bioactivity, which is modulated by their 
physicochemical properties and by the presence of specific 
functional groups. Moreover, there are increasing evidences 
that materials, which proved to be biocompatible in bulk, may 
have very different biological properties in a nanostructured 
form [8-10]. Therefore, the development of NPs for medical 
applications has to be associated to detailed cytotoxicity studies 
in order to assess biocompatibility and safe medical use. 
Silica and ORganically MOdified SILica (ORMOSIL) NPs 
appear particularly appealing as carriers for drug delivery 
because of some unique properties, which include structural 
stability in different solvents and at different pH, relative low 
chemical reactivity, the low cost of synthesis and the possibility 
of easily obtaining complex structures with different shapes and 
porosity [11-14]. Silica and ORMOSIL NPs are generally 
considered biocompatible, however an increasing number of 
recent reports indicate that they may have several toxic effects 
[15-25]. Surface charge, aggregation, size and shape have been 
considered in relation to cytotoxicity of silica NPs but, in some 
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cases, general conclusions on the precise role of these factors in 
determining toxic effects are still lacking. Amorphous silica 
NPs of 15 and 46 nm similarly reduced the viability of human 
lung carcinoma cells (A549) to 76% of control [15], while 
silica NPs of 20 nm and 50 nm caused a significant different 
cytotoxicity toward human embryonic kidney cells (HEK293) 
[26]. The influence of shape was studied with mesoporous 
silica NPs and the results indicated that long rod shaped NPs 
were internalised more efficiently than sphere shaped NPs with 
consequent greater impact on different cellular functions 
including proliferation, apoptosis, adhesion and cytoskeleton 
organisation [27]. The characteristics of the surface of NPs are 
also particularly important in determining their efficiency of 
cell internalisation which is strongly influenced by their ability 
to capture biological molecules from cellular environment or 
body fluids creating a protein corona [28,29]. Nanoparticles 
designed for medical use, and in particular for drug delivery, 
need to be properly functionalised on their surface to guarantee 
prolonged residence in the bloodstream which is essential 
prerequisite for sustained release of the drug to the targeted 
tissue. The coating of NP surface with polyethyleneglycol 
(PEG) is an effective approach to inhibit adsorption of blood 
proteins on NPs and capture by the phagocytic cells of the 
reticulo-endothelial system (RES) [30-33]; PEGylation should 
also reduce the cytotoxicity of NPs as reported for quantum 
dots and dendrimers [34-36]. We have previously reported on 
the preparation of highly PEGylated ORMOSIL NPs (PEG 
NPs) by one-pot reaction that allows the control of the NP size 
in the 20-150 nm range [37]. The high density coat of 
covalently linked PEG confers to NPs excellent stealth 
properties as demonstrated by the almost negligible capture by 
human macrophages in vitro in comparison to the non 
PEGylated counterparts (non-PEG NPs). In addition, PEG NPs 
are not toxic to macrophages and are hemocompatible; 
importantly, they have a very poor pro-coagulant activity when 
compared with their non PEGylated version [38].
In this study, we have further investigated the cytotoxicity of 
non-PEG and PEG ORMOSIL NPs by analysing the responses 
elicited in different human lung cells in vitro. We used the 
alveolar carcinoma epithelial cell line A549 that has been used 
in a number of nanotoxicology studies, in particular to assess 
the cytotoxicity of silica NPs [15,16,23,39] and we compared 
the responses to ORMOSIL NPs to those elicited in the
adenocarcinoma non-small cell lung cells NCI-H2347 and 
normal fibroblasts CCD-34Lu. We are developing PEG 
ORMOSIL NPs as carriers of anticancer drugs and for this 
reason most of the studies were focused on the understanding of 
the PEG NP-induced morphological and functional alterations 
in the CCD-34Lu normal fibroblasts and in A549 carcinoma 
cells as models of healthy and diseased cells. To better 
understand the cellular effects induced by PEG NPs, we 
combined some traditional cytotoxicity tests to determine 
reduction of cell viability, alterations of plasma membrane, 
ROS production and inflammation with a genome-wide 
transcriptome analysis to assess NP-induced alterations of gene 
expression.
Results and Discussion 
Characterization of ORMOSIL NPs 
The ORMOSIL NPs were prepared by ammonia catalyzed co-
polymerization of vinyltriethoxysilane and, for PEGylated NPs, 
a suitable PEG2000 trimethoxysilane derivative in aqueous 
solutions of Brij 35, as reported previously [37]. The residual 
concentration of Brij 35 in the NP preparations was always 
lower than 1 μM and was not toxic to the cells (data not 
shown). The NPs had a spherical shape with a mean diameter of 
70  10 nm, as determined by Dynamic Light Scattering (DLS) 
measurements, and confirmed by transmission electron 
microscopy (TEM) analyses (Figure 1 A,C,D). Zeta potential in 
phosphate buffered saline (PBS, pH 7.4) was -5.9 and -4.3 mV 
respectively for non-PEGylated and PEGylated NPs, indicating 
a scarce electrostatic stabilization of the nanoparticles against 
aggregation. Thermogravimetric analysis (TGA) of the non-
PEGylated NPs revealed an organic content of about 30% of
the total weight, as expected on the basis of an average minimal 
formula of SiO1.5C2H3 of the VTES-ORMOSIL material 
(Figure 1 B). In the case of PEGylated NPs TGA revealed that 
the coat of PEG-2000 accounted for an additional 25% of NPs 
weight and for an estimated surface footprint of 0.63 nm2 for 
each PEG molecule. The presence of such a dense PEG 
protecting layer provides an effective steric stabilization against 
aggregation, as confirmed by the observation that the 
PEGylated NPs were stable for months when kept in an 
aqueous medium and did not aggregate in solutions of high 
ionic strength nor in the cell culture medium as indicated by the 
DLS measurements performed in these media (Additional file 
1). On the other hand, we have already reported that non-
PEGylated ORMOSIL NPs slowly aggregate in saline aqueous 
solutions but not in the presence of serum [40].
Figure 1 Characterization of ORMOSIL nanoparticles. A) DLS 
size distribution by number (average size 70 10 nm) of non-
PEGylated (black line) and PEGylated NPs (red line). B)
Thermogravimetric (TGA) profiles in air of non-PEGylated (black 
line) and PEGylated NPs (red line) (residual weight at 700°C is 
57%, coating PEG footprint was calculated by assuming a 1.5 
g/cm3 density for the ORMOSIL core). C) TEM micrograph of 
non-PEGylated NPs. D) TEM micrograph of PEGylated NPs.
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ORMOSIL NPs exhibit different cytotoxicity toward 
different types of lung cells 
We first analyzed in which manner the coating with a PEG 
corona of ORMOSIL NPs influenced the cytotoxicity of the 
particles in CCD-34Lu normal lung fibroblasts and A549 and 
NCI-H2347 lung cancer cells. Cytotoxicity was assessed with 
the MTS assay by measuring proliferation/viability of cells 
incubated with increasing concentrations (up to 1.5 mg/ml) of 
non-PEG or PEG NPs for 24 h (i.e. 24 h) as well as of cells 
incubated 24 h with NPs and released for additionally 24 h in 
NP-free medium (i.e. 24 + 24 h) (Figure 2).
Incubation with non-PEG NPs for 24 h caused a severe 
concentration-dependent loss of the viability in all types of cells 
with IC50 of 0.31, 0.82 and >1.5 mg/ml for respectively A549, 
NCI-H2347 and CCD-34Lu cells. On the contrary, PEG NPs in 
the same range of concentrations exerted a significant cytotoxic 
effect only in A549 cells (IC50 0.74 mg/ml); in CCD-34Lu and 
NCI-H2347 cells incubated with PEG NPs the viability was 
significantly reduced only after 24 + 24 h incubation, but by no 
more than 10-15% at the highest NP concentrations. Thus, it 
appeared that the coating of NPs with PEG-2000 strongly 
reduced and almost abolished the cytotoxicity to some types of 
lung cells, as fibroblasts and adenocarcinoma cells (as NCI-
2347 cells), while had only minor effects in decreasing the 
toxicity toward A549 cells derived from type II cells of the 
alveolar epithelium. The latter cell type was more sensitive to 
ORMOSIL NPs than the other two cell lines used in our study, 
however the loss of viability was similar to that reported by 
other authors with comparable concentrations of bare silica 
(SiO2) NPs of various size [15-17,39]. Interestingly, in a recent 
work we reported higher cell mortality for CCD-34Lu 
fibroblasts than for A549 carcinoma cells after exposure to 
commercial Ludox SiO2 NPs (SM30, AS30) [41]. Differently to 
ORMOSIL NPs, Ludox form aggregates in medium added with 
serum [41,42] and the different cytotoxic profile may be 
attributed to different interactions of NP aggregates versus 
mono-dispersed NPs with the cells. Data on the cytotoxicity of 
PEG ORMOSIL NPs in A549 cells are lacking and only few 
data are available on PEG NPs of other materials [43] and also 
in other cell lines [44,45]. Chang and colleagues [17] reported 
that normal MRC-5 fibroblasts are more susceptible than A549 
cells to injury induced by silica and identified in the lower 
metabolic activity of normal cells, determined by the longer 
doubling time, the major determinant of the higher 
susceptibility. In our case, normal CCD-34Lu fibroblasts and 
A549, or NCI-H2347 carcinoma cells have similar doubling 
time and very likely a similar metabolic activity; therefore a 
different metabolic activity does not appear responsible for the 
higher susceptibility of A549 cells to PEG ORMOSIL. 
Interestingly, Jing Wang et al. [46] reported that PEG 
phospholipid micelles induced an endoplasmic reticulum-
dependent apoptosis in A549 cells, but not normal MRC-5 and 
293T cells, due to ER accumulation of the particles. Our results 
showed a completely different response to PEG NPs in the two 
cancer cell lines (i.e. A549 and NCI-H2347), excluding a 
correlation between NP cytotoxicity and tumoral phenotype. To 
gain insight into the factors determining the different 
cytotoxicity we selected CCD-34Lu normal fibroblasts and 
A549 cancer cells for detailed studies on the uptake and 
intracellular fate of ORMOSIL NPs.
Cell interaction and uptake of ORMOSIL NPs
In general, it is expected that the efficiency of cell 
internalization correlates with the extent of NP cytotoxicity. 
Thus, because of the different toxicity of non-PEG and PEG 
ORMOSIL toward A549 and CCD-34Lu cells, we found 
important to determine the modalities of NP interactions with 
Figure 2 Cytotoxicity of non-PEG and PEG ORMOSIL 
nanoparticles toward different lung cells. A) alveolar 
carcinoma A549, B) normal fibroblasts CCD-34Lu and C)
adenocarcinoma NCIH-2347. Cell viability measured by the MTS 
assay after 24 h of NP exposure (24 h) and after additional 24 h of 
incubation in NP-free medium (24 + 24 h). The results are means 
± SD of at least three independent experiments carried out in 
triplicate. 
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the two types of cells and the efficiency of internalisation. We 
used scanning electron microscopy (SEM) to analyze particle 
interactions with cell surface as well as cell morphological 
alterations induced by a 24 h exposure to NPs. In agreement 
with the cell viability results (Figure 2A), A549 cells exposed 
to 0.1 mg/ml (Additional file 2) or 0.3 mg/ml of non-PEG or 
PEG NPs (Figure 3 B and C) showed profound alterations of 
the morphology with respect to controls, with numbers of blebs 
on cell surface. On the contrary, advanced cell death features 
were visible in CCD-34Lu only when exposed to 0.5 mg/ml of 
non-PEG NPs (Figure 3 E). As expected, the hydrophilic 
character of the coat of PEG diminished the interactions of NPs 
with cells. As shown in the images of Figure 3 and in the 
additional file 3, non-PEG NPs tightly interacted with and 
covered almost completely several areas of the surfaces of both 
types of cells while PEG NPs were much less abundant. To 
assess if the reduced cell adhesion of PEG NPs decreased cell 
internalization, we measured the uptake of ORMOSIL labeled 
with rhodamine covalently linked to the matrix of NPs. 
Fluorescence microscopy investigations confirmed the 
“stealthy” properties of our PEG NPs and showed clear reduced 
uptake in both cell types with respect to their bare counterpart 
(Figure 4). Furthermore, flow cytometry measurements of cells 
incubated with the sub-lethal NP concentration of 0.1 mg/ml, 
indicated an uptake of PEG NPs equivalent to about 24 and 
19% that of non-PEG NPs respectively in A549 and CCD 34Lu 
cells. Interestingly, PEG NPs were internalized to a very similar 
extent in the two cell lines (mean rhodamine fluorescence 
intensities (a.u.) of 153.6 ± 37.72 and 163.2 ± 29.1 respectively 
in A549 and CCD-34Lu), indicating that the NP-induced 
cytotoxicity in A549 cells cannot be ascribed to a higher ability 
to capture PEG NPs. Subsequently, TEM was used to better 
investigate on the NP-induced ultrastructural damages as well 
as the intracellular localization of NPs. TEM images of control 
A549 cells (Figure 5 A-D) showed the typical ultrastructural 
features of alveolar type II (AE2) epithelial cells [47], such as 
microvilli, tonofilaments and lamellar bodies (LBs). In fact, 
AE2 cells synthesize and store pulmonary surfactants in these 
lamellate structures [48], which are secreted together with their 
content in the lumen of alveoli to form a lipid monolayer film 
in order to maintain low surface tension at the air-liquid 
interface to prevent alveolar collapse during expiration. TEM 
images of A549 cells incubated for 24 h with non-PEG NPs 
(Figure 5 E-H) showed evident vacuolation of cytoplasm and of 
LBs containing numbers of particles internalized mainly in 
Figure 3 SEM images of A549 and CCD-34Lu cells incubated with non-PEGylated and PEGylated ORMOSIL for 24 h. A549 cells not 
incubated with NPs (A), incubated with 0.3 mg/ml non-PEGylated (B), or PEGylated NPs (C). CCD-34Lu cells not incubated with NPs (D), 
incubated with 0.5 mg/ml non-PEGylated (E), or PEGylated NPs (F).
Figure 4 Intracellular uptake of rhodamine-labelled 
ORMOSIL NPs in A549 and CCD-34Lu cells. Fluorescence 
microscopy images of cells exposed for 24 h to NPs. A549 control 
cells (A), A549 cells incubated with 0.1 mg/ml of non-PEGylated 
NPs (C) or PEGylated NPs (E). CCD-34Lu control cells (B), 
CCD-34Lu cells incubated with 0.1 mg/ml of non-PEGylated NPs 
D) or PEG NPs F).
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these lipid vesicles, many of which appeared to have lost their 
characteristic multivesicular/multilamellar structure. As already 
observed with SEM, many NPs lied on plasma membrane and 
were entrapped within the surfactant layer that appeared less 
dense and with fewer vesicles when compared to controls.
Vacuoles were not visible in A549 cells incubated with the 
same dose of PEG NPs (Figure 5 I-N). However, some NPs 
were internalized and localized in the LBs, which appeared 
much reduced in numbers and size as compared to controls; in 
addition some NPs interacted with the components of the 
surfactant film. Both type of particles, with PEG NPs to a 
minor extent, induced mitochondrial swelling and 
disappearance of tonofilaments in A549 cells. On the other 
hand, CCD-34Lu fibroblasts treated with non-PEG NPs (Figure 
6 E-H) showed an increased number of vacuoles and of NP-
containing vesicles while those treated with the PEGylated NPs 
showed no evident ultrastructural alterations (Figure 6 I-N) 
with respect to controls (Figure 6 A-D). In these cells NPs free 
in the cytosol as well as entrapped in endosomes/lysosomes or  
associated to microtubules were observed. Non-PEG NPs were 
probably taken up by cells by clathrin-mediated endocytosis 
since a number of coated pits were clearly visible throughout 
the cell membrane (Figure 6 H). It appeared that for non-PEG 
NPs and in both types of cells, the cytotoxic effect was mainly 
induced by the high numbers of particles internalized which 
promote cytoplasmatic vacuolization as well as by the particles 
interacting with plasma membrane. 
PEGylated ORMOSIL NPs increased the permeability of 
plasma membrane 
Being interested mainly at evaluating the safety in using 
PEGylated ORMOSIL NPs as nanocarriers for the delivery of 
anticancer drugs, further investigations aimed at elucidating the 
mechanism of cytotoxicity were restricted to the PEGylated 
version of ORMOSIL NPs. To better understand the effects of 
NPs on plasma membrane, we measured the release of the 
cytosolic enzyme lactate dehydrogenase (LDH). Upon a 24 h of 
exposure to NPs, considerable amounts of LDH were released  
Figure 5 Intracellular uptake of ORMOSIL NPs in A549 cells. TEM micrographs of cells exposed for 24 h to nanoparticles. A-D) cells not 
incubated with NPs; E-H) cells incubated with 0.3 mg/ml of non-PEGylated NPs; I-M) incubated with 0.3 mg/ml of PEGylated NPs. Blue arrows 
denote NPs, asterisks indicate lamellar bodies while M, TF and SF indicate mitochondria, tonofilaments and the surfactant film, respectively.
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in the culture medium only by A549 cells (Figure 7 A). This 
assay indicated that an increased permeability of the plasma 
membrane induced by PEG-NPs could be responsible for the 
death of A549 cells. Accordingly, by increasing the NP dose, 
an increasing number of A549 cells became positive to PI 
staining (Figure 7 B), with almost 100% of positive cells at the 
highest tested concentration of 1.5 mg/ml (Additional file 4), 
indicating occurrence of cell death very likely by necrosis; 
indeed, morphological changes typical of apoptosis could not 
be detected during the TEM analysis. On the other hand, 
consistently with the results of cell viability and LDH release, 
in CCD-34Lu the PI staining showed increased permeability of 
the plasma membrane only in ~ 20% of the cells after 
incubation with 1.5 mg/ml of NPs (Additional file 4). 
Production of intracellular ROS triggered by PEGylated 
ORMOSIL was not the major determinant of death in A549 
cells 
It is well accepted that oxidative stress is implicated in NP 
induced-cytotoxicity and most of the cellular responses are 
explained with the activation of different pathways leading to  
cell death, inflammation, induction of antioxidant agents 
subsequent to the formation of reactive oxygen species (ROS) 
[8,19]. Thus, we measured the production of ROS in cells 
exposed and not exposed to NPs (endogenous ROS level) by 
flow cytometry, after staining the cells with a specific probe 
that is converted to a fluorescent product only in the presence 
of intracellular ROS. In both cell lines exposed to 0.1 mg/ml 
NPs, we could not measure a production of ROS above the 
basal level at all time points considered of 5, 24 and 24 + 24 h 
(data not shown). On the contrary, with NP concentrations of 
0.3 and 0.5 mg/ml, in A549 cells the level of ROS was 
significantly increased at all time points (Figure 8 A), while in 
CCD-34Lu cells ROS exceeded the basal level only at the end 
of the 24 h of NP exposure (Figure 8 B). Twenty four h after 
the removal of NPs from the medium, in A549 cells the level of 
ROS was still higher than the basal level, while CCD-34Lu 
cells had already restored the basal oxidative stress conditions. 
Thus it appeared that PEG NPs, notwithstanding their reduced 
uptake when compared to the non-PEGylated version, can 
cause an oxidative stress to the cells, as do many types of 
nanomaterials [39,49,50] and in particular bare commercial 
Figure 6 Intracellular uptake of ORMOSIL NPs in CCD-34Lu cells. TEM micrographs of cells exposed for 24 h to nanoparticles. A-D) cells 
not incubated with NPs; E-H) cells incubated with 0.5 mg/ml of non-PEGylated NPs; I-M) incubated with 0.5 mg/ml of PEGylated NPs. Blue 
arrows denote NPs while M and V indicate mitochondria and vacuoles, respectively.
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silica NPs [16,16,19-22,51]. It is also expected that antioxidant 
agents such as superoxide dismutase (SOD), catalase (CAT) 
and N-acetylcysteine (NAC), are able to protect the cells from 
the oxidative stress induced by NPs [16,50, 52]. To gain more 
insight into the types of ROS produced in the cells following 
the exposure to NPs, we performed experiments in which the 
cells were incubated with PEG NPs in the presence of the 
antioxidant agents SOD and CAT given alone or in 
combination (Figure 8 A, B). In general, CAT alone was much 
more effective than SOD alone in reducing the level of ROS 
suggesting that hydrogen peroxide was the most abundant 
among the ROS produced. SOD alone caused a slight decrease 
of ROS level only in A549 cells indicating that some 
superoxide anion is also produced. In all cases when SOD and 
CAT were combined, the highest reduction of ROS level was 
observed. Nevertheless, while SOD and CAT were effective in 
reducing the level of intracellular ROS they were unable to 
protect A549 cells from death induced by NPs. In fact A549 
cells incubated for 24 h with 0.3 mg/ml of NPs in the presence 
of SOD and CAT, alone or in combination, showed a reduction 
of viability similar to that of the cells incubated with NPs in the 
absence of antioxidants (Figure 8 C). Therefore, these data 
suggest that the oxidative stress is not the major determinant of 
the cytotoxic effect induced by PEG ORMOSIL NPs in A549 
cells. 
PEG ORMOSIL NPs modulate the gene expression profiles 
of A549 cells
To understand if PEG NPs exposure forced the cells to 
modulate their gene expression profiles, we performed 
microarray analyses hybridizing mRNA, extracted from 
samples treated with 0.1 mg/ml of NPs, on the Agilent Human 
Whole microarray platform. SAM analysis revealed that mRNA 
expression was significantly altered only in A549 cells, with 
133 and 45 genes differentially expressed at 24 h and at 24 + 24 
h, respectively (Figure 9). The complete lists of differentially 
expressed genes (d.e.g.) in A549 cells at the two time points are 
provided in the Additional files 5 and 6. The heat map profiles 
of d.e.g shown in Figure 9 (A and B) emphasized that in A549 
cells incubated for 24 h with NPs most genes were over-
expressed (110/133). Generally, the expression values of up-
regulated genes returned to values close to zero during the 
following 24 h of cell incubation in NP-free medium, indicating 
that up-regulation was mainly promoted by the presence of NPs 
in the medium and suggesting that cell damages elicited by 0.1 
mg/ml of NPs were not severe enough to compromise the 
regulation of the gene expression. On the contrary, down-
regulated genes maintained negative expression values. Indeed, 
no d.e.g. were found in NP-treated fibroblasts with respect to 
controls, confirming the unresponsiveness of CCD-34Lu cells 
to PEG NPs also from a transcriptional point of view.
For few selected A549 d.e.g. (IL8, PTGS2, KRT4) microarray 
data were confirmed by quantitative RT-PCR (qRT-PCR, 
Additional file 7). In general, the results of qRT-PCR showed a 
gene induction greater than that measured by microarray 
analysis, probably due to the higher sensitivity of qRT-PCR 
technique. Microarray results were confirmed with the 
exception of PTGS2 gene which was found down-regulated 
only in qRT-PCR analysis, in both cell lines at 24 + 24 h.
To assess the effect of PEG NP exposure on cellular functions, 
we uploaded A549 d.e.g. in DAVID annotation tool to classify 
them based on the Gene Ontology (GO) categories. The most 
significant GO terms were regrouped and represented in Figure 
9 D and E, while the complete lists of GO functional categories 
identified by DAVID are reported in the Additional files 8 and 
9. The d.e.g. at the end of the 24 h of NP incubation belonged 
to 42 different GO terms (Additional file 8) which can be 
grouped in 5 major biological processes, namely, signal 
transduction, cell death, cell proliferation, response to stimulus 
and inflammation (Figure 9 D).
Several authors reported that the exposure to nanomaterials 
activates the transcription of inflammatory mediators/activators 
both in vivo and in vitro [9,53,54], with oxidative stress 
identified as the major underlying mechanism driving NP-
induced inflammation, especially in lung tissues [55]. In 
particular, commercial silica NPs stimulate mRNA over-
expression of inflammation-related genes, such as IL-8, IL-6, 
Figure 7 Effects of PEGylated ORMOSIL NPs on permeability 
of plasma membrane in A549 and CCD-34Lu cells. A) LDH 
release in the culture medium of cells incubated for 24 h with 
increasing doses of NPs; the data show the percentage of the total 
LDH content of the cells and are means ± SD of at least three 
independent experiments carried out in triplicate. * p < 0.05; ** p < 
0.01; *** p < 0.001 vs controls (t test). B) Images of A549 and 
CCD-34Lu cells incubated for 24 h with NPs and stained with 
propidium iodide.
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IL-1ß, TNF-α, iNOS in various cell lines [18,39,56]. Segat et al. 
[57] studied the pro-inflammatory effects of bare and PEG 
ORMOSIL NPs and showed NP stimulation of IL-1ß, IL-6, 
TNF-α and IL-8 in monocytes and IL-8 in polymorphonuclear 
leukocytes (PMNs) in vitro. Similarly, our microarray data 
showed that PEG NPs triggered an inflammatory response in 
A549 cells by stimulating the transcription of several 
inflammation-related genes (ADRB2, CSF1R, CXCL5, 
CXCR7, IL8, IL11, LTB, NT5E, OSMR, PTGS2, SERPINF1, 
TGM2; Additional file 5). Since expression and release of 
cytokines have an important role in the induction and in the 
regulation of the inflammatory response, we measured the 
mRNA expression level of IL-8, IL-6 and IL-1ß by qRT-PCR. 
IL-8 mRNA was the most over-expressed transcript in A549 
cells exposed to PEG NPs, but also IL-6 and IL-1ß mRNA 
transcription was found to be increased during the 24 h of NP 
exposure (Figure 10 A). Indeed, after NP removal, mRNA 
transcription of IL-8 and IL-1ß decreased dramatically, while 
IL-6 transcription did not change significantly with the 
incubation times and after NP removal. In addition, an ELISA-
based immunoassay was used to confirm that the NP-promoted 
transcriptional activation of the interleukin genes (IL8 in 
particular) correlated with the increased synthesis of the 
corresponding proteins (Figure 10 B). Our results on IL-8
protein release are similar to those obtained by Choi et al. [39] 
after exposure of A549 cells to non-PEGylated Aerosil -200 
silica nanoparticles, suggesting that the PEG-coating does not 
abolish the inflammatory response in this cell line. 
The PTGS2 gene, also known as cyclooxygenase 2 (COX-2), is 
a pro-inflammatory related gene that encodes for an enzyme  
Figure 8 ROS production induced by PEGylated ORMOSIL NPs in A549 and CCD-34Lu cells. ROS produced in A549 A) and CCD-34Lu 
B) cells after exposure to PEG ORMOSIL NPs. Cells were incubated with 0.3 or 0.5 mg/ml of NPs for 5 h, 24 h or 24 + 24 h. Incubation with 
NPs was carried out in the absence and presence of ROS inhibitors SOD, CAT or SOD + CAT. At the end of incubation time cells were analyzed 
by flow cytometry after staining with ROS Detection probe. Cell viability determined by the trypan blue exclusion test, of A549 cells C) or CCD-
34Lu cells D) incubated for 24 h with 0.3 mg/ml of PEGylated NPs in the absence or in the presence of ROS inhibitors. The results are means ± 
SD of at least three independent experiments.
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that catalyzes the conversion of arachidonic acid to 
prostaglandins [58]. Our microarray and qRT-PCR analysis 
showed an up-regulation of this gene in A549 cells at 24 h and 
the GO research indicated that it is involved in different 
biological processes such as response to extracellular stimulus, 
second-messenger mediated signalling, regulation of 
inflammatory response, cell proliferation and apoptosis 
(Additional file 8). Over-expression of PTGS2 has been already 
reported as a consequence of the oxidative stress induced in 
cells exposed to different nanomaterials [50,59]. In some cases 
PTGS2 expression was preceded by the activation of MAPKs 
signalling pathway, which is one of the most widespread 
mechanism pertaining to eukaryotic cell regulation [60], but we 
found no direct evidence of the activation of the MAPKs 
signalling pathway in A549 cells exposed to PEG ORMOSIL 
NPs. Also the transcription of genes as JNK, p53 and NF-kB, 
implicated in silica NP-induced apoptosis and inflammation 
[39], was not affected, very likely because necrosis is the 
predominant mechanism of cell death induced by our PEG NPs.
Furthermore, the GO analysis of A549 d.e.g. revealed that the 
most enriched biological processes were those of the signal 
transduction; in particular, the relevant GO terms were related 
to cell surface receptor linked signal transduction (Additional 
file 8). These data suggest that NP interaction from the outside 
of the cell involved some membrane receptors, which in turn 
activated a signalling cascade of activation/perturbation of 
cellular processes, such as induction of inflammatory response 
together with regulation of proliferation and activation of death 
programs. Also for PEG NPs the interaction with cell 
membrane can be mediated by proteins adsorbed on their 
surface [61-64]. Previously, we have shown that serum proteins 
adsorb very efficiently on the surface of bare ORMOSIL NPs 
and PEGylation reduced but did not abolish protein adsorption 
[40]. Therefore, the possibility still exists of interaction 
Figure 9 Gene expression profile alterations induced by PEGylated ORMOSIL NPs in A549 cells and GO analysis of differentially 
expressed genes. Heat map profiles of differentially expressed genes in A549 cells, identified using TMEV 4_5_1 A, B): pseudo-color scale 
indicates the expression value [log2 (NP-treated cells/controls)]; range of expression value is from -0.7 (green, down-regulation) to 0.7 (red, up-
regulation). In the upper heat map A), expression values of the 133 differentially expressed genes at 24 h are correlated with their expression 
values after NP removal (24 + 24 h), while in the bottom heat map B) expression values of the 45 differentially expressed genes at 24 + 24 h are 
correlated with their expression values during NP incubation (24 h). The Venn diagram C) shows the total number of differentially expressed 
genes at the end of 24 h of NP incubation and after additional 24 h of cells incubation in NP-free medium. Comparison of the gene ontology 
(GO) categories among the annotatable genes differentially expressed during the 24 h of NP incubation D) and 24 h after NP removal E). GO 
terms of biological processes (BP) were represented at FAT level using the Database for Annotation, Visualization and Integrated Discovery 
functional annotation tool (DAVID, http://david.abcc.ncifcrf.gov/). BP are plotted as a function of significance (-log p value), using p < 0.05 as 
cut-off threshold; the number of genes involved in each GO BP is indicated on the right of each bar.
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between NP-associated proteins and cell surface receptors. 
Moreover, adsorption of different proteins may trigger the 
activation of different membrane receptors in different types of 
cells. Recently, it was shown that the clathrin dependent 
endocytosis of amorphous silica engineered NPs and the 
secretion of proinflammatory cytokines are strongly correlated 
with the expression of scavenger receptor A [65]. Thus, future 
investigations may be addressed to the identification of proteins 
and plasma membrane receptors involved in PEG ORMOSIL 
NPs uptake and/or responsible for the NP-promoted activation 
of intracellular signalling cascade leading to cell death. 
After NP removal (24 + 24 h), only GO terms related to 
response to wounding, cell motility and cell migration remained 
perturbed in A549 cells (Figure 9 E, Additional file 9). 
Interestingly, enrichment in genes involved in the cytoskeleton 
organization (ANG, ANK3, CNN1, KRT4, RND1, VIL1) was 
found, suggesting that this type of rebound on cell organization 
and morphology is a persisting and irreversible effect. In fact, 
after NP removal, the down-regulation of these genes, some of 
which are correlated with actin-filament interaction and 
consequently with cell structure organization, proliferation, cell 
cycle progression (CNN1 excluded) increased [66,67]. 
Cytoskeleton disturbance induced by NPs, as well as reduced 
cell adhesion were confirmed by TEM and SEM analyses 
(Figure 5 and 3) respectively. TEM clearly showed decreased 
presence of tonofilaments very likely due to the reduced 
expression of keratin proteins, while SEM images, showing 
wizen cells with spherical shape, indicated loss of cell adhesion 
in agreement with the microarray data indicating that some 
genes involved in cell adhesion (CDCP1, CDH16, CNN1, 
COL13A1, FGB, GJB1, NOV, PHLDA1, PODXL, ZEB2) and 
extracellular matrix degradation (ANPEP, ANTXR2, MMP1, 
PLAU) were differentially expressed. 
We attempted to find reasons for the completely different 
responses elicited by PEGylated ORMOSIL NPs in A549 and 
CCD-34Lu cells by comparing the gene expression profiles of 
the two types of untreated cells. SAM analysis reported 2842 
d.e.g between the two cell lines (data not shown) and the GO 
analysis classified the annotated genes in 401 significant GO 
terms (cut-off of p < 0.05 and filtering out of processes 
represented by less than 10 genes). However, this comparison 
was very time consuming and poorly informative with few 
exceptions. By uploading in DAVID only genes over-expressed 
in CCD-34Lu cells with respect to A549 cells, an enrichment of 
about 30 genes involved in response to inorganic substances 
and response to oxidative stress was found (Additional file 10). 
The SOD3 gene encoding a member of the superoxide 
dismutase protein family, was expressed 9.57-fold more in 
fibroblasts with respect to A549 cells, together with other genes 
such as SEPP1 and SCARA3 (Additional file 10) encoding for 
antioxidants active in extracellular space and able to deplete 
ROS. Consistently with the microarray data, qRT-PCR showed 
a relative fold change of SOD3 mRNA in CCD-34Lu with 
respect to A549 of 6.96. This highlighted that fibroblasts 
possess more efficient mechanisms of defence against oxidative 
stress in agreement with the faster return, when compared to 
A549 cells, to basal ROS levels found when NPs were removed 
from the medium (Figure 8).
PEG ORMOSIL NPs interacted with pulmonary surfactant 
components of A549 cells
The evidence that in A549 cells ORMOSIL NPs localized in 
LBs, suggested that this unique intracellular localization could 
be the reason leading to cytotoxicity, differently to CCD-34Lu 
cells. Similarly to our PEG ORMOSIL, fine and ultrafine TiO2
particles [68,69], single walled carbon nanotubes [70] and lipid-
coated gold NPs [71] were reported to localize in the LBs of 
A549. It was suggested that gold NPs are endocytosed and then 
excreted by the cells using the same pathways of pulmonary 
surfactants [71]. Thus, we can speculate that similarly to gold 
NPs, also ORMOSIL NPs may negatively interfere with 
surfactant machinery, leading to cytotoxicity. The association 
of lipids and surfactant proteins with nanomaterials has been 
well investigated with surfactant monolayer models in vitro
[72-76] while less in known about these interactions in cellular 
systems. Mühlfeld and colleagues [77] hypothesized that the 
particles internalized by the cells interfered with surfactant 
metabolism and decreased the levels of surfactant proteins 
because of adsorption to NPs with consequent increased 
pulmonary inflammatory status. This is well in agreement with 
our results showing a reduced number LBs (Figure 5 I and L) 
and an inflammatory response in A549 cells exposed to PEG 
ORMOSIL. Thus, to assess whether PEGylated ORMOSIL 
Figure 10 Cytokine mRNA over-expression and release of IL-8
protein induced by PEGylated ORMOSIL NPs. A) Quantitative 
RT-PCR measurements of mRNA expression of IL-8, IL-6 and IL-
1ß genes in A549 cells incubated for 1, 5, 24 and 24 + 24 h with 0.1 
mg/ml PEGylated ORMOSIL NPs. ELISA measurements of protein 
IL-8 released in the supernatants of A549 cells (B) and CCD-34Lu 
(C) cells incubated for 5 or 24 h with 0, 0.1, 0.5 mg/ml of 
PEGylated ORMOSIL NPs. The results are mean ± SD of at least 
three independent experiments each carried out in duplicate. * p < 
0.01; ** p < 0.001 vs controls (t test).
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could interfere with secretion/recycling of the surfactant 
components, we used immunofluorescence to detect possible 
alterations of the level and distribution of surfactant protein A 
(SP-A) and surfactant protein C (SP-C) in A549 cells. SP-A is a 
hydrophilic protein and, together with surfactant protein D (SP-
D), plays a role in the innate immune defense of the lung [78] 
and surfactant lipid metabolism and homeostasis [79] while the 
small hydrophobic polypeptides SP-C, with surfactant protein B 
(SP-B), is mainly involved in the surface activity of the 
surfactant film. As shown in Figure 11, while the expression of 
SP-A was only slightly reduced after exposure to PEG NPs, SP-
C gradually disappeared by increasing the NP concentration. 
SP-C localizes within LBs and is co-secreted with LB content 
while SP-A secretion is LB-independent [80]; thus the 
immunofluorescence data confirmed an interference of PEG 
ORMOSIL NPs with LB functioning as suggested by the TEM 
analyses (Figure 5 I and L). We can speculate that the stronger 
reduction of SP-C with respect to SP-A may be related to the 
hydrophobic nature of this protein that favors the association 
with the PEG coat of our NPs. In any case, further 
investigations are needed to quantitatively/qualitatively 
measure the association of lipids and proteins of the surfactant 
with PEG-ORMOSIL NPs. SPs and lipids are normally 
recycled by alveolar epithelial type II cells via clathrin-
mediated endocytosis [81] and re-included in LBs, with SPs 
playing an important role in the stimulation of this recycling 
mechanism. Thus, it may be that NP association with SPs on 
plasma membrane triggered recycling, with NPs internalized 
together with surfactants and included in LBs. Sachan and  
colleagues [75] studied the interaction of AmOrSil20 NPs with 
a model surfactant monolayer and reported strong association at 
high concentration of NPs (3 mg/ml) with surfactant 
components with consequent slowing down of vesicle insertion 
rate and inhibition of surfactant recycling. NP interference with 
surfactant regeneration very likely occurred also in our 
experiments, as shown by the reduction of the film thickness 
(Figure 5 G, H, M, N) and disappearance of the lipid vesicles 
clearly visible in the TEM images of the control cells (Figure 5 
C and D). Reduction of vesicle size was measured also in the 
model film Infasurf exposed to hydroxyapaptite (HA) NPs [73] 
and the adsorption of proteins on NPs was identified as 
determinant of smaller vesicles formation with consequent 
inhibited surface activity of the surfactant film. In addition, it 
has been reported that NPs covered themselves with lipids 
[74,82] becoming integral part of surfactant film and disturbing 
lipid surface structure and function [72]. Translating these 
observations to our alveolar epithelial cell model, it may be that 
the destabilization of surfactant layer lead to the enhanced 
plasma membrane permeability measured after PEG ORMOSIL 
NP exposure.
Taking together, all these information indicated that the higher 
sensitivity of A549 cells to ORMOSIL NP treatment with 
respect to other lung cell lines may be attributed to interactions 
of the NPs with the surfactant film as well as to an impaired re-
spreading/recycling of surfactants. 
Conclusions
We have reported on the responses elicited in different lung cell 
Figure 11 PEGylated ORMOSIL NPs affected the expression of surfactant protein (SP) A and C in A549 cells. Representative 
immunofluorescence images showing the decrease expression of SP-A A-C) and SP-C protein D-F) in A549 cells incubated for 24 h with 
PEGylated ORMOSIL NPs. A and D cells not exposed to NPs; B and E cells incubated with 0.1 mg/ml NPs; C and F cells incubated with 0.3 
mg/ml of NPs.
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lines by PEGylated ORMOSIL NPs designed for medical 
application. Our data showed that the addition of the PEG 
corona abolished the toxicity of ORMOSIL NPs toward normal 
fibroblasts CCD-34Lu and adenocarcinoma cells NCI-H2347 
while had only a minor effect in reducing the toxicity toward 
A549 carcinoma cells. The uptake of PEG NPs in the cells was 
about 20% that of their bare counterpart, due to reduced 
interactions of NPs with plasma membrane as expected because 
of the hydrophilic PEG coating. In spite of the reduced uptake, 
PEG ORMOSIL were still toxic to A549 cells. Investigations 
on the effects of PEG NPs on cellular functions in A549 
alveolar cells and in CCD-34Lu fibroblasts revealed ROS 
production in both types of cells even if the oxidative stress was 
not the major cause of A549 NP-induced cytotoxicity. Only in 
A549 cells, PEG NP exposure caused alteration of plasma 
membrane permeability and up-regulation of genes involved 
mainly in inflammation, cell death and cell signalling mediated 
by membrane receptors, with consequent death via necrosis. All 
the above mentioned cellular events were probably triggered by 
NP interactions and interference with the surfactant production 
and recycling peculiar of alveolar type II epithelial cells. The 
TEM images clearly showed that NPs were internalized in the 
lamellar bodies, very likely interacted with surfactant film 
components (i.e. lipids/proteins) sequestering part of them as 
well as interfering with film functions and surfactant recycling. 
However, additional investigations are needed to identify the 
surfactant components which interact with PEGylated 
ORMOSIL NPs. 
Methods 
Preparation and characterization of ORMOSIL 
nanoparticles
The detailed procedure of preparation of PEGylated and non-
PEGylated ORMOSIL NPs was described previously [37,38].
Briefly, Brij 35 (5 mM) was dissolved under stirring in 5 ml of 
water into a thermostated reaction vessel. A DMSO solution 
(10 μl) of a rhodamine-triethoxysilane derivative (11 mM) [83] 
and, when required, O-(2-(4-(2-trimethoxysilyl-ethyl)-
benzensulfonammido))ethyl)-O'-methylpolyethylene glycol 
(MPEG2000triethoxysilane, (3 mM)), 150 L of n-butanol and 
finally 80 l of VTES were added. The mixture was stirred for 
30 min and then 5 l of aqueous ammonia were added to start 
the polymerization. The stirring was continued overnight at 30 
°C, the reaction mixture was then extensively ultrafiltered with 
Milli-Q water, using a cellulose membrane with a cut-off size 
of 10 kDa and eventually filtered with a 0.20 μm cellulose 
acetate membranes. In the case of PEGylated nanoparticles, to 
reduce ultrafiltration times, the crude reaction mixture was 
stirred with Bio-Beads  SM (14.3 mg per mg of Brij 35) for 3 
hours before ultrafiltration. 
The particle sizes were measured by Dynamic Light Scattering 
(DLS) with a Malvern Zetasizer Nano-S with a HeNe laser (633 
nm): temperature of 25 °C, aqueous suspension, viscosity of 
0.8872 cP. Zeta potenzial (ζ) was measured with the same 
instrument using disposable cells. Transmission electron 
microscopy (TEM) analysis was carried outwith a Jeol 300PX 
instrument. One drop of NP suspension was placed on the 
sample grid and the solvent as allowed to evaporate. For 
fluorescence-labelled NPs, dye content was determined on the 
basis of rhodamine absorption at 566 nm, using the ε value of 
95000 cm-1 M-1, measured with a Lambda 45 Perkin-Elmer 
spectrophotometer. Dye emission was measured using a LS50B 
Perkin-Elmer fluorimeter. Thermogravimetric analysis (TGA) 
were run on 1 mg lyophilized nanoparticle samples using a 
Q5000-IR model TA instrument from 30 to 1000 °C under a 
continuous air flow. 
Cell culture and incubation with ORMOSIL NPs 
A549 human lung carcinoma cells, CCD-34Lu human normal 
lung fibroblasts and NCI-H2347 human adenocarcinoma non-
small lung cells were obtained from American Type Culture 
Collection (ATCC, Rockville, MD, USA). The cells were 
maintained at 37 °C in a humidified atmosphere containing 5% 
CO2. A549 cells were cultured in F-12K medium supplemented 
with 10% heat-inactivated foetal bovine serum (FBS, Life 
Technologies, Milan, Italy), 2 mM L-glutamine, 2.5 g/l sodium 
bicarbonate, 38 units/ml streptomycin and 100 units/ml 
penicillin G (Sigma-Aldrich, St Louis, MO, USA). CCD-34Lu 
fibroblasts were grown in DMEM medium with 3.7 g/l sodium 
bicarbonate, 4.5 g/l glucose, and supplemented with 38 units/ml 
streptomycin and 100 units/ml penicillin G, 0.1 mM MEM non 
essential amino acids, 0.02 M HEPES and 10% FBS. NCI-
H2347 cells were grown in RPMI-1640 medium with 1.5 g/l
sodium bicarbonate, and supplemented with 38 units/ml 
streptomycin and 100 units/ml penicillin G, 4.5 g/l D-glucose, 2 
mM glutamine, 10 mM HEPES, 1 mM sodium piruvate and
10% FBS. In all cases, the cells were seeded and maintained for 
24 h in culture medium supplemented with 10% FBS before 
starting the NP treatment; then, the medium was replaced with 
DMEM, F-12K or RPMI-1640 containing 3% FBS, in which 
the NP stock suspensions were freshly diluted. Cells were 
incubated for 24 h with increasing concentrations of NPs (0.1-
1.5 mg/ml). Afterwards, cell responses were analyzed 
immediately (24 h time point), or after additional 24 h of 
incubation of cells in NP-free complete medium (24 + 24 h 
time point).
Assessment of NP cytotoxicity
MTS assay. Reduction of cell proliferation/viability after NP 
incubation was measured by MTS [(3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium)] assay. The CellTiter 96® Aqueous One Solution 
Cell Proliferation Assay (Promega Co, Madison, WI, USA) was 
used. Briefly, A549, CCD-34Lu and NCI-H2347 cells were 
seeded in triplicate in 96-well plates (3000 cells/well) and 24 h 
later incubated with increasing concentrations of non-PEG or 
PEG NPs. Cell viability was measured at 24 h time point as 
well as at 24 + 24 h. For the assay, the cell medium was 
replaced with 100 μl of serum free medium plus 20 μl of 
CellTiter 96 Reagent and the plates were incubated for 1.5 h at 
37°C. Afterward, the absorbance at 492 nm of the formazan 
produced was measured with a Biotrak II (GE Healthcare, 
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Piscataway, NJ, USA) visible plate reader. The viability of 
treated cells was expressed as percentage of the absorbance of 
controls that was taken as 100% viability. 
LDH release assay. The activity of lactate dehydrogenase 
(LDH) released in the cell culture medium during incubation  
with PEG NPs was measured using the CytoTox 96 Non-
Radioactive Cytotoxicity Assay (Promega Co, Madison, WI, 
USA). The cells were seeded in 96-well plates and treated as 
for the MTS assay. Following the 24 h of treatment, the LDH 
activity was measured according to the manufacturer’s 
instructions. The activities of the total cellular LDH content and 
of that released in the cell culture medium were measured in 
order to calculate the percentage of enzyme released during the 
exposure of the cells to PEG NPs. 
Propidium iodide (PI) staining. Morphological changes and 
plasma membrane permeabilization in cells treated for 24 h
with PEG NPs were analyzed using the DM 5000B 
fluorescence microscope (Leica Microsystems Srl; Milan, 
Italy). At the end of NP incubation, cells were incubated with 
10 μg/ml of PI (Sigma-Aldrich, St Louis, MO, USA) in 
phosphate buffered saline (PBS) for 5 minutes at room 
temperature and then visualized under the microscope. The 
percentage of PI positive cells (% of necrotic cells) in each 
sample was obtained counting at least 400 cells/sample. 
Scanning electron microscopy (SEM) and transmission 
electron microscopy (TEM) 
A549 and CCD-34Lu cells were seeded in 35 mm culture 
dishes (100000 cells/well) and, after 24 h of growth, were 
treated with non-PEG or PEG NPs for 24 h. For SEM, the cells 
seeded on a coverslip, were primary fixed in 2.5% 
glutaraldehyde in 0.1 M phosphate buffer at pH 7.4 for 1 h at 
room temperature and then washed 3 times with phosphate 
buffer (10 min each wash). The samples were post-fixed in 1% 
osmium tetroxide in 0.1 M phosphate buffer pH 7.4 for 1 h at 
room temperature and dehydrated in ethanol from 10% to100% 
(3 times) for 10 min each step. The samples were then critical 
point dried, gold sputtered and observed with a Stereoscan 260 
scanning electron microscope (Cambridge Scientific 
Instruments Ltd., Ely, UK) operating at 15 kV. For TEM, cells 
were fixed and dehydrated in ethanol as for SEM and finally 
included in epoxy resin. The samples were sectioned with a 
Ultrotome V ultramicrotome (LKB instruments, Victoria, TX, 
USA). Thin sections (80-100 nm) were counterstained with 
uranyl acetate and lead citrate and then observed with a Tecnai 
G2 transmission electron microscope (FEI Company, Hillsboro, 
OR, USA) operating at 100 kV.
Uptake of rhodamine labeled non-PEG and PEG 
ORMOSIL NPs
Flow cytometry was used for a comparative evaluation of the 
uptake of NPs in A549 and CCD-34Lu cells. The cells were 
incubated for 24 h with a sub-lethal dose (0.1 mg/ml) of NPs 
covalently labelled with rhodamine. After cell harvesting, 
10000 events/sample were acquired and analysed by flow 
cytometry. The internalization and localisation of rhodamine-
labeled NPs in the cells was also inspected with a DM 5000B 
fluorescence microscope (Leica Microsystems Srl, Milan, 
Italy).
ROS measurements
ROS generation within cells was measured using the Total ROS 
Detection Kit (Enzo Life Sciences International Inc., Plymouth 
Meeting, PA, USA). The kit includes a non-fluorescent cell 
permeable probe (Oxidative Stress Detection Reagent) which 
reacts directly with various types of ROS, yielding a green 
fluorescent product indicative of cellular ROS production. Cells 
were seeded in 24-well plates (15000 cells/well) and, after 24 h 
of growth, were treated with PEG NPs for 5, 24 or 24 + 24 h. 
Afterwards, the cells were washed twice with 1X Wash Buffer, 
harvested and centrifuged for 5 min at 400xg. Cell pellets were 
incubated with 500 μl of ROS Detection Solution (25 μM 
Oxidative Stress Detection Reagent in Wash Buffer 1X) and 
incubated at 37° C in the dark for 30 min. Ten thousand 
events/sample were analyzed by flow cytometry (BD 
FACSCantoTM II instrument, Becton Dickinson, San Jose, CA, 
USA) using 488-nm laser and FITC detection channel (515-545
nm). The capability of antioxidant agents such as catalase 
(CAT) and superoxide dismutase (SOD) to deactivate ROS was 
analyzed in cells exposed to PEG NPs. The cells were pre-
incubated for 1 h with CAT (1000 U/ml), SOD (1000 U/ml) or 
SOD + CAT (1000 U/ml of each) (Sigma-Aldrich, St Louis, 
MO, USA) and then NPs were added for 24 h. The viability of 
the cells exposed to NPs in the presence of CAT and SOD was 
measured with the trypan blue exclusion test. This test was used 
because of the interference of antioxidants with the MTS test 
[84]. The cells treated as those for ROS detection experiments 
were harvested, centrifuged and 30 μl of cell suspension were 
stained with 30 μl of trypan blue (Sigma-Aldrich, St Louis, 
MO, USA). Cells negative to trypan blue staining were counted 
using a Burker Chamber and the viability of treated cells was 
expressed as percentage of the cell number of controls that was
taken as 100% viability.
Gene expression analysis
Microarray experiments. 0.5 x 106 A549 or CCD-34Lu cells 
were seeded in 100 mm culture dishes for 24 h and then 
exposed to a sub-lethal dose (0.1 mg/ml) of PEG NPs for 24 h 
or 24 + 24 h. Total RNA was extracted from control and NP-
treated cells with TRIZOL (Life Technologies, Milan, Italy) 
according to the manufacturer’s instructions. Extracted RNA 
was quantified by spectrophotometric analysis (NanoDrop®
ND-1000, CELBIO, Milan, Italy) and checked for quality and 
integrity with an Agilent Bioanalyzer 2100 (Agilent Small 
RNA kit and Nano kit, Agilent Technologies, Palo Alto, CA, 
USA). The One-Color Microarray-Based Gene Expression 
Analysis was performed using the Whole Human Genome 
(4x44K) Oligo Microarray Kit with SurePrint (Agilent), 
according to the manufacture’s guidelines. One μg of RNA 
from three different experimental replicates/sample was 
amplified and labeled using the Quick Amp Labeling Kit 
(Agilent) to generate Cyanine-3-CTP labeled complementary 
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RNA (cRNA) using T7 RNA polymerase. Spike-in control 
transcripts were added to each sample and monitored to verify 
hybridization integrity. cRNA samples were purified with 
RNeasy Mini spin columns (Qiagen Sciences, Germantown, 
MD, USA) and quantified using NanoDrop®. Before the 
hybridization on the microarray platform, 1.65 μg of 
RNA/samples was fragmented using the Gene Expression 
Hybridization Kit (Agilent) by incubation with 25x 
Fragmentation Buffer and 10x Blocking Agent for 30 min at 
60°C. Fragmented RNA was hybridized to 4x44 K Whole 
Genome Human Chip that contains about 41000 60-mer 
oligoprobe for human genes and transcripts that have been 
empirically and experimentally validated. Samples were 
hybridized in Hybridization Buffer of Gene Expression 
Hybridization kit using gasket slides within the Agilent 
SureHib chamber for 17 h at 65° C and with a rotation of 10 
rpm. Slides were scanned at 5 μm resolution on a DNA 
Microarray Scanner (Agilent). Images were analyzed with the 
Agilent Feature Extraction Software 10.5.1.1 and 4 Quality 
Control (QC) for array were extracted. Microarray data were 
first normalized both intra-array (multiplicatively detrended 
analysis) and inter-array (quantile analysis) and then filtered 
according to the parameters of spots recognition and 
background exclusion. Using TMEV 4_5_1 [85], the 
Significance Analysis of Microarray (SAM) two class unpaired 
statistic analysis was performed: normalized values of gene 
expression were converted to a logarithmic scale and genes 
resulting with Log2 (expression values NPs/controls) > +0.7 
and < −0.7 and with a False Discovery Rate (FDR) < 4% were 
considered as up-regulated and down-regulated, respectively. 
SAM was used also to obtain d.e.g. between A549 and CCD-
34Lu un-treated cells, applying for the analysis a FDR of 0%. 
Raw data of microarray experiments are available on the 
National Center for Biotechnology Information Gene 
Expression Omnibus (GEO) website 
(http://www.ncbi.nlm.nih.gov/geo/) [GSE25991]. 
Cluster and Gene ontology analysis. Heat map images and 
cluster analysis of d.e.g. in A549 cells were performed using 
TMEV 4_5_1. Lists of d.e.g were uploaded in the Database for 
Annotation, Visualization and Integrated Discovery functional 
annotation tool (DAVID 6.7b version; 
http://david.abcc.ncifcrf.gov/) which is able to extract 
biologically relevant gene ontology terms (GO terms) [86,87]. 
The analysis was focused on the enrichment in GO-terms in 
biological processes on FAT level (GOTERM_BP FAT chart) 
which filters out very broad GO terms based on a measured 
specificity of each term (not level-specificity). For a biological 
process term to be considered significantly enriched, we used a 
cut-off of p < 0.05 after multiple testing corrections. Moreover, 
the processes represented by less than 5 genes were filtered out 
to identify only those pathways most perturbed by NPs. 
Biological processes terms that represented complete subsets of 
other biological processes were rolled up to the highest level of 
GO hierarchy, eliminating redundancy. 
Quantitative Real time PCR (qRT-PCR)
One μg of total RNA/sample extracted from cells untreated or 
treated with PEG NPs was converted to complementary DNA 
(cDNA) via reverse transcriptase with oligo-dT priming 
(Improm-IITM Reverse Transcription System, Promega Co., 
Madison, WI, USA) according to the manufacturer’s
instructions. Primer pairs designed to amplify cDNA encoding 
target genes were prepared using the Universal ProbeLibrary 
Assay Design Center (Roche Applied Science, Indianapolis, IN, 
USA). qRT-PCR analysis was performed using the 7500 Real-
Time PCR system (Applied Biosystems, Life Technologies 
Corporation, Carlsbad, CA, USA) and data were analyzed using 
the Sequence Detection software version 1.4 (Applied 
Biosystems). Differences in gene expression were normalized 
to GAPDH transcript levels with invariant abundance in our 
experimental conditions. Normalized ratios in NP-treated 
samples were reported as mean fold-change (sometimes 
transformed in Log2 scale) compared with untreated controls 
(Relative Expression, RE).
Detection of IL-8 protein in culture supernatants
The concentrations of IL-8 protein in the supernatant of cells 
treated for 5 h or 24 h with different doses of PEG NPs were 
measured with the Human IL-8/NAP-1 Instant ELISA assay 
(Bender MedSystems, Wien, Austria) according to the 
manufacturer’s instructions.
Immunofluorescence of pulmonary surfactant proteins
The surfactant protein A (SP-A) and the surfactant protein C 
(SP-C) were selected among the four specific proteins of 
pulmonary surfactant, secreted by alveolar type II cells, and the 
modulation of their expression was analyzed by 
immunofluorescence in A549 after incubation with PEG NPs. 
The cells (105) were grown in 35 mm tissue culture dishes 
containing a glass cover slip for 24 h and then exposed to 0.1 or 
0.3 mg/ml of NPs for 24 h. Cells were then washed twice with 
PBS and fixed in 4% paraformaldehyde in PBS for 15 min at 
room temperature. The fixed cells were washed again three 
times with PBS, permeabilized in 0.2% Triton X-100 PBS 
(permeabilization solution) for 10 min at 37 °C and then 
incubated in 10% goat serum (GS) in PBS for 1 h at room 
temperature to suppress non specific antibody binding. The 
cells were then incubated for 90 min at room temperature with 
the primary antibodies: rabbit polyclonal anti-Prosurfactant 
Protein C antibody and mouse monoclonal anti-surfactant 
Protein A antibody (Abcam, Cambridge, UK) diluted 1:200 and 
1:100, respectively, in permeabilization solution added with 
10% GS. The slides were washed three times in PBS and 
incubated in the dark for 1 h with the secondary antibodies 
Alexa Fluor 488 donkey anti-rabbit and Alexa Fluor 488 goat-
anti-mouse for SP-C and SP-A, respectively, diluted 1:350 in 
permeabilization solution added with 10% GS. After three 
additional  washes in PBS, cells were counterstained with 2 μg 
ml-1 DAPI (4,6-diamidino-2-fenilindole) in antifade solution 
(Vectashield, Vector Laboratories, Burlingame, CA, USA) and 
glass cover slip were mounted and analyzed with a Leica SP5 
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confocal laser microscope (Leica Microsystems Srl, Milan, 
Italy). 
Statistical analysis 
The Primer software for biostatistics (McGraw-Hill, Columbus, 
OH, USA) was used for statistical analysis of the data. The data 
are expressed as means ± standard deviations (S.D.) of at least 
3 experiments. The differences between groups were evaluated 
with the Student’s t-test and considered significant for p < 0.05.
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Additional files 
PEGylation of ORMOSIL nanoparticles abolishes the toxicity toward 
some lung cells but not alveolar type II epithelial cells in vitro
Francesca Moret, Francesco Selvestrel, Elisa Lubian, Chiara Compagnin, Maddalena Mognato, 
Lucia Celotti, Fabrizio Mancin and Elena Reddi. 
Additional file 1. DLS size distribution of PEGylated ORMOSIL nanoparticles in different 
media. DLS size distribution of PEG NPs incubated in water (blue curve, average size 67  15 nm), 
cell culture medium (red curve, average size 73  15 nm), cell culture medium supplemented with 
10% serum (green curve, average size 78 15 nm). 
Additional file 2. SEM micrographs of A549 cells incubated 24 h with 0.1 mg/ml of non-
PEGylated (A) or PEGylated ORMOSIL NPs (B). 
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Additional file 3. SEM images of A549 and CCD-34Lu cells exposed 24 h to ORMOSIL NPs. 
A549 cells A) not incubated with NPs, B) incubated with 0.3 mg/ml non-PEGylated NPs, C)
incubated with 0.3 mg/ml PEGylated NPs. CCD-34Lu cells D) not incubated with NPs, E) 
incubated with 0.5 mg/ml non-PEGylated NPs, F) incubated with 0.5 mg/ml PEG NPs. 
Additional file 4. Percentage of propidium iodide positive A549 and CCD-34Lu cells. The cells 
were stained with PI after exposure for 24 h to increasing concentrations of PEG ORMOSIL NPs.
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Additional file 5. List of genes differentially expressed in A549 cells after 24 h incubation with 
0.1 mg/ml PEGylated NPs. Data from this table were used to obtain heat map diagrams (Figure 9 
A) and the GO terms related to biological function perturbed by NP treatments (Figure 9 D). 
Gene name Systematic name Description Log2 NPs/C 24h FDR (%)
A_23_P103951 A_23_P103951 unknown 0.98 4%
A_23_P170719 A_23_P170719 unknown 0.95 0%
A_23_P206741 A_23_P206741 unknown 1.05 4%
A_32_P167212 A_32_P167212 unknown 0.73 4%
ADFP NM_001122 adipose differentiation-related protein 0.87 0%
ADRB2 NM_000024 adrenergic ß-2-receptor 0.81 0%
AI359640 AI359640 0.88 4%
AKAP12 NM_144497 kinase A  anchor protein 12 (PRKA) 0.73 4%
AL390143 AL390143 0.93 4%
AMPD3 NM_000480 adenosine monophosphate deaminase 0.80 4%
ANGPTL4 NM_139314 angiopoietin-like 4 0.90 4%
ANPEP NM_001150 alanyl aminopeptidase (membrane) 1.37 4%
ANTXR2 NM_058172 anthrax toxin receptor 2 1.01 4%
ARHGEF4 NM_032995 Rho guanine nucleotide exchange factor 4 0.84 4%
ATAD4 NM_024320 ATPase family, AAA domain containing 4 -1.41 0%
ATP8B3 NM_138813 ATPase, Class I, type 8B, member 3 -0.84 4%
BAAT NM_001701 bile acid Coenzyme A -1.10 4%
BC012036 BC012036 1.05 4%
BG993059 BG993059 0.77 4%
BM129308 BM129308 Melton normalized human islet 4 1.5 4%
BMP6 NM_001718 bone morphogenetic protein 6 0.95 4%
BU674073 BU674073 1.24 4%
C6orf141 BC036917 chromosome 6 open reading frame 141 0.72 4%
CCDC68 NM_025214 coiled-coil domain containing 68 0.87 4%
CD274 NM_014143 CD274 molecule 1.31 4%
CD274 ENST00000381577 programmed death ligand 1 1.06 4%
CD55 NM_000574 CD55 molecule 0.92 0%
CDCP1 NM_022842 CUB domain containing protein 1 1.37 0%
CDH16 NM_004062 cadherin 16 -0.98 4%
CEBPD NM_005195 CCAAT/enhancer binding protein -0.85 4%
CNIH3 NM_152495 cornichon homolog 3 1.27 4%
CNN1 NM_001299 calponin 1 -1.47 4%
COL13A1 NM_005203 collagen, type XIII 2.09 0%
CSF1R NM_005211 colony stimulating factor 1 receptor 0.77 4%
CXCL5 NM_002994 chemokine ligand 5 0.92 0%
CXCL5 NM_002994 chemokine ligand 5 1.10 4%
CXCR7 NM_020311 chemokine receptor 7 -0.85 4%
CYP11A1 NM_000781 cytochrome P450, family 11, subfamily A 0.9 4%
DCLK1 NM_004734 doublecortin and CaM kinase-like 1 2.41 4%
DDIT4 NM_019058 DNA-damage-inducible transcript 4 0.70 0%
DNMBP BC041628 dynamin binding protein 1.02 0%
F2RL1 NM_005242 coagulation factor II thrombin receptor 0.80 4%
FAM49A NM_030797 family with sequence similarity 49 1.09 4%
FGB NM_005141 fibrinogen beta chain -1.02 4%
FOXD1 NM_004472 forkhead box D1 0.86 4%
FOXJ1 NM_001454 forkhead box J1 -0.78 4%
FOXQ1 NM_033260 forkhead box Q1 0.74 4%
FST NM_013409 follistatin 1.29 0%
G0S2 NM_015714  G0/G1 switch 2 0.82 0%
GEM NM_005261 GTP binding protein 1.01 0%
GJB1 NM_000166 gap junction protein, ß 1 -1.33 4%
HAS2 NM_005328 hyaluronan synthase 2 1.45 4%
HRK NM_003806 BCL2 interacting protein 0.95 0%
IL11 NM_000641 interleukin 11 0.97 0%
IL8 NM_000584 interleukin 8 1.16 4%
KCNJ16 NM_170741 potassium inwardly-rectifying channel -0.81 4%
KCNMA1 NM_001014797 potassium  calcium-activated channel 0.89 4%
KIAA1199 NM_018689 1.19 0%
KRT4 NM_002272 keratin 4 -1.02 4%
LGALS2 NM_006498 lectin, galactoside-binding -1.50 0%
LINGO1 NM_032808 leucine rich repeat and Ig domain 0.72 4%
LIPG NM_006033  endothelial lipase 1.71 4%
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LOC145837 BC064586 hypothetical protein -1.45 4%
LOC283454 AK094730 0.90 0%
LOC284542 AK090467 FLJ00388 protein 1.57 4%
LOC399959 AK021552 FLJ11490 fis clone 1.23 4%
LY6K NM_017527  lymphocyte antigen 6 complex 1.16 0%
LY6K NM_017527 lymphocyte antigen 6 complex 1.09 0%
MARCH4 NM_020814 membrane-associated ring finger 4 1.33 0%
MCTP1 AK025997 1.80 0%
MCTP1 NM_024717 transmembrane multiple C2 domains  1.57 0%
MIG7 DQ080207  MIG7 mRNA 1.23 4%
MMP1 NM_002421 matrix metallopeptidase 1 1.17 0%
MT1E NM_175617 metallothionein 1E 0.73 4%
MT1L X97261 metallothionein isoform 1R 0.76 4%
MT1X NM_005952 metallothionein 1X 0.74 4%
NEFH NM_021076 neurofilament, heavy polypeptide 200kDa -1.58 4%
NFE2 NM_006163 nuclear factor (erythroid-derived 2), 45kDa -0.86 4%
NOV NM_002514 nephroblastoma overexpressed gene 0.82 4%
NR1D1 NM_021724 nuclear receptor subfamily 1,  member 1 0.91 4%
NT5E NM_002526 5'-nucleotidase (CD73) 1.27 0%
NT5E NM_002526 5'-nucleotidase (CD73) 1.13 4%
NTSR1 NM_002531 neurotensin receptor 1 0.81 4%
OTUB2 NM_023112  OTU domain, ubiquitin aldehyde binding 2 0.75 4%
PALM2-AKAP2 NM_007203 PALM2-AKAP2 protein 1.11 4%
PDK4 NM_002612 pyruvate dehydrogenase kinase, isozyme 4 0.75 4%
PDZK1 NM_002614 PDZ domain containing 1 -0.76 4%
PHLDA1 NM_007350 pleckstrin homology-like domain 0.71 4%
PLAU NM_002658 plasminogen activator, urokinase 0.83 0%
PLAUR NM_001005377 plasminogen activator, urokinase receptor 0.73 4%
PODXL NM_005397 podocalyxin-like , transcript variant 2 0.82 0%
PRKCE NM_005400 protein kinase C 0.80 4%
PTGS2 NM_000963 prostaglandin synthase and cyclooxygenase 1.01 0%
PTPRR NM_002849 protein tyrosine phosphatase receptor 1.98 4%
PTX3 NM_002852 pentraxin-related gene, induced by IL-1 ß 1.62 4%
RGS2 NM_002923 regulator of G-protein signalling 2 0.88 0%
RNF182 NM_152737 ring finger protein 182 0.96 0%
RPS6KA5 NM_004755 ribosomal protein S6 kinase, 90kDa 0.93 0%
RPS6KA5 NM_004755 ribosomal protein S6 kinase, 90kDa 1.08 4%
RUNX2 NM_004348 runt-related transcription factor 2 1.05 4%
SAMD11 NM_152486 sterile α motif domain containing 11 -0.70 4%
SERPINB8 NM_198833 serpin peptidase inhibitor, clade B, member 8 1.03 4%
SERPINF1 NM_002615 α-2 antiplasmin epithelium derived factor -0.91 0%
SFMBT2 ENST00000361972 Scm-like with four MBT domains protein 2 0.98 4%
SFRP1 NM_003012 secreted frizzled-related protein 1 0.90 4%
SFRP4 NM_003014 secreted frizzled-related protein 4 -1.10 4%
SH2D5 AK124869 0.71 4%
SHC3 NM_016848 Src2 domain containing transforming protein 3 2.75 4%
SLC6A15 NM_018057 solute carrier family 6 1.80 4%
SMOX NM_175839 spermine oxidase 0.85 4%
SP5 NM_001003845 Sp5 transcription factor 1.00 4%
SPHK1 NM_021972 sphingosine kinase 1 0.88 0%
SPOCD1 AK097227 1.56 4%
SPOCD1 NM_144569 SPOC domain containing 1 1.05 4%
SSTR5 NM_001053 somatostatin receptor 5 1.48 4%
STC2 NM_003714 stanniocalcin 2 1.30 0%
TGM2 NM_004613 transglutaminase 2 0.98 4%
THC2655811 THC2655811 unknown 1.44 0%
THC2667205 THC2667205 unknown 0.71 4%
THC2677780 THC2677780 unknown 0.89 4%
THC2682291 THC2682291 unknown -1.10 4%
THC2682885 THC2682885 -0.88 4%
TMEM158 NM_015444 transmembrane protein 158 1.50 0%
TMEM37 NM_183240 transmembrane protein 37 -1.02 4%
TNFRSF25 NM_148965 tumor necrosis factor receptor superfamily 0.88 4%
TNS4 NM_032865 tensin 4 0.80 4%
TOX2 NM_032883 TOX high mobility group box family member 2 0.73 4%
U79293 U79293 0.70 4%
U85992 U85992 1.46 0%
UAP1L1 NM_207309 UDP-N-acteylglucosamine pyrophosphorylase 0.74 4%
VEGFC NM_005429 vascular endothelial growth factor C 0.82 4%
WDR33 NM_018383 WD repeat domain 33 1.15 4%
ZEB2 NM_014795 zinc finger E-box binding homeobox 2 1.00 4%
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Additional file 6. List of genes differentially expressed in A549 cells after 24 + 24 h of PEG NP 
incubation. Data from this table were used to obtain heat map diagrams (Figure 9 B) and the GO 
terms related to biological function perturbed by NP treatments (Figure 9 E). 
Gene name Systematic name Description Log2 NPs/C 24 + 24 h FDR (%)
A_24_P315256 A_24_P315256 unknown -0.91 4%
ANG NM_001145 angiogenin, ribonuclease, RNase A family, 5 -1.02 4%
ANK3 NM_020987 ankyrin 3, node of Ranvier -0.73 4%
ANPEP NM_001150 alanyl  aminopeptidase 1.43 0%
ANXA9 NM_003568 annexin A9 -0.80 4%
CA9 NM_001216 carbonic anhydrase IX -0.94 4%
CCK NM_000729 cholecystokinin 1.00 4%
CNN1 NM_001299 calponin 1 -1.38 0%
COL13A1 NM_005203 collagen, type XIII 1.20 0%
CTGF NM_001901 connective tissue growth factor -0.82 4%
DCLK1 NM_004734 doublecortin and CaM kinase-like 1 1.55 0%
ENST00000380683 ENST00000380683 unknown -0.86 4%
FGA NM_021871 fibrinogen alpha chain -1.05 0%
FGA NM_000508 fibrinogen alpha chain -1.22 4%
GPR92 NM_020400 G protein-coupled receptor 92 -1.42 4%
HGD NM_000187 homogentisate 1,2-dioxygenase -0.96 0%
ITIH5 NM_030569 inter-α (globulin) inhibitor H5 -0.73 4%
KCNJ16 NM_170741 potassium  channel, subfamily J, member 16 -1.13 0%
KRT4 NM_002272  keratin 4 -1.84 0%
LBH NM_030915 limb bud and heart development homolog -1.10 4%
LGALS2 NM_006498 lectin, galactoside-binding 2 -2.10 0%
LOC553137 AK124400 -0.74 4%
LTB NM_002341 lymphotoxin ß (TNF superfamily, member 3) -1.05 4%
LY6K NM_017527 lymphocyte antigen 6 complex 1.39 4%
LY6K NM_017527 lymphocyte antigen 6 complex 1.33 4%
NCF2 NM_000433 neutrophil cytosolic factor 2 -0.87 4%
PDZK1 NM_002614  PDZ domain containing 1 -0.84 4%
PROC NM_000312 protein C -0.95 4%
PTX3 NM_002852 pentraxin-related gene, induced by IL-1 ß 1.35 0%
QPRT NM_014298 quinolinate phosphoribosyltransferase -0.83 4%
RASGRP3 NM_170672 RAS guanyl releasing protein 3 -1.07 4%
RNASE4 NM_194430 ribonuclease, RNase A family 4 -0.92 4%
RND1 NM_014470 Rho family GTPase 1 -1.22 4%
SAA1 NM_000331 serum amyloid A1 -0.99 4%
SAMD11 NM_152486 sterile alpha motif domain containing 11 -0.77 4%
SFRP4 NM_003014  secreted frizzled-related protein 4 -0.90 4%
SLC7A7 NM_003982 solute carrier family 7 -1.01 0%
SLPI NM_003064 secretory leukocyte peptidase inhibitor -0.93 4%
ST6GALNAC1 NM_018414 ST6 -1.08 4%
SULT2B1 NM_004605 sulfotransferase family, member 1 -0.94 0%
TF NM_001063 transferrin -1.23 4%
THC2581431 THC2581431 VIL1 protein -1.49 0%
TMEM45B NM_138788 transmembrane protein 45B -0.82 4%
TNNC1 NM_003280 troponin C type 1 (slow) -1.27 0%
VIL1 NM_007127 villin 1 -1.58 0%
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Additional file 7. qRT-PCR measurements of mRNA expression of IL-8, PTGS2 and KRT4 
gene in A549 cells incubated with 0.1 mg/ml of PEG NPs for 24 h or 24 + 24 h. Data are 
represented as Log2 (Relative Expression) ± range derived from quadruplicate RT-PCR reactions.
-0.23 ± 0.06not significant24 + 24KRT4
-1.75 ± 0.01not significant24 + 24PTGS2
-0.1 ± 0.01not significant24 + 24IL8
0.09 ± 0.07not significant24KRT4CCD-34Lu
0.39 ± 0.01not significant24PTGS2
-0.41 ± 0.17not significant24IL8
-2.4 ± 0.01-1.8424 + 24KRT4
-1.11 ± 0.010.000824 + 24PTGS2
-0.71 ± 0.18-0.1324 + 24IL8A549
-1.86 ± 0.02-1.0224KRT4
1.49 ± 0.041.0124PTGS2
1.44 ± 0.461.1624IL8
RT-PCR 
(log2 RE)
Microarray 
(Log2 NPs/C)
time 
(h)Gene name
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Additional file 8. List of GO terms relative to differentially expressed genes in A549 cells after 
24 h PEG NP incubation. Full list of significant GO terms (p value < 0.05) obtained uploading in 
DAVID genes differentially expressed in A549 cells at the end of the 24 h of NP incubation. F.E.: 
Fold Enrichment.
GO Term Description p value F.E. Gene
GO:0007166 cell surface receptor linked signal transduction 4,00E-03 1,9 AKAP12, CD274, GEM, SHC3, ADRB2, BMP6, CXCL5, CXCR7, F2RL1,
CSFR1, FST, IL8, NTSR1, RPS6KA5, SFRP1, SFRP4, SSTR5, SPHK1,
STC2, TGM2, TNFRSF25, VEGFC
GO:0023034 intracellular signaling cascade 2,20E-02 1,9 GEM, ARHGEF4, SHC3, ADRB2, CNIH3, DCLK1, IL8, LINGO1, MCTP1,
PRKCE, RPS6KA5, SSTR5, SPHK1, TGM2
GO:0042127 regulation of cell proliferation 1,10E-03 2,8 CD274, ADRB2, CXCL5, FOXJ1, IL11, IL8, KRT4, PLAU, PTGS2, RUNX2,
SSTR5, SPHK1, TGM2, VEGFC
GO:0042981 regulation of apoptosis 1,10E-02 2,4 ARGHGEF4, ADRB2, ANGPLT4, HRK, PHLDA1, KCNMA1, PTGS2, PRKCE,
SFRP1, SPHK1, TGM2, TNFRSF25
GO:0043067 regulation of programmed cell death 1,10E-02 2,4 ARGHGEF4, ADRB2, ANGPLT4, HRK, PHLDA1, KCNMA1, PTGS2, PRKCE,
SFRP1, SPHK1, TGM2, TNFRSF25
GO:0010941 regulation of cell death 1,20E-02 2,3 ARGHGEF4, ADRB2, ANGPLT4, HRK, PHLDA1, KCNMA1, PTGS2, PRKCE,
SFRP1, SPHK1, TGM2, TNFRSF25
GO:0043065 positive regulation of apoptosis 5,20E-03 3,3 ARHGEF4, ADRB2, HRK, PHLDA1, KCNMA1, PTGS2, PRKCE, TGM2, 
TNFRSF25
GO:0043068 positive regulation of programmed cell death 5,40E-03 3,3 ARHGEF4, ADRB2, HRK, PHLDA1, KCNMA1, PTGS2, PRKCE, TGM2, 
TNFRSF25
GO:0010942 positive regulation of cell death 5,50E-03 3,3 ARHGEF4, ADRB2, HRK, PHLDA1, KCNMA1, PTGS2, PRKCE, TGM2, 
TNFRSF25
GO:0007610 behavior 8,60E-03 3,1 CXCL5, CYP11A1, IL8, KCNMA1, NTSR1, PLAU, PLAUR, PTGS2, SHC3
GO:0006928 cell motion 9,20E-03 3 DCLK1, FOXJ1, IL8, PLAU, PLAUR, PODXL, PTGS2, VEGFC, ZEB2
GO:0009611 response to wounding 1,70E-02 2,7 BMP6, CD55, F2RL1, FGB, IL11, IL8, PLAU, PLAUR, PTX3
GO:0032101 regulation of response to external stimulus 5,80E-05 8 ADRB2, F2RL1, IL8, NT5E, PLAU, PTGS2, SERFPINF1, TGM2
GO:0051094 positive regulation of developmental process 1,70E-03 4,6 ADRB2, ANGPTL4, BMP6, FST, RUNX2, SERPINF1, SPHK1, VEGFC
GO:0008284 positive regulation of cell proliferation 1,40E-02 3,1 ADRB2, CXCL5, IL11, PTGS2, RUNX2, SPHK1, TGM2, VEGFC
GO:0008283 cell proliferation 1,90E-02 2,9 ADRB2, CXCL5, IL11, PTGS2, RUNX2, SPHK1, TGM2, VEGFC
GO:0050878 regulation of body fluid levels 2,40E-04 7,9 F2RL1, FGB, IL11, NFE2, PLAU, PLAUR, KCNMA1
GO:0016477 cell migration 7,40E-03 4 DCLK1, FOXJ1, IL8, PLAU, PODXL, VEGFC, ZEB2
GO:0048870 cell motility 1,20E-02 3,6 DCLK1, FOXJ1, IL8, PLAU, PODXL, VEGFC, ZEB2
GO:0051674 localization of cell 1,20E-02 3,6 DCLK1, FOXJ1, IL8, PLAU, PODXL, VEGFC, ZEB2
GO:0007167 enzyme linked receptor protein signaling pathway 2,00E-02 3,3 ADRB2, BMP6, CSFR1, FST, RPS6KA5, SHC3, VEGFC
GO:0007599 hemostasis 5,50E-04 8,8 F2RL1, FGB, IL11, NFE2, PLAU, PLAUR
GO:0048514 blood vessel morphogenesis 1,00E-02 4,5 ANPEP, ANGPTL4, IL8, PLAU, TGM2, VEGFC
GO:0019932 second-messenger-mediated signaling 1,50E-02 4,1 ADRB2, IL8, MCTP1, SSTR5, SPHK1, TGM2
GO:0051240 positive regulation of multicellular organismal process 1,80E-02 3,9 ADRB2, BMP6, FST, LIPG, PTGS2, SPHK1
GO:0001568 blood vessel development 1,80E-02 3,9 ANPEP, ANGPTL4, IL8, PLAU, TGM2, VEGFC
GO:0001944 vasculature development 2,00E-02 3,8 ANPEP, ANGPTL4, IL8, PLAU, TGM2, VEGFC
GO:0007626 locomotory behavior 2,80E-02 3,5 CXCL5, IL8, NTSR1, PLAU, PLAUR, KCNMA1
GO:0044057 regulation of system process 4,30E-02 3,1 ADRB2, CNN1, FST, KCNMA1, PTGS2, SPHK1
GO:0006917 induction of apoptosis 4,90E-02 3 ARGHGEF4, HRK, PHLDA1, PRKCE, TGM2, TNFRSF25
GO:0012502 induction of programmed cell death 4,90E-02 3 ARGHGEF4, HRK, PHLDA1, PRKCE, TGM2, TNFRSF25
GO:0006937 regulation of muscle contraction 1,00E-03 11,1 ADRB2, CNN1, KCNMA1, PTGS2, SPHK1
GO:0050727 regulation of inflammatory response 1,30E-03 10,5 ADRB2, NT5E, PTGS2, SERPINF1, TGM2
GO:0050817 coagulation 3,70E-03 7,8 F2RL1, FGB, IL11, PLAU, PLAUR
GO:0007596 blood coagulation 3,70E-03 7,8 F2RL1, FGB, IL11, PLAU, PLAUR
GO:0010038 response to metal ion 8,50E-03 6,2 CYP11A1, FGB, MT1X, KCNMA1, PTGS2
GO:0001525 angiogenesis 1,40E-02 5,4 ANPEP, ANGPTL4, IL8, PLAU, VEGFC
GO:0040007 growth 2,70E-02 4,3 BMP6, DCLK1, PLAU, PLAUR, PTGS2
GO:0042060 wound healing 3,10E-02 4,2 F2RL1, FGB, IL11, PLAU, PLAUR
GO:0031667 response to nutrient levels 3,40E-02 4 CYP11A1, FGB, LIPG, PTGS2, STC2
GO:0010035 response to inorganic substance 3,90E-02 3,9 CYP11A1, FGB, MT1X, KCNMA1, PTGS2
GO:0009991 response to extracellular stimulus 4,80E-02 3,6 CYP11A1, HRK, LIPG, PTGS2, STC2
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Additional file 9. List of GO terms relative to differentially expressed genes in A549 cells after 
24 + 24 h PEG NP incubation. Full list of significant GO terms (p value < 0.05) obtained 
uploading in DAVID genes differentially expressed in A549 cells incubated for 24 h with NPs and 
released in NP-free medium for additional 24 h (24 + 24 h). F.E.: Fold Enrichment.
GO Term Description p value F.E. Gene
GO:0009611 response to wounding 7,60E-03 4,6 CTGF, FGA, PTX3, PROC, SAA1, TF
GO:0006928 cell motion 4,80E-03 5,2 ANG, ANK3, CCK, CTGF, DCLK1, SAA1
GO:0007010 cytoskeleton organization 3,30E-03 5,6 ANG, ANK3, CNN1, KRT4, RND1, VIL1
GO:0044057 regulation of system process 5,80E-03 6,6 CNN1, CCK, LTB, TF, TNNC1
GO:0051674 localization of cell 5,70E-03 6,7 ANG, CCK, CTGF, DCLK1, SAA1
GO:0048870 cell motility 5,70E-03 6,7 ANG, CCK, CTGF, DCLK1, SAA1
GO:0016477 cell migration 3,90E-03 7,4 ANG, CCK, CTGF, DCLK1, SAA1
GO:0051050 positive regulation of transport 1,80E-03 9,2 PDZK1, ANG, LTB, PTX3, SAA1
GO:0006461 protein complex assembly 3,00E-02 4,1 ANG, FGA, QPRT, SCL7A7, VIL1
GO:0070271 protein complex biogenesis 3,00E-02 4,1 ANG, FGA, QPRT, SCL7A7, VIL1
Additional file 10. List of genes, obtained uploading in DAVID genes over-expressed in CCD-
34Lu controls with respect to A549 controls, showing only those genes belonging to 4 different GO 
terms related to the response to oxidative stress and/or inorganic substance.
Gene name Systematic name Description Log2 (CCD-34Lu) Log2 (A549) Log2 (CCD-34Lu/A549)
ABAT NM_020686 4-aminobutyrate aminotransferase 7,82 5,58 2,24
BCL2 NM_000633 B-cell CLL/lymphoma 2 6,96 4,87 2,09
SEC31A NM_014933 SEC31 homolog A 12,21 10,28 1,93
AHRR NM_020731 aryl-hydrocarbon receptor repressor 9,42 4,75 4,67
COL1A1 Z74615 mRNA for prepro-α1 collagen 15,92 6,48 9,44
CRYAB NM_001885 crystallin α B 13,12 6,79 6,32
CYBRD1 NM_024843 cytochrome b reductase 1 13,07 10,69 2,38
ERCC2 NM_000400 excision repair cross-complementing 2 10,43 7,55 2,88
GJA3 NM_021954 gap junction protein, α 3 8,90 3,71 5,19
GSN NM_198252 gelsolin, transcript variant 2 14,14 11,86 2,27
HVCN1 NM_032369 hydrogen voltage-gated channel 1 8,27 4,03 4,24
LCAT NM_000229 lecithin-cholesterol acyltransferase 8,73 6,60 2,13
MMP14 NM_004995 matrix metallopeptidase 14 10,59 4,92 5,68
MT1H NM_005951 metallothionein 1H 16,25 12,96 3,29
MT1X NM_005952 metallothionein 1X 9,37 6,19 3,18
PXDN NM_012293 peroxidasin homolog 8,88 3,41 5,47
PDGFRA AA599881 bone marrow stromal cells cDNA clone 11,12 4,51 6,61
KCNMA1 NM_001014797 potassium large conductance calcium-activated channel 8,72 5,45 3,27
PML NM_033244 promyelocytic leukemia, transcript variant 5 12,20 10,16 2,04
PTGS1 NM_000962 prostaglandin-endoperoxide synthase 1 13,10 5,81 7,29
SCARA3 NM_016240 scavenger receptor class A, member 3 15,70 12,92 2,78
SEPP1 NM_005410 selenoprotein P 8,09 4,54 3,55
SLC8A1 NM_021097 solute carrier family 8 (sodium/calcium exchanger), member 1 11,43 5,68 5,74
SOD3 NM_003102 superoxide dismutase 3 13,00 3,43 9,57
SNCA NM_007308 synuclein α 8,92 6,59 2,33
TXNIP NM_006472 thioredoxin interacting protein 9,98 5,56 4,42
THBS1 NM_003246 thrombospondin 1 13,80 10,81 2,99
TRPA1 NM_007332 transient receptor potential cation channel, subfamily A, member 1 9,92 5,86 4,06
TNFRSF11B NM_002546 tumor necrosis factor receptor superfamily, member 11b 14,20 3,92 10,28
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Conclusions and future perspectives 
Despite the improvements of photodynamic therapy clinical outcomes obtained using second 
generation PSs, the use of PS engineered nanoparticle-based formulations appears to offer 
unique opportunities for limiting the side effects observed with the conventional PS 
formulations. Recently, unlike the first general enthusiasm demonstrated towards nanosized drug 
delivery systems and despite the approval of several nano-drugs for clinical trials, criticism 
arises also toward nanomedicine approaches. In this context, in this PhD thesis a critical 
evaluation on the benefits but also the limits connected to the delivery of the PS m-THPC by 
liposomes, PLGA NPs or ORMOSIL NPs, properly PEGylated or functionalized for targeted 
PDT is presented. 
In general, the in vitro studies on m-THPC uptake in different cellular systems revealed that all 
the nanovehicles were internalized by cells and were able to deliver the PS, even if reduced 
amounts of drug were measured with respect to the drug delivered by the standard formulation 
(Foscan®). The reduced uptake was very like related to the different interaction of the particles 
and of the free drug with serum proteins and in turn with the cells, with a strong influence of the 
presence of the PEG corona on NP surface. In fact, the PEGylation of the delivery system 
minimized NP/cell surface interactions leading to a reduced uptake of the nanovehicles and of its 
cargo, as measured for PLGA and for ORMOSIL NPs. In particular, the presence of a high 
density PEG layer coating the surface of ORMOSIL NPs, negatively affects PS internalization, 
as measured with an about 95% reduced delivery of m-THPC using these NPs with respect to the 
delivery using the m-THPC standard formulation. Nevertheless, since PEGylation represents one 
of the most successful strategies for imparting stealth properties to NPs improving their 
circulation in the bloodstream in vivo, the density and the length of the PEG chains which 
compose the corona have to be properly modulated in order to balance the reduced clearance by 
the RES with an efficient drug delivery in target tissues. The effect of PEGylation on m-THPC 
delivery was well characterized using liposomes (Fospeg®). Only modest differences in the 
uptake and in the phototoxicity of four different liposomal formulations were found in vitro, but 
the results indicated Fospeg® with 8% of PEGylation was the most suitable to improve liposome 
uptake but also to reduce m-THPC dark cytotoxicity. In fact, from the data of paper I and III, it is 
clear that the presence of the delivery system, despite decreasing m-THPC cellular uptake, 
significantly reduced the drug cytotoxicity in the absence of light, toxicity that represents one of 
the major side effects of PS administration for photodynamic treatments. 
Regarding drug release, it is widely reported in literature that PSs physically entrapped in NPs, 
tend to escape from NPs when incubated in the presence of serum proteins. The phenomenon, 
that can be explains with a higher affinity of the hydrophobic PS for serum proteins leading to 
the formation of PS-protein complexes, can occurs before cell internalization as well as after the 
drug has entered the cells still entrapped in the delivery system. The results on m-THPC PLGA 
NPs, while indicating that ~ the 20% and the 50% of the PS is released in the first 24 h of 
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incubation from non-PEG and PEG NPs, respectively,, showed the characteristic intracellular 
localization of Foscan® in Golgi apparatus and endoplasmic reticulum but also accumulation in 
endosomes/lysosomes as expected for PLGA NPs. Very likely the release of m-THPC was much 
more sustained from Fospeg® and it occurred after as well as before cell internalization of 
liposomes. This is based on the fact that differently from liposomes labelled with covalently 
linked rhodamine which localized in the acidic compartments of cells, m-THPC delivered with 
Fospeg® accumulated exclusively in the Golgi apparatus and endoplasmic reticulum also in the 
absence of serum in the incubation medium. The problem of drug escape from NPs was 
elegantly abolished by the derivatisation of m-THPC with silane moieties that allowed covalent 
attachment of the PS to the matrix of ORMOSIL NPs, without perturbing to a great extent the PS 
photophysical properties. Nevertheless, because of poor internalization of PEGylated ORMOSIL 
NPs measured in cells in vitro, higher m-THPC and light doses were required to obtained uptake 
and phototoxic effects comparable to those obtained with the free drug. In A549 cells irradiated 
with 0.24 J/cm2 the IC50 for m-THPC NPs and for Foscan® was corresponding to m-THPC doses 
of 0.47 μM and 0.07 μM, respectively (unpublished results, see Appendix Figure 1). On the 
other hand, the higher PDT efficiency measured for Fospeg® and PEG PLGA NPs is very likely 
related to m-THPC release from particles before entering cells. Therefore, it can be hypothesized 
that, despite the significant reduced PS uptake, the intracellular localization of m-THPC in Golgi 
apparatus and endoplasmic reticulum regardless the type of delivery, only slightly affects PDT-
induced cellular damages. On contrary, different intracellular targets of PDT damages have to be 
considered using PEG ORMOSIL NPs which after cellular internalization, localized together 
with the transported m-THPC in endosomes and lysosomes. 
Thus, the functionalisation of the drug delivery systems with targeting agents in order to improve 
both uptake and selectivity of m-THPC delivery in tumour cells was extensively explored with 
PEGylated liposomes and ORMOSIL NPs while only few attempts were directed to the 
conjugation of PEG PLGA NPs with epidermal growth factor (EGF), which in turn demonstrated 
to be ineffective as targeting molecule (data not shown). 
Regarding the targeting of nanocarriers with folate, despite the higher PDT efficiency obtained 
using FA-Fospeg with respect to un-targeted liposomes, in Paper II it was clearly demonstrated 
that only a little fraction of targeted liposomes entered the cells by specific endocytosis mediated 
by folate-receptor, being non-specific internalization the prevailing mechanism of liposome 
uptake. Instead, targeting efficiency was completely abolished when folate was conjugated to 
PEG ORMOSIL NPs (Paper IV) The inefficient targeting is very likely explained with the poor 
exposure of the hydrophobic folate molecules on the surface of the ORMOSIL NPs due to 
interference with the PEG corona has hypothesized by others (Valencia et al. 2011) for different 
types of NPs. Thus, it can be that not only folate but also the long PEG spacers carrying the 
targeting agent (PEG 5000 for liposomes and PEG 3300 for ORMOSIL NPs) folds and buries in 
the PEG corona. The extent of PEGylation, being the 8% for Fospeg and approx. 25% for 
ORMOSIL NPs, seem to affect targeting efficiency with the lower PEG density favourably 
150
affecting cell internalisation of NPs with more encouraging results. NP selective uptake was 
improved using RGD peptide or Cetuximab antibody as targeting agents, with increased NP 
accumulation in target cells of ~2 and 20-fold, respectively. The modest selectivity showed by 
RGD conjugated NPs may be explained again with PEG interference hypothesis while the size of 
Cetuximab limited the interaction with the corona. In any case, the m-THPC phototoxicity 
measured with our targeted ORMOSIL NPs was only slightly improved and this highlighted the 
difficulties of obtaining significant improvement of PDT effects. With ORMOSIL targeted with 
Cetuximab good selectivity of uptake was obtained but the amount of internalised m-THPC was 
too low to produce efficient cell photokilling. Thus, new strategies have to be developed in order 
to increase drug-cell loading using particles and in order to promote drug accumulation in 
intracellular target sites more suitable for the improvement of PDT effectiveness. Instead of 
using PEG for NP coating alternative polymers can be evaluated both for liposomes and silica 
NPs, but also the addition of different targeting molecules can be considered in the future design 
of targeted nanovehicles. A very interesting example of multicomponent NP for the targeting of 
hepatocellular carcinoma was reported recently by Ashley and co-workers which combined 
features of mesoporous silica NPs and liposomes in the so called ‘protocell’. They synthesized a 
particle-supported lipid bilayer with a nanoporous silica core with very high capacity to carry 
therapeutics and imaging agents and conjugated with a targeting peptide (SP94) displaying high 
affinity for hepatocellular receptors as well as with a histidine-rich fusogenic peptide (H5WYG) 
able to prevent the degradation of sensitive cargos in the acidic compartments of cells and to 
promote endosomal escape and cytosolic dispersion of the cargos. Therefore, using this 
multivalent protocell loaded with DOX or with a drug cocktail (DOX, 5-fluorouracil and 
cisplatin) they measured a 106-fold improvement of the killing efficiency of drug-resistant 
hepatocellular carcinoma cells with respect of using liposomes in vitro. Nevertheless, it must be 
considered that promising in vitro results not always translated into comparable in vivo
outcomes, and therefore studies on animal models are of fundamental importance during the 
design of drug delivery systems. Regarding the in vivo behaviour of our m-THPC delivery 
systems, a study recently published by our collaborators (Bovis et al. 2012) compared the 
biodistribution and the PDT efficacy of Foscan® and Fospeg® (2%, 8%) in normal and tumour 
bearing rats. They found increased tumour selectivity for Fospeg® with respect to Foscan® very 
likely related to the combination of increased blood plasma circulation and increased 
accumulation in the tumour vasculature due to PEGylation-induced EPR effect. In addition they 
reported a maximal tumour to skin ratio < 24 h for both Fospeg® formulations, suggesting that a 
shorter drug light interval could be used with respect to the longer intervals currently adopted in 
clinic for Foscan®. Moreover, improved PDT-induced tumour necrosis was measured for 
Fospeg® with respect to Foscan® in rats i.v injected with 0.05 mg kg-1 of m-THPC and irradiated 
(2 J) 24 h post-injection. 
Therefore, these in vivo results together with the in vitro results reported in this thesis, propose 
PEGylated liposomes as the most promising m-THPC carrier, even if further efforts have to be
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directed to the optimisation of targeting and to the prevention of drug release. Similarly, the 
promises offered by PLGA NPs in vitro have to be investigated in vivo as well as targeting 
strategies have to be developed to further improve the selective delivery of m-THPC. 
Finally, the potential adverse effects to human health related to nanoparticle use represents one 
of the major concern on the introduction of non biodegradable NPs in the medical field. Thus, 
the potential toxicity of ORMOSIL NPs was faced in Paper V by evaluating their cytotoxic 
profiles in different lung cell models. It was shown that the PEGylation of NPs completely 
abolish the high NP-induced cytotoxicity in some type of cells (CCD-34Lu, NCIH-2347) but not 
in the alveolar epithelial II lung (A549) cells. As it has been reported often in the literature, these 
results highlight the strong dependence of NP cytotoxicity profiles on the cell model used in 
vitro. Therefore it is expected that a more realistic portrait on the safe use of ORMOSIL NPs as 
drug delivery systems has be to carried out in vivo.
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Figure 1: PDT efficacy in A549 cells incubated for 24 h with increasing concentrations of m-
THPC free or covalently linked in PEGylated ORMOSIL NPs and irradiated with 2.4 J/cm2 of 
red light (600-700 nm). Cell viability was measured with MTS test 24 h after irradiation. Free m-
THPC or m-THPC-loaded NP doses had comparable uptake in correspondence of the irradiation 
time as measured by flow cytometry experiments (data not shown).
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